id	sid	tid	token	lemma	pos
ajlm-2099	1	1	abstract	abstract	ADJ
ajlm-2099	1	2	introduction	introduction	NOUN
ajlm-2099	1	3	methods	method	NOUN
ajlm-2099	1	4	results	result	VERB
ajlm-2099	1	5	discussion	discussion	NOUN
ajlm-2099	1	6	acknowledgements	acknowledgement	NOUN
ajlm-2099	1	7	references	reference	NOUN
ajlm-2099	1	8	about	about	ADP
ajlm-2099	1	9	the	the	DET
ajlm-2099	1	10	author(s	author(s	NOUN
ajlm-2099	1	11	)	)	PUNCT
ajlm-2099	1	12	alshymaa	alshymaa	PROPN
ajlm-2099	1	13	a.	a.	PROPN
ajlm-2099	1	14	ahmed	ahmed	PROPN
ajlm-2099	1	15	department	department	PROPN
ajlm-2099	1	16	of	of	ADP
ajlm-2099	1	17	clinical	clinical	ADJ
ajlm-2099	1	18	pathology	pathology	NOUN
ajlm-2099	1	19	,	,	PUNCT
ajlm-2099	1	20	faculty	faculty	NOUN
ajlm-2099	1	21	of	of	ADP
ajlm-2099	1	22	medicine	medicine	NOUN
ajlm-2099	1	23	,	,	PUNCT
ajlm-2099	1	24	zagazig	zagazig	PROPN
ajlm-2099	1	25	university	university	PROPN
ajlm-2099	1	26	,	,	PUNCT
ajlm-2099	1	27	zagazig	zagazig	PROPN
ajlm-2099	1	28	city	city	PROPN
ajlm-2099	1	29	,	,	PUNCT
ajlm-2099	1	30	egypt	egypt	PROPN
ajlm-2099	1	31	alia	alia	PROPN
ajlm-2099	1	32	a.	a.	PROPN
ajlm-2099	1	33	el	el	PROPN
ajlm-2099	1	34	shahawy	shahawy	PROPN
ajlm-2099	1	35	department	department	PROPN
ajlm-2099	1	36	of	of	ADP
ajlm-2099	1	37	medical	medical	ADJ
ajlm-2099	1	38	microbiology	microbiology	NOUN
ajlm-2099	1	39	and	and	CCONJ
ajlm-2099	1	40	immunology	immunology	NOUN
ajlm-2099	1	41	,	,	PUNCT
ajlm-2099	1	42	faculty	faculty	NOUN
ajlm-2099	1	43	of	of	ADP
ajlm-2099	1	44	medicine	medicine	NOUN
ajlm-2099	1	45	,	,	PUNCT
ajlm-2099	1	46	zagazig	zagazig	PROPN
ajlm-2099	1	47	university	university	PROPN
ajlm-2099	1	48	,	,	PUNCT
ajlm-2099	1	49	zagazig	zagazig	PROPN
ajlm-2099	1	50	city	city	PROPN
ajlm-2099	1	51	,	,	PUNCT
ajlm-2099	1	52	egypt	egypt	PROPN
ajlm-2099	1	53	heba	heba	PROPN
ajlm-2099	1	54	m.	m.	PROPN
ajlm-2099	1	55	kadry	kadry	PROPN
ajlm-2099	1	56	department	department	PROPN
ajlm-2099	1	57	of	of	ADP
ajlm-2099	1	58	medical	medical	ADJ
ajlm-2099	1	59	microbiology	microbiology	NOUN
ajlm-2099	1	60	and	and	CCONJ
ajlm-2099	1	61	immunology	immunology	NOUN
ajlm-2099	1	62	,	,	PUNCT
ajlm-2099	1	63	faculty	faculty	NOUN
ajlm-2099	1	64	of	of	ADP
ajlm-2099	1	65	medicine	medicine	NOUN
ajlm-2099	1	66	,	,	PUNCT
ajlm-2099	1	67	zagazig	zagazig	PROPN
ajlm-2099	1	68	university	university	PROPN
ajlm-2099	1	69	,	,	PUNCT
ajlm-2099	1	70	zagazig	zagazig	PROPN
ajlm-2099	1	71	city	city	PROPN
ajlm-2099	1	72	,	,	PUNCT
ajlm-2099	1	73	egypt	egypt	PROPN
ajlm-2099	1	74	nora	nora	PROPN
ajlm-2099	1	75	m.	m.	PROPN
ajlm-2099	1	76	said	say	VERB
ajlm-2099	1	77	department	department	NOUN
ajlm-2099	1	78	of	of	ADP
ajlm-2099	1	79	clinical	clinical	ADJ
ajlm-2099	1	80	pathology	pathology	NOUN
ajlm-2099	1	81	,	,	PUNCT
ajlm-2099	1	82	faculty	faculty	NOUN
ajlm-2099	1	83	of	of	ADP
ajlm-2099	1	84	medicine	medicine	NOUN
ajlm-2099	1	85	,	,	PUNCT
ajlm-2099	1	86	zagazig	zagazig	PROPN
ajlm-2099	1	87	university	university	PROPN
ajlm-2099	1	88	,	,	PUNCT
ajlm-2099	1	89	zagazig	zagazig	PROPN
ajlm-2099	1	90	city	city	PROPN
ajlm-2099	1	91	,	,	PUNCT
ajlm-2099	1	92	egypt	egypt	PROPN
ajlm-2099	1	93	citation	citation	PROPN
ajlm-2099	1	94	ahmed	ahme	VERB
ajlm-2099	1	95	aa	aa	PROPN
ajlm-2099	1	96	,	,	PUNCT
ajlm-2099	1	97	el	el	PROPN
ajlm-2099	1	98	shahawy	shahawy	PROPN
ajlm-2099	1	99	aa	aa	PROPN
ajlm-2099	1	100	,	,	PUNCT
ajlm-2099	1	101	kadry	kadry	VERB
ajlm-2099	1	102	hm	hm	INTJ
ajlm-2099	1	103	,	,	PUNCT
ajlm-2099	1	104	said	say	VERB
ajlm-2099	1	105	,	,	PUNCT
ajlm-2099	1	106	nm	nm	PROPN
ajlm-2099	1	107	.	.	PUNCT
ajlm-2099	2	1	performance	performance	NOUN
ajlm-2099	2	2	of	of	ADP
ajlm-2099	2	3	two	two	NUM
ajlm-2099	2	4	multiplex	multiplex	NOUN
ajlm-2099	2	5	flow	flow	NOUN
ajlm-2099	2	6	cytometric	cytometric	ADJ
ajlm-2099	2	7	assays	assay	NOUN
ajlm-2099	2	8	for	for	ADP
ajlm-2099	2	9	antibody	antibody	NOUN
ajlm-2099	2	10	detection	detection	NOUN
ajlm-2099	2	11	in	in	ADP
ajlm-2099	2	12	egyptian	egyptian	ADJ
ajlm-2099	2	13	patients	patient	NOUN
ajlm-2099	2	14	.	.	PUNCT
ajlm-2099	3	1	afr	afr	PROPN
ajlm-2099	3	2	j	j	PROPN
ajlm-2099	3	3	lab	lab	PROPN
ajlm-2099	3	4	med	med	PROPN
ajlm-2099	3	5	.	.	PUNCT
ajlm-2099	4	1	2023;12(1	2023;12(1	NUM
ajlm-2099	4	2	)	)	PUNCT
ajlm-2099	4	3	,	,	PUNCT
ajlm-2099	4	4	a2099	a2099	PROPN
ajlm-2099	4	5	.	.	PROPN
ajlm-2099	4	6	https://doi.org/10.4102/ajlm.v12i1.2099	https://doi.org/10.4102/ajlm.v12i1.2099	PRON
ajlm-2099	4	7	note	note	VERB
ajlm-2099	4	8	:	:	PUNCT
ajlm-2099	4	9	additional	additional	ADJ
ajlm-2099	4	10	supporting	support	VERB
ajlm-2099	4	11	information	information	NOUN
ajlm-2099	4	12	may	may	AUX
ajlm-2099	4	13	be	be	AUX
ajlm-2099	4	14	found	find	VERB
ajlm-2099	4	15	in	in	ADP
ajlm-2099	4	16	the	the	DET
ajlm-2099	4	17	online	online	ADJ
ajlm-2099	4	18	version	version	NOUN
ajlm-2099	4	19	of	of	ADP
ajlm-2099	4	20	this	this	DET
ajlm-2099	4	21	article	article	NOUN
ajlm-2099	4	22	as	as	SCONJ
ajlm-2099	4	23	online	online	ADJ
ajlm-2099	4	24	supplementary	supplementary	ADJ
ajlm-2099	4	25	document	document	NOUN
ajlm-2099	4	26	1	1	NUM
ajlm-2099	4	27	original	original	ADJ
ajlm-2099	4	28	research	research	NOUN
ajlm-2099	4	29	performance	performance	NOUN
ajlm-2099	4	30	of	of	ADP
ajlm-2099	4	31	two	two	NUM
ajlm-2099	4	32	multiplex	multiplex	NOUN
ajlm-2099	4	33	flow	flow	NOUN
ajlm-2099	4	34	cytometric	cytometric	ADJ
ajlm-2099	4	35	assays	assay	NOUN
ajlm-2099	4	36	for	for	ADP
ajlm-2099	4	37	antibody	antibody	NOUN
ajlm-2099	4	38	detection	detection	NOUN
ajlm-2099	4	39	in	in	ADP
ajlm-2099	4	40	egyptian	egyptian	ADJ
ajlm-2099	4	41	patients	patient	NOUN
ajlm-2099	4	42	alshymaa	alshymaa	VERB
ajlm-2099	4	43	a.	a.	NOUN
ajlm-2099	4	44	ahmed	ahmed	PROPN
ajlm-2099	4	45	,	,	PUNCT
ajlm-2099	4	46	alia	alia	ADV
ajlm-2099	4	47	a.	a.	PROPN
ajlm-2099	4	48	el	el	PROPN
ajlm-2099	4	49	shahawy	shahawy	PROPN
ajlm-2099	4	50	,	,	PUNCT
ajlm-2099	4	51	heba	heba	PROPN
ajlm-2099	4	52	m.	m.	PROPN
ajlm-2099	4	53	kadry	kadry	PROPN
ajlm-2099	4	54	,	,	PUNCT
ajlm-2099	4	55	nora	nora	PROPN
ajlm-2099	4	56	m.	m.	PROPN
ajlm-2099	4	57	said	say	VERB
ajlm-2099	4	58	received	receive	VERB
ajlm-2099	4	59	:	:	PUNCT
ajlm-2099	4	60	14	14	NUM
ajlm-2099	4	61	oct	oct	PROPN
ajlm-2099	4	62	.	.	PROPN
ajlm-2099	4	63	2022	2022	NUM
ajlm-2099	4	64	;	;	PUNCT
ajlm-2099	4	65	accepted	accept	VERB
ajlm-2099	4	66	:	:	PUNCT
ajlm-2099	4	67	22	22	NUM
ajlm-2099	4	68	mar	mar	PROPN
ajlm-2099	4	69	.	.	PROPN
ajlm-2099	4	70	2023	2023	NUM
ajlm-2099	4	71	;	;	PUNCT
ajlm-2099	4	72	published	publish	VERB
ajlm-2099	4	73	:	:	PUNCT
ajlm-2099	4	74	18	18	NUM
ajlm-2099	4	75	may	may	PROPN
ajlm-2099	4	76	2023	2023	NUM
ajlm-2099	4	77	copyright	copyright	NOUN
ajlm-2099	4	78	:	:	PUNCT
ajlm-2099	4	79	©	©	PROPN
ajlm-2099	4	80	2023	2023	NUM
ajlm-2099	4	81	.	.	PUNCT
ajlm-2099	5	1	the	the	DET
ajlm-2099	5	2	author(s	author(s	NOUN
ajlm-2099	5	3	)	)	PUNCT
ajlm-2099	5	4	.	.	PUNCT
ajlm-2099	6	1	licensee	licensee	NOUN
ajlm-2099	6	2	:	:	PUNCT
ajlm-2099	6	3	aosis	aosis	NOUN
ajlm-2099	6	4	.	.	PUNCT
ajlm-2099	7	1	this	this	PRON
ajlm-2099	7	2	is	be	AUX
ajlm-2099	7	3	an	an	DET
ajlm-2099	7	4	open	open	ADJ
ajlm-2099	7	5	access	access	NOUN
ajlm-2099	7	6	article	article	NOUN
ajlm-2099	7	7	distributed	distribute	VERB
ajlm-2099	7	8	under	under	ADP
ajlm-2099	7	9	the	the	DET
ajlm-2099	7	10	terms	term	NOUN
ajlm-2099	7	11	of	of	ADP
ajlm-2099	7	12	the	the	DET
ajlm-2099	7	13	creative	creative	ADJ
ajlm-2099	7	14	commons	common	NOUN
ajlm-2099	7	15	attribution	attribution	NOUN
ajlm-2099	7	16	license	license	NOUN
ajlm-2099	7	17	,	,	PUNCT
ajlm-2099	7	18	which	which	PRON
ajlm-2099	7	19	permits	permit	VERB
ajlm-2099	7	20	unrestricted	unrestricted	ADJ
ajlm-2099	7	21	use	use	NOUN
ajlm-2099	7	22	,	,	PUNCT
ajlm-2099	7	23	distribution	distribution	NOUN
ajlm-2099	7	24	,	,	PUNCT
ajlm-2099	7	25	and	and	CCONJ
ajlm-2099	7	26	reproduction	reproduction	NOUN
ajlm-2099	7	27	in	in	ADP
ajlm-2099	7	28	any	any	DET
ajlm-2099	7	29	medium	medium	NOUN
ajlm-2099	7	30	,	,	PUNCT
ajlm-2099	7	31	provided	provide	VERB
ajlm-2099	7	32	the	the	DET
ajlm-2099	7	33	original	original	ADJ
ajlm-2099	7	34	work	work	NOUN
ajlm-2099	7	35	is	be	AUX
ajlm-2099	7	36	properly	properly	ADV
ajlm-2099	7	37	cited	cite	VERB
ajlm-2099	7	38	.	.	PUNCT
ajlm-2099	8	1	abstract	abstract	ADJ
ajlm-2099	8	2	background	background	NOUN
ajlm-2099	8	3	:	:	PUNCT
ajlm-2099	8	4	autoantibodies	autoantibody	NOUN
ajlm-2099	8	5	are	be	AUX
ajlm-2099	8	6	vital	vital	ADJ
ajlm-2099	8	7	biomarkers	biomarker	NOUN
ajlm-2099	8	8	for	for	ADP
ajlm-2099	8	9	the	the	DET
ajlm-2099	8	10	diagnosis	diagnosis	NOUN
ajlm-2099	8	11	,	,	PUNCT
ajlm-2099	8	12	assessment	assessment	NOUN
ajlm-2099	8	13	and	and	CCONJ
ajlm-2099	8	14	prognostic	prognostic	ADJ
ajlm-2099	8	15	determination	determination	NOUN
ajlm-2099	8	16	of	of	ADP
ajlm-2099	8	17	various	various	ADJ
ajlm-2099	8	18	autoimmune	autoimmune	ADJ
ajlm-2099	8	19	disorders	disorder	NOUN
ajlm-2099	8	20	.	.	PUNCT
ajlm-2099	9	1	objective	objective	NOUN
ajlm-2099	9	2	:	:	PUNCT
ajlm-2099	9	3	this	this	DET
ajlm-2099	9	4	study	study	NOUN
ajlm-2099	9	5	aimed	aim	VERB
ajlm-2099	9	6	to	to	PART
ajlm-2099	9	7	evaluate	evaluate	VERB
ajlm-2099	9	8	the	the	DET
ajlm-2099	9	9	performance	performance	NOUN
ajlm-2099	9	10	of	of	ADP
ajlm-2099	9	11	the	the	DET
ajlm-2099	9	12	two	two	NUM
ajlm-2099	9	13	athena	athena	PROPN
ajlm-2099	9	14	multi	multi	PROPN
ajlm-2099	9	15	-	-	ADJ
ajlm-2099	9	16	lyte	lyte	ADJ
ajlm-2099	9	17	®	®	NOUN
ajlm-2099	9	18	systems	system	NOUN
ajlm-2099	9	19	for	for	ADP
ajlm-2099	9	20	the	the	DET
ajlm-2099	9	21	detection	detection	NOUN
ajlm-2099	9	22	of	of	ADP
ajlm-2099	9	23	various	various	ADJ
ajlm-2099	9	24	autoantibodies	autoantibody	NOUN
ajlm-2099	9	25	.	.	PUNCT
ajlm-2099	10	1	methods	method	NOUN
ajlm-2099	10	2	:	:	PUNCT
ajlm-2099	10	3	a	a	DET
ajlm-2099	10	4	total	total	NOUN
ajlm-2099	10	5	of	of	ADP
ajlm-2099	10	6	105	105	NUM
ajlm-2099	10	7	systemic	systemic	ADJ
ajlm-2099	10	8	lupus	lupus	NOUN
ajlm-2099	10	9	erythematosus	erythematosus	PROPN
ajlm-2099	10	10	patients	patient	NOUN
ajlm-2099	10	11	,	,	PUNCT
ajlm-2099	10	12	35	35	NUM
ajlm-2099	10	13	patients	patient	NOUN
ajlm-2099	10	14	with	with	ADP
ajlm-2099	10	15	other	other	ADJ
ajlm-2099	10	16	autoimmune	autoimmune	ADJ
ajlm-2099	10	17	diseases	disease	NOUN
ajlm-2099	10	18	(	(	PUNCT
ajlm-2099	10	19	diseased	diseased	ADJ
ajlm-2099	10	20	controls	control	NOUN
ajlm-2099	10	21	)	)	PUNCT
ajlm-2099	10	22	,	,	PUNCT
ajlm-2099	10	23	and	and	CCONJ
ajlm-2099	10	24	30	30	NUM
ajlm-2099	10	25	healthy	healthy	ADJ
ajlm-2099	10	26	volunteers	volunteer	NOUN
ajlm-2099	10	27	(	(	PUNCT
ajlm-2099	10	28	healthy	healthy	ADJ
ajlm-2099	10	29	controls	control	NOUN
ajlm-2099	10	30	)	)	PUNCT
ajlm-2099	10	31	at	at	ADP
ajlm-2099	10	32	zagazig	zagazig	PROPN
ajlm-2099	10	33	university	university	PROPN
ajlm-2099	10	34	hospitals	hospital	NOUN
ajlm-2099	10	35	,	,	PUNCT
ajlm-2099	10	36	zagazig	zagazig	PROPN
ajlm-2099	10	37	city	city	PROPN
ajlm-2099	10	38	,	,	PUNCT
ajlm-2099	10	39	al	al	PROPN
ajlm-2099	10	40	sharqia	sharqia	PROPN
ajlm-2099	10	41	governorate	governorate	PROPN
ajlm-2099	10	42	were	be	AUX
ajlm-2099	10	43	tested	test	VERB
ajlm-2099	10	44	for	for	ADP
ajlm-2099	10	45	anti	anti	ADJ
ajlm-2099	10	46	-	-	ADJ
ajlm-2099	10	47	double	double	ADJ
ajlm-2099	10	48	-	-	PUNCT
ajlm-2099	10	49	stranded	strand	VERB
ajlm-2099	10	50	dna	dna	NOUN
ajlm-2099	10	51	(	(	PUNCT
ajlm-2099	10	52	anti	anti	ADJ
ajlm-2099	10	53	-	-	ADJ
ajlm-2099	10	54	dsdna	dsdna	ADJ
ajlm-2099	10	55	)	)	PUNCT
ajlm-2099	10	56	antibodies	antibodie	VERB
ajlm-2099	10	57	using	use	VERB
ajlm-2099	10	58	indirect	indirect	ADJ
ajlm-2099	10	59	immunofluorescence	immunofluorescence	NOUN
ajlm-2099	10	60	(	(	PUNCT
ajlm-2099	10	61	iif	iif	PROPN
ajlm-2099	10	62	)	)	PUNCT
ajlm-2099	10	63	and	and	CCONJ
ajlm-2099	10	64	the	the	DET
ajlm-2099	10	65	athena	athena	PROPN
ajlm-2099	10	66	multi	multi	PROPN
ajlm-2099	10	67	-	-	ADJ
ajlm-2099	10	68	lyte	lyte	ADJ
ajlm-2099	10	69	®	®	NOUN
ajlm-2099	10	70	anti	anti	ADJ
ajlm-2099	10	71	-	-	ADJ
ajlm-2099	10	72	nuclear	nuclear	ADJ
ajlm-2099	10	73	antibodies	antibody	NOUN
ajlm-2099	10	74	-	-	PUNCT
ajlm-2099	10	75	ii	ii	NOUN
ajlm-2099	10	76	system	system	NOUN
ajlm-2099	10	77	between	between	ADP
ajlm-2099	10	78	may	may	PROPN
ajlm-2099	10	79	2020	2020	NUM
ajlm-2099	10	80	and	and	CCONJ
ajlm-2099	10	81	april	april	PROPN
ajlm-2099	10	82	2022	2022	NUM
ajlm-2099	10	83	.	.	PUNCT
ajlm-2099	11	1	seventy	seventy	NUM
ajlm-2099	11	2	-	-	PUNCT
ajlm-2099	11	3	five	five	NUM
ajlm-2099	11	4	patients	patient	NOUN
ajlm-2099	11	5	with	with	ADP
ajlm-2099	11	6	clinically	clinically	ADV
ajlm-2099	11	7	suspected	suspect	VERB
ajlm-2099	11	8	autoimmune	autoimmune	ADJ
ajlm-2099	11	9	vasculitis	vasculitis	PROPN
ajlm-2099	11	10	(	(	PUNCT
ajlm-2099	11	11	aiv	aiv	PROPN
ajlm-2099	11	12	)	)	PUNCT
ajlm-2099	11	13	and	and	CCONJ
ajlm-2099	11	14	25	25	NUM
ajlm-2099	11	15	healthy	healthy	ADJ
ajlm-2099	11	16	volunteers	volunteer	NOUN
ajlm-2099	11	17	were	be	AUX
ajlm-2099	11	18	also	also	ADV
ajlm-2099	11	19	tested	test	VERB
ajlm-2099	11	20	for	for	ADP
ajlm-2099	11	21	anti	anti	ADJ
ajlm-2099	11	22	-	-	ADJ
ajlm-2099	11	23	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	11	24	and	and	CCONJ
ajlm-2099	11	25	anti	anti	ADJ
ajlm-2099	11	26	-	-	ADJ
ajlm-2099	11	27	proteinase	proteinase	ADJ
ajlm-2099	11	28	3	3	NUM
ajlm-2099	11	29	antibodies	antibody	NOUN
ajlm-2099	11	30	using	use	VERB
ajlm-2099	11	31	iif	iif	PROPN
ajlm-2099	11	32	,	,	PUNCT
ajlm-2099	11	33	the	the	DET
ajlm-2099	11	34	athena	athena	PROPN
ajlm-2099	11	35	multi	multi	PROPN
ajlm-2099	11	36	-	-	ADJ
ajlm-2099	11	37	lyte	lyte	ADJ
ajlm-2099	11	38	®	®	NOUN
ajlm-2099	11	39	aiv	aiv	NOUN
ajlm-2099	11	40	system	system	NOUN
ajlm-2099	11	41	,	,	PUNCT
ajlm-2099	11	42	and	and	CCONJ
ajlm-2099	11	43	enzyme	enzyme	NOUN
ajlm-2099	11	44	-	-	PUNCT
ajlm-2099	11	45	linked	link	VERB
ajlm-2099	11	46	immunosorbent	immunosorbent	NOUN
ajlm-2099	11	47	assay	assay	PROPN
ajlm-2099	11	48	(	(	PUNCT
ajlm-2099	11	49	elisa	elisa	NOUN
ajlm-2099	11	50	)	)	PUNCT
ajlm-2099	11	51	.	.	PUNCT
ajlm-2099	12	1	results	result	NOUN
ajlm-2099	12	2	:	:	PUNCT
ajlm-2099	12	3	the	the	DET
ajlm-2099	12	4	athena	athena	PROPN
ajlm-2099	12	5	anti	anti	ADJ
ajlm-2099	12	6	-	-	ADJ
ajlm-2099	12	7	dsdna	dsdna	ADJ
ajlm-2099	12	8	test	test	NOUN
ajlm-2099	12	9	(	(	PUNCT
ajlm-2099	12	10	98.5	98.5	NUM
ajlm-2099	12	11	%	%	NOUN
ajlm-2099	12	12	)	)	PUNCT
ajlm-2099	12	13	was	be	AUX
ajlm-2099	12	14	more	more	ADV
ajlm-2099	12	15	specific	specific	ADJ
ajlm-2099	12	16	than	than	ADP
ajlm-2099	12	17	iif	iif	PROPN
ajlm-2099	12	18	(	(	PUNCT
ajlm-2099	12	19	96.9	96.9	NUM
ajlm-2099	12	20	%	%	NOUN
ajlm-2099	12	21	)	)	PUNCT
ajlm-2099	12	22	for	for	ADP
ajlm-2099	12	23	diagnosing	diagnose	VERB
ajlm-2099	12	24	systemic	systemic	ADJ
ajlm-2099	12	25	lupus	lupus	PROPN
ajlm-2099	12	26	erythematosus	erythematosus	PROPN
ajlm-2099	12	27	,	,	PUNCT
ajlm-2099	12	28	but	but	CCONJ
ajlm-2099	12	29	both	both	DET
ajlm-2099	12	30	tests	test	NOUN
ajlm-2099	12	31	had	have	VERB
ajlm-2099	12	32	the	the	DET
ajlm-2099	12	33	same	same	ADJ
ajlm-2099	12	34	sensitivity	sensitivity	NOUN
ajlm-2099	12	35	(	(	PUNCT
ajlm-2099	12	36	38.1	38.1	NUM
ajlm-2099	12	37	%	%	NOUN
ajlm-2099	12	38	)	)	PUNCT
ajlm-2099	12	39	.	.	PUNCT
ajlm-2099	13	1	combining	combine	VERB
ajlm-2099	13	2	both	both	DET
ajlm-2099	13	3	methods	method	NOUN
ajlm-2099	13	4	increased	increase	VERB
ajlm-2099	13	5	sensitivity	sensitivity	NOUN
ajlm-2099	13	6	to	to	ADP
ajlm-2099	13	7	47.6	47.6	NUM
ajlm-2099	13	8	%	%	NOUN
ajlm-2099	13	9	,	,	PUNCT
ajlm-2099	13	10	while	while	SCONJ
ajlm-2099	13	11	increasing	increase	VERB
ajlm-2099	13	12	the	the	DET
ajlm-2099	13	13	cut	cut	NOUN
ajlm-2099	13	14	-	-	PUNCT
ajlm-2099	13	15	off	off	NOUN
ajlm-2099	13	16	of	of	ADP
ajlm-2099	13	17	the	the	DET
ajlm-2099	13	18	athena	athena	NOUN
ajlm-2099	13	19	anti	anti	ADJ
ajlm-2099	13	20	-	-	ADJ
ajlm-2099	13	21	dsdna	dsdna	ADJ
ajlm-2099	13	22	test	test	NOUN
ajlm-2099	13	23	to	to	ADP
ajlm-2099	13	24	134	134	NUM
ajlm-2099	13	25	international	international	ADJ
ajlm-2099	13	26	units	unit	NOUN
ajlm-2099	13	27	/	/	SYM
ajlm-2099	13	28	ml	ml	X
ajlm-2099	13	29	increased	increase	VERB
ajlm-2099	13	30	specificity	specificity	NOUN
ajlm-2099	13	31	to	to	ADP
ajlm-2099	13	32	100	100	NUM
ajlm-2099	13	33	%	%	NOUN
ajlm-2099	13	34	.	.	PUNCT
ajlm-2099	14	1	the	the	DET
ajlm-2099	14	2	athena	athena	PROPN
ajlm-2099	14	3	multi	multi	PROPN
ajlm-2099	14	4	-	-	ADJ
ajlm-2099	14	5	lyte	lyte	ADJ
ajlm-2099	14	6	aiv	aiv	NOUN
ajlm-2099	14	7	system	system	NOUN
ajlm-2099	14	8	exhibited	exhibit	VERB
ajlm-2099	14	9	substantial	substantial	ADJ
ajlm-2099	14	10	agreement	agreement	NOUN
ajlm-2099	14	11	with	with	ADP
ajlm-2099	14	12	iif	iif	PROPN
ajlm-2099	14	13	regarding	regard	VERB
ajlm-2099	14	14	anti	anti	ADJ
ajlm-2099	14	15	-	-	ADJ
ajlm-2099	14	16	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	14	17	testing	testing	NOUN
ajlm-2099	14	18	(	(	PUNCT
ajlm-2099	14	19	κ	κ	X
ajlm-2099	14	20	=	=	NOUN
ajlm-2099	14	21	0.65	0.65	NUM
ajlm-2099	14	22	)	)	PUNCT
ajlm-2099	14	23	and	and	CCONJ
ajlm-2099	14	24	almost	almost	ADV
ajlm-2099	14	25	perfect	perfect	ADJ
ajlm-2099	14	26	agreement	agreement	NOUN
ajlm-2099	14	27	with	with	ADP
ajlm-2099	14	28	elisa	elisa	PROPN
ajlm-2099	14	29	(	(	PUNCT
ajlm-2099	14	30	κ	κ	X
ajlm-2099	14	31	=	=	PUNCT
ajlm-2099	14	32	0.85	0.85	NUM
ajlm-2099	14	33	)	)	PUNCT
ajlm-2099	14	34	.	.	PUNCT
ajlm-2099	15	1	the	the	DET
ajlm-2099	15	2	athena	athena	PROPN
ajlm-2099	15	3	multi	multi	PROPN
ajlm-2099	15	4	-	-	ADJ
ajlm-2099	15	5	lyte	lyte	ADJ
ajlm-2099	15	6	®	®	NOUN
ajlm-2099	15	7	aiv	aiv	NOUN
ajlm-2099	15	8	system	system	NOUN
ajlm-2099	15	9	exhibited	exhibit	VERB
ajlm-2099	15	10	perfect	perfect	ADJ
ajlm-2099	15	11	agreement	agreement	NOUN
ajlm-2099	15	12	with	with	ADP
ajlm-2099	15	13	iif	iif	PROPN
ajlm-2099	15	14	(	(	PUNCT
ajlm-2099	15	15	κ	κ	NOUN
ajlm-2099	15	16	=	=	NOUN
ajlm-2099	15	17	1	1	NUM
ajlm-2099	15	18	)	)	PUNCT
ajlm-2099	15	19	and	and	CCONJ
ajlm-2099	15	20	substantial	substantial	ADJ
ajlm-2099	15	21	agreement	agreement	NOUN
ajlm-2099	15	22	with	with	ADP
ajlm-2099	15	23	elisa	elisa	NOUN
ajlm-2099	15	24	for	for	ADP
ajlm-2099	15	25	anti	anti	ADJ
ajlm-2099	15	26	-	-	ADJ
ajlm-2099	15	27	proteinase	proteinase	ADJ
ajlm-2099	15	28	3	3	NUM
ajlm-2099	15	29	testing	testing	NOUN
ajlm-2099	15	30	(	(	PUNCT
ajlm-2099	15	31	κ	κ	X
ajlm-2099	15	32	=	=	NOUN
ajlm-2099	15	33	0.63	0.63	NUM
ajlm-2099	15	34	)	)	PUNCT
ajlm-2099	15	35	.	.	PUNCT
ajlm-2099	16	1	conclusion	conclusion	NOUN
ajlm-2099	16	2	:	:	PUNCT
ajlm-2099	16	3	athena	athena	PROPN
ajlm-2099	16	4	multi	multi	PROPN
ajlm-2099	16	5	-	-	ADJ
ajlm-2099	16	6	lyte	lyte	ADJ
ajlm-2099	16	7	®	®	NOUN
ajlm-2099	16	8	systems	system	NOUN
ajlm-2099	16	9	appear	appear	VERB
ajlm-2099	16	10	to	to	PART
ajlm-2099	16	11	be	be	AUX
ajlm-2099	16	12	reliable	reliable	ADJ
ajlm-2099	16	13	for	for	ADP
ajlm-2099	16	14	anti	anti	ADJ
ajlm-2099	16	15	-	-	ADJ
ajlm-2099	16	16	dsdna	dsdna	ADJ
ajlm-2099	16	17	,	,	PUNCT
ajlm-2099	16	18	anti	anti	ADJ
ajlm-2099	16	19	-	-	ADJ
ajlm-2099	16	20	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	16	21	,	,	PUNCT
ajlm-2099	16	22	and	and	CCONJ
ajlm-2099	16	23	anti	anti	ADJ
ajlm-2099	16	24	-	-	ADJ
ajlm-2099	16	25	proteinase	proteinase	ADJ
ajlm-2099	16	26	3	3	NUM
ajlm-2099	16	27	screening	screening	NOUN
ajlm-2099	16	28	and	and	CCONJ
ajlm-2099	16	29	may	may	AUX
ajlm-2099	16	30	be	be	AUX
ajlm-2099	16	31	an	an	DET
ajlm-2099	16	32	optimal	optimal	ADJ
ajlm-2099	16	33	choice	choice	NOUN
ajlm-2099	16	34	for	for	ADP
ajlm-2099	16	35	monitoring	monitor	VERB
ajlm-2099	16	36	anti	anti	ADJ
ajlm-2099	16	37	-	-	ADJ
ajlm-2099	16	38	dsdna	dsdna	ADJ
ajlm-2099	16	39	levels	level	NOUN
ajlm-2099	16	40	.	.	PUNCT
ajlm-2099	17	1	what	what	PRON
ajlm-2099	17	2	this	this	DET
ajlm-2099	17	3	study	study	NOUN
ajlm-2099	17	4	adds	add	VERB
ajlm-2099	17	5	:	:	PUNCT
ajlm-2099	17	6	it	it	PRON
ajlm-2099	17	7	is	be	AUX
ajlm-2099	17	8	necessary	necessary	ADJ
ajlm-2099	17	9	to	to	PART
ajlm-2099	17	10	evaluate	evaluate	VERB
ajlm-2099	17	11	various	various	ADJ
ajlm-2099	17	12	autoantibodies	autoantibody	NOUN
ajlm-2099	17	13	detection	detection	NOUN
ajlm-2099	17	14	assays	assay	NOUN
ajlm-2099	17	15	to	to	PART
ajlm-2099	17	16	increase	increase	VERB
ajlm-2099	17	17	both	both	DET
ajlm-2099	17	18	sensitivity	sensitivity	NOUN
ajlm-2099	17	19	and	and	CCONJ
ajlm-2099	17	20	specificity	specificity	NOUN
ajlm-2099	17	21	of	of	ADP
ajlm-2099	17	22	autoimmune	autoimmune	ADJ
ajlm-2099	17	23	diseases	disease	NOUN
ajlm-2099	17	24	diagnostic	diagnostic	ADJ
ajlm-2099	17	25	approaches	approach	NOUN
ajlm-2099	17	26	.	.	PUNCT
ajlm-2099	18	1	athena	athena	PROPN
ajlm-2099	18	2	multi	multi	PROPN
ajlm-2099	18	3	-	-	ADJ
ajlm-2099	18	4	lyte	lyte	ADJ
ajlm-2099	18	5	®	®	NOUN
ajlm-2099	18	6	systems	system	NOUN
ajlm-2099	18	7	appear	appear	VERB
ajlm-2099	18	8	to	to	PART
ajlm-2099	18	9	be	be	AUX
ajlm-2099	18	10	reliable	reliable	ADJ
ajlm-2099	18	11	for	for	ADP
ajlm-2099	18	12	anti	anti	ADJ
ajlm-2099	18	13	-	-	ADJ
ajlm-2099	18	14	dsdna	dsdna	ADJ
ajlm-2099	18	15	,	,	PUNCT
ajlm-2099	18	16	anti	anti	ADJ
ajlm-2099	18	17	-	-	ADJ
ajlm-2099	18	18	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	18	19	,	,	PUNCT
ajlm-2099	18	20	and	and	CCONJ
ajlm-2099	18	21	anti	anti	ADJ
ajlm-2099	18	22	-	-	ADJ
ajlm-2099	18	23	proteinase	proteinase	ADJ
ajlm-2099	18	24	3	3	NUM
ajlm-2099	18	25	screening	screening	NOUN
ajlm-2099	18	26	and	and	CCONJ
ajlm-2099	18	27	may	may	AUX
ajlm-2099	18	28	be	be	AUX
ajlm-2099	18	29	an	an	DET
ajlm-2099	18	30	optimal	optimal	ADJ
ajlm-2099	18	31	choice	choice	NOUN
ajlm-2099	18	32	for	for	ADP
ajlm-2099	18	33	monitoring	monitor	VERB
ajlm-2099	18	34	anti	anti	ADJ
ajlm-2099	18	35	-	-	ADJ
ajlm-2099	18	36	dsdna	dsdna	ADJ
ajlm-2099	18	37	levels	level	NOUN
ajlm-2099	18	38	.	.	PUNCT
ajlm-2099	19	1	keywords	keyword	NOUN
ajlm-2099	19	2	:	:	PUNCT
ajlm-2099	19	3	autoantibodies	autoantibody	NOUN
ajlm-2099	19	4	;	;	PUNCT
ajlm-2099	19	5	anti	anti	ADJ
ajlm-2099	19	6	-	-	ADJ
ajlm-2099	19	7	double	double	ADJ
ajlm-2099	19	8	-	-	PUNCT
ajlm-2099	19	9	stranded	strand	VERB
ajlm-2099	19	10	dna	dna	NOUN
ajlm-2099	19	11	;	;	PUNCT
ajlm-2099	19	12	anti	anti	ADJ
ajlm-2099	19	13	-	-	ADJ
ajlm-2099	19	14	neutrophil	neutrophil	ADJ
ajlm-2099	19	15	cytoplasmic	cytoplasmic	ADJ
ajlm-2099	19	16	antibodies	antibody	NOUN
ajlm-2099	19	17	;	;	PUNCT
ajlm-2099	20	1	multiplex	multiplex	NOUN
ajlm-2099	20	2	;	;	PUNCT
ajlm-2099	20	3	performance	performance	NOUN
ajlm-2099	20	4	.	.	PUNCT
ajlm-2099	21	1	introduction	introduction	NOUN
ajlm-2099	21	2	systemic	systemic	ADJ
ajlm-2099	21	3	lupus	lupus	PROPN
ajlm-2099	21	4	erythematosus	erythematosus	NOUN
ajlm-2099	21	5	(	(	PUNCT
ajlm-2099	21	6	sle	sle	PROPN
ajlm-2099	21	7	)	)	PUNCT
ajlm-2099	21	8	and	and	CCONJ
ajlm-2099	21	9	systemic	systemic	ADJ
ajlm-2099	21	10	vasculitis	vasculitis	PROPN
ajlm-2099	21	11	are	be	AUX
ajlm-2099	21	12	multisystem	multisystem	ADJ
ajlm-2099	21	13	autoimmune	autoimmune	ADJ
ajlm-2099	21	14	diseases	disease	NOUN
ajlm-2099	21	15	characterised	characterise	VERB
ajlm-2099	21	16	by	by	ADP
ajlm-2099	21	17	the	the	DET
ajlm-2099	21	18	generation	generation	NOUN
ajlm-2099	21	19	of	of	ADP
ajlm-2099	21	20	circulating	circulate	VERB
ajlm-2099	21	21	autoantibodies	autoantibody	NOUN
ajlm-2099	21	22	specific	specific	ADJ
ajlm-2099	21	23	to	to	ADP
ajlm-2099	21	24	different	different	ADJ
ajlm-2099	21	25	target	target	NOUN
ajlm-2099	21	26	antigens	antigen	NOUN
ajlm-2099	21	27	.	.	PUNCT
ajlm-2099	22	1	the	the	DET
ajlm-2099	22	2	incidence	incidence	NOUN
ajlm-2099	22	3	and	and	CCONJ
ajlm-2099	22	4	prevalence	prevalence	NOUN
ajlm-2099	22	5	of	of	ADP
ajlm-2099	22	6	both	both	DET
ajlm-2099	22	7	sle	sle	NOUN
ajlm-2099	22	8	and	and	CCONJ
ajlm-2099	22	9	anti	anti	ADJ
ajlm-2099	22	10	-	-	ADJ
ajlm-2099	22	11	neutrophil	neutrophil	ADJ
ajlm-2099	22	12	cytoplasmic	cytoplasmic	ADJ
ajlm-2099	22	13	antibody	antibody	NOUN
ajlm-2099	22	14	(	(	PUNCT
ajlm-2099	22	15	anca)-associated	anca)-associated	PROPN
ajlm-2099	22	16	vasculitis	vasculitis	PROPN
ajlm-2099	22	17	(	(	PUNCT
ajlm-2099	22	18	aav	aav	NOUN
ajlm-2099	22	19	)	)	PUNCT
ajlm-2099	22	20	show	show	VERB
ajlm-2099	22	21	wide	wide	ADJ
ajlm-2099	22	22	geographical	geographical	ADJ
ajlm-2099	22	23	variations.1	variations.1	NOUN
ajlm-2099	22	24	the	the	DET
ajlm-2099	22	25	overall	overall	ADJ
ajlm-2099	22	26	incidence	incidence	NOUN
ajlm-2099	22	27	of	of	ADP
ajlm-2099	22	28	sle	sle	PROPN
ajlm-2099	22	29	ranges	range	VERB
ajlm-2099	22	30	from	from	ADP
ajlm-2099	22	31	0.3	0.3	NUM
ajlm-2099	22	32	cases	case	NOUN
ajlm-2099	22	33	per	per	ADP
ajlm-2099	22	34	100	100	NUM
ajlm-2099	22	35	000	000	NUM
ajlm-2099	22	36	population	population	NOUN
ajlm-2099	22	37	per	per	ADP
ajlm-2099	22	38	year	year	NOUN
ajlm-2099	22	39	in	in	ADP
ajlm-2099	22	40	ukraine	ukraine	NOUN
ajlm-2099	22	41	to	to	ADP
ajlm-2099	22	42	31.5	31.5	NUM
ajlm-2099	22	43	per	per	ADP
ajlm-2099	22	44	100	100	NUM
ajlm-2099	22	45	000	000	NUM
ajlm-2099	22	46	per	per	ADP
ajlm-2099	22	47	year	year	NOUN
ajlm-2099	22	48	among	among	ADP
ajlm-2099	22	49	afro	afro	NOUN
ajlm-2099	22	50	-	-	PUNCT
ajlm-2099	22	51	caribbean	caribbean	ADJ
ajlm-2099	22	52	people	people	NOUN
ajlm-2099	22	53	living	live	VERB
ajlm-2099	22	54	in	in	ADP
ajlm-2099	22	55	the	the	DET
ajlm-2099	22	56	united	united	PROPN
ajlm-2099	22	57	kingdom.2	kingdom.2	PROPN
ajlm-2099	22	58	in	in	ADP
ajlm-2099	22	59	egypt	egypt	PROPN
ajlm-2099	22	60	,	,	PUNCT
ajlm-2099	22	61	the	the	DET
ajlm-2099	22	62	estimated	estimate	VERB
ajlm-2099	22	63	prevalence	prevalence	NOUN
ajlm-2099	22	64	of	of	ADP
ajlm-2099	22	65	adult	adult	NOUN
ajlm-2099	22	66	sle	sle	NOUN
ajlm-2099	22	67	is	be	AUX
ajlm-2099	22	68	6.1	6.1	NUM
ajlm-2099	22	69	cases	case	NOUN
ajlm-2099	22	70	per	per	ADP
ajlm-2099	22	71	100	100	NUM
ajlm-2099	22	72	000	000	NUM
ajlm-2099	22	73	persons	person	NOUN
ajlm-2099	22	74	,	,	PUNCT
ajlm-2099	22	75	with	with	ADP
ajlm-2099	22	76	a	a	DET
ajlm-2099	22	77	higher	high	ADJ
ajlm-2099	22	78	prevalence	prevalence	NOUN
ajlm-2099	22	79	(	(	PUNCT
ajlm-2099	22	80	11.3	11.3	NUM
ajlm-2099	22	81	per	per	ADP
ajlm-2099	22	82	100	100	NUM
ajlm-2099	22	83	000	000	NUM
ajlm-2099	22	84	)	)	PUNCT
ajlm-2099	22	85	reported	report	VERB
ajlm-2099	22	86	among	among	ADP
ajlm-2099	22	87	women.3	women.3	PROPN
ajlm-2099	23	1	anti	anti	ADJ
ajlm-2099	23	2	-	-	ADJ
ajlm-2099	23	3	neutrophil	neutrophil	ADJ
ajlm-2099	23	4	cytoplasmic	cytoplasmic	ADJ
ajlm-2099	23	5	antibody	antibody	NOUN
ajlm-2099	23	6	-	-	PUNCT
ajlm-2099	23	7	associated	associate	VERB
ajlm-2099	23	8	vasculitis	vasculitis	PROPN
ajlm-2099	23	9	inflicts	inflict	VERB
ajlm-2099	23	10	considerable	considerable	ADJ
ajlm-2099	23	11	global	global	ADJ
ajlm-2099	23	12	effects	effect	NOUN
ajlm-2099	23	13	,	,	PUNCT
ajlm-2099	23	14	including	include	VERB
ajlm-2099	23	15	elevated	elevate	VERB
ajlm-2099	23	16	mortality	mortality	NOUN
ajlm-2099	23	17	rates	rate	NOUN
ajlm-2099	23	18	,	,	PUNCT
ajlm-2099	23	19	poor	poor	ADJ
ajlm-2099	23	20	quality	quality	NOUN
ajlm-2099	23	21	of	of	ADP
ajlm-2099	23	22	life	life	NOUN
ajlm-2099	23	23	,	,	PUNCT
ajlm-2099	23	24	and	and	CCONJ
ajlm-2099	23	25	socio	socio	NOUN
ajlm-2099	23	26	-	-	PUNCT
ajlm-2099	23	27	economic	economic	ADJ
ajlm-2099	23	28	burdens,4	burdens,4	NOUN
ajlm-2099	23	29	and	and	CCONJ
ajlm-2099	23	30	studies	study	NOUN
ajlm-2099	23	31	have	have	AUX
ajlm-2099	23	32	demonstrated	demonstrate	VERB
ajlm-2099	23	33	an	an	DET
ajlm-2099	23	34	aav	aav	NOUN
ajlm-2099	23	35	prevalence	prevalence	NOUN
ajlm-2099	23	36	of	of	ADP
ajlm-2099	23	37	between	between	ADP
ajlm-2099	23	38	48	48	NUM
ajlm-2099	23	39	and	and	CCONJ
ajlm-2099	23	40	184	184	NUM
ajlm-2099	23	41	cases	case	NOUN
ajlm-2099	23	42	per	per	ADP
ajlm-2099	23	43	million	million	NUM
ajlm-2099	23	44	individuals.1	individuals.1	NOUN
ajlm-2099	23	45	in	in	ADP
ajlm-2099	23	46	egypt	egypt	PROPN
ajlm-2099	23	47	,	,	PUNCT
ajlm-2099	23	48	aav	aav	PROPN
ajlm-2099	23	49	constitutes	constitute	VERB
ajlm-2099	23	50	about	about	ADV
ajlm-2099	23	51	3.6	3.6	NUM
ajlm-2099	23	52	%	%	NOUN
ajlm-2099	23	53	of	of	ADP
ajlm-2099	23	54	vasculitides.5,6	vasculitides.5,6	NOUN
ajlm-2099	23	55	however	however	ADV
ajlm-2099	23	56	,	,	PUNCT
ajlm-2099	23	57	there	there	PRON
ajlm-2099	23	58	is	be	VERB
ajlm-2099	23	59	inadequate	inadequate	ADJ
ajlm-2099	23	60	data	datum	NOUN
ajlm-2099	23	61	to	to	PART
ajlm-2099	23	62	identify	identify	VERB
ajlm-2099	23	63	the	the	DET
ajlm-2099	23	64	prevalence	prevalence	NOUN
ajlm-2099	23	65	of	of	ADP
ajlm-2099	23	66	aav	aav	PROPN
ajlm-2099	23	67	in	in	ADP
ajlm-2099	23	68	africa	africa	PROPN
ajlm-2099	23	69	and	and	CCONJ
ajlm-2099	23	70	south	south	ADJ
ajlm-2099	23	71	asia.7	asia.7	NOUN
ajlm-2099	23	72	autoantibodies	autoantibody	NOUN
ajlm-2099	23	73	are	be	AUX
ajlm-2099	23	74	crucial	crucial	ADJ
ajlm-2099	23	75	biomarkers	biomarker	NOUN
ajlm-2099	23	76	that	that	PRON
ajlm-2099	23	77	guide	guide	VERB
ajlm-2099	23	78	the	the	DET
ajlm-2099	23	79	diagnosis	diagnosis	NOUN
ajlm-2099	23	80	,	,	PUNCT
ajlm-2099	23	81	treatment	treatment	NOUN
ajlm-2099	23	82	,	,	PUNCT
ajlm-2099	23	83	and	and	CCONJ
ajlm-2099	23	84	follow	follow	VERB
ajlm-2099	23	85	-	-	PUNCT
ajlm-2099	23	86	up	up	NOUN
ajlm-2099	23	87	of	of	ADP
ajlm-2099	23	88	autoimmune	autoimmune	ADJ
ajlm-2099	23	89	disorders.8	disorders.8	PROPN
ajlm-2099	23	90	new	new	ADJ
ajlm-2099	23	91	automated	automate	VERB
ajlm-2099	23	92	high	high	ADJ
ajlm-2099	23	93	-	-	PUNCT
ajlm-2099	23	94	throughput	throughput	NOUN
ajlm-2099	23	95	assays	assay	NOUN
ajlm-2099	23	96	are	be	AUX
ajlm-2099	23	97	continuously	continuously	ADV
ajlm-2099	23	98	being	be	AUX
ajlm-2099	23	99	developed	develop	VERB
ajlm-2099	23	100	to	to	PART
ajlm-2099	23	101	replace	replace	VERB
ajlm-2099	23	102	conventional	conventional	ADJ
ajlm-2099	23	103	assays	assay	NOUN
ajlm-2099	23	104	for	for	ADP
ajlm-2099	23	105	detecting	detect	VERB
ajlm-2099	23	106	these	these	DET
ajlm-2099	23	107	autoantibodies	autoantibody	NOUN
ajlm-2099	23	108	.	.	PUNCT
ajlm-2099	24	1	however	however	ADV
ajlm-2099	24	2	,	,	PUNCT
ajlm-2099	24	3	an	an	DET
ajlm-2099	24	4	accurate	accurate	ADJ
ajlm-2099	24	5	evaluation	evaluation	NOUN
ajlm-2099	24	6	of	of	ADP
ajlm-2099	24	7	these	these	DET
ajlm-2099	24	8	new	new	ADJ
ajlm-2099	24	9	techniques	technique	NOUN
ajlm-2099	24	10	is	be	AUX
ajlm-2099	24	11	mandatory	mandatory	ADJ
ajlm-2099	24	12	to	to	PART
ajlm-2099	24	13	ensure	ensure	VERB
ajlm-2099	24	14	that	that	SCONJ
ajlm-2099	24	15	they	they	PRON
ajlm-2099	24	16	are	be	AUX
ajlm-2099	24	17	clinically	clinically	ADV
ajlm-2099	24	18	valuable	valuable	ADJ
ajlm-2099	24	19	and	and	CCONJ
ajlm-2099	24	20	can	can	AUX
ajlm-2099	24	21	improve	improve	VERB
ajlm-2099	24	22	various	various	ADJ
ajlm-2099	24	23	medical	medical	ADJ
ajlm-2099	24	24	decisions.9	decisions.9	PROPN
ajlm-2099	24	25	according	accord	VERB
ajlm-2099	24	26	to	to	ADP
ajlm-2099	24	27	the	the	DET
ajlm-2099	24	28	guidelines	guideline	NOUN
ajlm-2099	24	29	provided	provide	VERB
ajlm-2099	24	30	by	by	ADP
ajlm-2099	24	31	the	the	DET
ajlm-2099	24	32	european	european	PROPN
ajlm-2099	24	33	league	league	PROPN
ajlm-2099	24	34	against	against	ADP
ajlm-2099	24	35	rheumatism	rheumatism	NOUN
ajlm-2099	24	36	and	and	CCONJ
ajlm-2099	24	37	the	the	DET
ajlm-2099	24	38	american	american	PROPN
ajlm-2099	24	39	college	college	PROPN
ajlm-2099	24	40	of	of	ADP
ajlm-2099	24	41	rheumatology	rheumatology	NOUN
ajlm-2099	24	42	,	,	PUNCT
ajlm-2099	24	43	patients	patient	NOUN
ajlm-2099	24	44	are	be	AUX
ajlm-2099	24	45	classified	classify	VERB
ajlm-2099	24	46	as	as	ADP
ajlm-2099	24	47	positive	positive	ADJ
ajlm-2099	24	48	for	for	ADP
ajlm-2099	24	49	sle	sle	PROPN
ajlm-2099	24	50	if	if	SCONJ
ajlm-2099	24	51	they	they	PRON
ajlm-2099	24	52	have	have	VERB
ajlm-2099	24	53	serum	serum	NOUN
ajlm-2099	24	54	anti	anti	ADJ
ajlm-2099	24	55	-	-	ADJ
ajlm-2099	24	56	nuclear	nuclear	ADJ
ajlm-2099	24	57	antibody	antibody	NOUN
ajlm-2099	24	58	titres	titre	NOUN
ajlm-2099	24	59	≥	≥	VERB
ajlm-2099	24	60	1:80.10	1:80.10	ADP
ajlm-2099	24	61	the	the	DET
ajlm-2099	24	62	presence	presence	NOUN
ajlm-2099	24	63	of	of	ADP
ajlm-2099	24	64	antibodies	antibody	NOUN
ajlm-2099	24	65	against	against	ADP
ajlm-2099	24	66	double	double	ADV
ajlm-2099	24	67	-	-	PUNCT
ajlm-2099	24	68	stranded	strand	VERB
ajlm-2099	24	69	dna	dna	NOUN
ajlm-2099	24	70	(	(	PUNCT
ajlm-2099	24	71	anti	anti	ADJ
ajlm-2099	24	72	-	-	ADJ
ajlm-2099	24	73	dsdna	dsdna	ADJ
ajlm-2099	24	74	)	)	PUNCT
ajlm-2099	24	75	is	be	AUX
ajlm-2099	24	76	the	the	DET
ajlm-2099	24	77	serological	serological	ADJ
ajlm-2099	24	78	hallmark	hallmark	NOUN
ajlm-2099	24	79	for	for	ADP
ajlm-2099	24	80	a	a	DET
ajlm-2099	24	81	diagnosis	diagnosis	NOUN
ajlm-2099	24	82	of	of	ADP
ajlm-2099	24	83	sle	sle	PROPN
ajlm-2099	24	84	.	.	PUNCT
ajlm-2099	25	1	an	an	DET
ajlm-2099	25	2	increased	increase	VERB
ajlm-2099	25	3	anti	anti	ADJ
ajlm-2099	25	4	-	-	ADJ
ajlm-2099	25	5	dsdna	dsdna	ADJ
ajlm-2099	25	6	titre	titre	NOUN
ajlm-2099	25	7	in	in	ADP
ajlm-2099	25	8	association	association	NOUN
ajlm-2099	25	9	with	with	ADP
ajlm-2099	25	10	low	low	ADJ
ajlm-2099	25	11	levels	level	NOUN
ajlm-2099	25	12	of	of	ADP
ajlm-2099	25	13	the	the	DET
ajlm-2099	25	14	complement	complement	NOUN
ajlm-2099	25	15	components	component	NOUN
ajlm-2099	25	16	c1q	c1q	PROPN
ajlm-2099	25	17	,	,	PUNCT
ajlm-2099	25	18	c3	c3	NOUN
ajlm-2099	25	19	,	,	PUNCT
ajlm-2099	25	20	and	and	CCONJ
ajlm-2099	25	21	c4	c4	NOUN
ajlm-2099	25	22	is	be	AUX
ajlm-2099	25	23	indicative	indicative	ADJ
ajlm-2099	25	24	of	of	ADP
ajlm-2099	25	25	an	an	DET
ajlm-2099	25	26	acute	acute	ADJ
ajlm-2099	25	27	sle	sle	PROPN
ajlm-2099	25	28	exacerbation.11,12	exacerbation.11,12	VERB
ajlm-2099	25	29	diverse	diverse	ADJ
ajlm-2099	25	30	methods	method	NOUN
ajlm-2099	25	31	have	have	AUX
ajlm-2099	25	32	been	be	AUX
ajlm-2099	25	33	developed	develop	VERB
ajlm-2099	25	34	for	for	ADP
ajlm-2099	25	35	the	the	DET
ajlm-2099	25	36	detection	detection	NOUN
ajlm-2099	25	37	of	of	ADP
ajlm-2099	25	38	anti	anti	ADJ
ajlm-2099	25	39	-	-	ADJ
ajlm-2099	25	40	dsdna	dsdna	ADJ
ajlm-2099	25	41	.	.	PUNCT
ajlm-2099	26	1	the	the	DET
ajlm-2099	26	2	crithidia	crithidia	NOUN
ajlm-2099	26	3	luciliae	luciliae	PROPN
ajlm-2099	26	4	immunofluorescence	immunofluorescence	NOUN
ajlm-2099	26	5	test	test	NOUN
ajlm-2099	26	6	is	be	AUX
ajlm-2099	26	7	remarkably	remarkably	ADV
ajlm-2099	26	8	specific	specific	ADJ
ajlm-2099	26	9	and	and	CCONJ
ajlm-2099	26	10	yields	yield	VERB
ajlm-2099	26	11	a	a	DET
ajlm-2099	26	12	high	high	ADJ
ajlm-2099	26	13	positive	positive	ADJ
ajlm-2099	26	14	predictive	predictive	ADJ
ajlm-2099	26	15	value	value	NOUN
ajlm-2099	26	16	for	for	ADP
ajlm-2099	26	17	sle	sle	PROPN
ajlm-2099	26	18	.	.	PUNCT
ajlm-2099	27	1	however	however	ADV
ajlm-2099	27	2	,	,	PUNCT
ajlm-2099	27	3	the	the	DET
ajlm-2099	27	4	sensitivity	sensitivity	NOUN
ajlm-2099	27	5	of	of	ADP
ajlm-2099	27	6	c.	c.	PROPN
ajlm-2099	27	7	luciliae	luciliae	PROPN
ajlm-2099	27	8	immunofluorescence	immunofluorescence	NOUN
ajlm-2099	27	9	test	test	NOUN
ajlm-2099	27	10	for	for	ADP
ajlm-2099	27	11	sle	sle	PROPN
ajlm-2099	27	12	diagnosis	diagnosis	NOUN
ajlm-2099	27	13	is	be	AUX
ajlm-2099	27	14	low	low	ADJ
ajlm-2099	27	15	(	(	PUNCT
ajlm-2099	27	16	ranging	range	VERB
ajlm-2099	27	17	from	from	ADP
ajlm-2099	27	18	20	20	NUM
ajlm-2099	27	19	%	%	NOUN
ajlm-2099	27	20	to	to	ADP
ajlm-2099	27	21	55	55	NUM
ajlm-2099	27	22	%	%	NOUN
ajlm-2099	27	23	,	,	PUNCT
ajlm-2099	27	24	depending	depend	VERB
ajlm-2099	27	25	on	on	ADP
ajlm-2099	27	26	the	the	DET
ajlm-2099	27	27	kit	kit	NOUN
ajlm-2099	27	28	supplier	supplier	NOUN
ajlm-2099	27	29	)	)	PUNCT
ajlm-2099	27	30	,	,	PUNCT
ajlm-2099	27	31	and	and	CCONJ
ajlm-2099	27	32	being	be	AUX
ajlm-2099	27	33	a	a	DET
ajlm-2099	27	34	semi	semi	ADJ
ajlm-2099	27	35	-	-	ADJ
ajlm-2099	27	36	quantitative	quantitative	ADJ
ajlm-2099	27	37	test	test	NOUN
ajlm-2099	27	38	,	,	PUNCT
ajlm-2099	27	39	it	it	PRON
ajlm-2099	27	40	is	be	AUX
ajlm-2099	27	41	not	not	PART
ajlm-2099	27	42	an	an	DET
ajlm-2099	27	43	optimal	optimal	ADJ
ajlm-2099	27	44	choice	choice	NOUN
ajlm-2099	27	45	for	for	ADP
ajlm-2099	27	46	clinical	clinical	ADJ
ajlm-2099	27	47	follow	follow	NOUN
ajlm-2099	27	48	-	-	PUNCT
ajlm-2099	27	49	ups	up	NOUN
ajlm-2099	27	50	and	and	CCONJ
ajlm-2099	27	51	disease	disease	NOUN
ajlm-2099	27	52	flare	flare	VERB
ajlm-2099	27	53	predictions.13,14,15	predictions.13,14,15	ADV
ajlm-2099	27	54	in	in	ADP
ajlm-2099	27	55	contrast	contrast	NOUN
ajlm-2099	27	56	,	,	PUNCT
ajlm-2099	27	57	the	the	DET
ajlm-2099	27	58	enzyme	enzyme	NOUN
ajlm-2099	27	59	-	-	PUNCT
ajlm-2099	27	60	linked	link	VERB
ajlm-2099	27	61	immunosorbent	immunosorbent	NOUN
ajlm-2099	27	62	assay	assay	PROPN
ajlm-2099	27	63	(	(	PUNCT
ajlm-2099	27	64	elisa	elisa	NOUN
ajlm-2099	27	65	)	)	PUNCT
ajlm-2099	27	66	is	be	AUX
ajlm-2099	27	67	more	more	ADV
ajlm-2099	27	68	sensitive	sensitive	ADJ
ajlm-2099	27	69	(	(	PUNCT
ajlm-2099	27	70	>	>	X
ajlm-2099	27	71	60	60	NUM
ajlm-2099	27	72	%	%	NOUN
ajlm-2099	27	73	)	)	PUNCT
ajlm-2099	27	74	than	than	ADP
ajlm-2099	27	75	c.	c.	PROPN
ajlm-2099	27	76	luciliae	luciliae	PROPN
ajlm-2099	27	77	immunofluorescence	immunofluorescence	NOUN
ajlm-2099	27	78	test	test	NOUN
ajlm-2099	27	79	but	but	CCONJ
ajlm-2099	27	80	has	have	VERB
ajlm-2099	27	81	a	a	DET
ajlm-2099	27	82	lower	low	ADJ
ajlm-2099	27	83	specificity	specificity	NOUN
ajlm-2099	27	84	for	for	ADP
ajlm-2099	27	85	sle.15,16	sle.15,16	PROPN
ajlm-2099	27	86	multiplex	multiplex	PROPN
ajlm-2099	27	87	bead	bead	NOUN
ajlm-2099	27	88	-	-	PUNCT
ajlm-2099	27	89	based	base	VERB
ajlm-2099	27	90	assays	assay	NOUN
ajlm-2099	27	91	provide	provide	VERB
ajlm-2099	27	92	the	the	DET
ajlm-2099	27	93	advantage	advantage	NOUN
ajlm-2099	27	94	of	of	ADP
ajlm-2099	27	95	assessing	assess	VERB
ajlm-2099	27	96	multiple	multiple	ADJ
ajlm-2099	27	97	antibody	antibody	NOUN
ajlm-2099	27	98	specificities	specificity	NOUN
ajlm-2099	27	99	simultaneously	simultaneously	ADV
ajlm-2099	27	100	in	in	ADP
ajlm-2099	27	101	small	small	ADJ
ajlm-2099	27	102	volumes	volume	NOUN
ajlm-2099	27	103	of	of	ADP
ajlm-2099	27	104	serum	serum	NOUN
ajlm-2099	27	105	.	.	PUNCT
ajlm-2099	28	1	one	one	NUM
ajlm-2099	28	2	such	such	ADJ
ajlm-2099	28	3	technique	technique	NOUN
ajlm-2099	28	4	is	be	AUX
ajlm-2099	28	5	the	the	DET
ajlm-2099	28	6	addressable	addressable	ADJ
ajlm-2099	28	7	laser	laser	NOUN
ajlm-2099	28	8	bead	bead	NOUN
ajlm-2099	28	9	immunoassay	immunoassay	PROPN
ajlm-2099	28	10	,	,	PUNCT
ajlm-2099	28	11	as	as	SCONJ
ajlm-2099	28	12	exemplified	exemplify	VERB
ajlm-2099	28	13	by	by	ADP
ajlm-2099	28	14	the	the	DET
ajlm-2099	28	15	commercially	commercially	ADV
ajlm-2099	28	16	available	available	ADJ
ajlm-2099	28	17	luminextm	luminextm	NOUN
ajlm-2099	28	18	platforms	platform	NOUN
ajlm-2099	28	19	.	.	PUNCT
ajlm-2099	29	1	the	the	DET
ajlm-2099	29	2	sensitivity	sensitivity	NOUN
ajlm-2099	29	3	of	of	ADP
ajlm-2099	29	4	addressable	addressable	ADJ
ajlm-2099	29	5	laser	laser	NOUN
ajlm-2099	29	6	bead	bead	NOUN
ajlm-2099	29	7	immunoassay	immunoassay	PROPN
ajlm-2099	29	8	is	be	AUX
ajlm-2099	29	9	similar	similar	ADJ
ajlm-2099	29	10	to	to	ADP
ajlm-2099	29	11	that	that	PRON
ajlm-2099	29	12	of	of	ADP
ajlm-2099	29	13	elisa	elisa	NOUN
ajlm-2099	29	14	for	for	ADP
ajlm-2099	29	15	the	the	DET
ajlm-2099	29	16	detection	detection	NOUN
ajlm-2099	29	17	of	of	ADP
ajlm-2099	29	18	anti	anti	ADJ
ajlm-2099	29	19	-	-	ADJ
ajlm-2099	29	20	dsdna	dsdna	ADJ
ajlm-2099	29	21	,	,	PUNCT
ajlm-2099	29	22	while	while	SCONJ
ajlm-2099	29	23	the	the	DET
ajlm-2099	29	24	specificity	specificity	NOUN
ajlm-2099	29	25	is	be	AUX
ajlm-2099	29	26	comparable	comparable	ADJ
ajlm-2099	29	27	to	to	ADP
ajlm-2099	29	28	that	that	PRON
ajlm-2099	29	29	of	of	ADP
ajlm-2099	29	30	c.	c.	PROPN
ajlm-2099	29	31	luciliae	luciliae	PROPN
ajlm-2099	29	32	immunofluorescence	immunofluorescence	NOUN
ajlm-2099	29	33	test.17	test.17	ADJ
ajlm-2099	29	34	existing	exist	VERB
ajlm-2099	29	35	guidelines	guideline	NOUN
ajlm-2099	29	36	for	for	ADP
ajlm-2099	29	37	the	the	DET
ajlm-2099	29	38	diagnosis	diagnosis	NOUN
ajlm-2099	29	39	and	and	CCONJ
ajlm-2099	29	40	follow	follow	VERB
ajlm-2099	29	41	-	-	PUNCT
ajlm-2099	29	42	up	up	NOUN
ajlm-2099	29	43	of	of	ADP
ajlm-2099	29	44	sle	sle	NOUN
ajlm-2099	29	45	such	such	ADJ
ajlm-2099	29	46	as	as	ADP
ajlm-2099	29	47	‘	'	PUNCT
ajlm-2099	29	48	the	the	DET
ajlm-2099	29	49	2019	2019	NUM
ajlm-2099	29	50	european	european	PROPN
ajlm-2099	29	51	league	league	PROPN
ajlm-2099	29	52	against	against	ADP
ajlm-2099	29	53	rheumatism	rheumatism	NOUN
ajlm-2099	29	54	and	and	CCONJ
ajlm-2099	29	55	the	the	DET
ajlm-2099	29	56	american	american	PROPN
ajlm-2099	29	57	college	college	PROPN
ajlm-2099	29	58	of	of	ADP
ajlm-2099	29	59	rheumatology	rheumatology	NOUN
ajlm-2099	29	60	classification	classification	NOUN
ajlm-2099	29	61	criteria	criterion	NOUN
ajlm-2099	29	62	for	for	ADP
ajlm-2099	29	63	systemic	systemic	ADJ
ajlm-2099	29	64	lupus	lupus	NOUN
ajlm-2099	29	65	erythematosus’18	erythematosus’18	PROPN
ajlm-2099	29	66	do	do	AUX
ajlm-2099	29	67	not	not	PART
ajlm-2099	29	68	specify	specify	VERB
ajlm-2099	29	69	a	a	DET
ajlm-2099	29	70	certain	certain	ADJ
ajlm-2099	29	71	assay	assay	NOUN
ajlm-2099	29	72	for	for	ADP
ajlm-2099	29	73	anti	anti	ADJ
ajlm-2099	29	74	-	-	ADJ
ajlm-2099	29	75	dsdna	dsdna	ADJ
ajlm-2099	29	76	detection	detection	NOUN
ajlm-2099	29	77	.	.	PUNCT
ajlm-2099	30	1	however	however	ADV
ajlm-2099	30	2	,	,	PUNCT
ajlm-2099	30	3	the	the	DET
ajlm-2099	30	4	guidelines	guideline	NOUN
ajlm-2099	30	5	advise	advise	VERB
ajlm-2099	30	6	that	that	SCONJ
ajlm-2099	30	7	positive	positive	ADJ
ajlm-2099	30	8	results	result	NOUN
ajlm-2099	30	9	should	should	AUX
ajlm-2099	30	10	be	be	AUX
ajlm-2099	30	11	confirmed	confirm	VERB
ajlm-2099	30	12	by	by	ADP
ajlm-2099	30	13	indirect	indirect	ADJ
ajlm-2099	30	14	immunofluorescence	immunofluorescence	NOUN
ajlm-2099	30	15	(	(	PUNCT
ajlm-2099	30	16	iif	iif	PROPN
ajlm-2099	30	17	)	)	PUNCT
ajlm-2099	30	18	or	or	CCONJ
ajlm-2099	30	19	a	a	DET
ajlm-2099	30	20	farr	farr	PROPN
ajlm-2099	30	21	assay.15,19	assay.15,19	NOUN
ajlm-2099	30	22	the	the	DET
ajlm-2099	30	23	detection	detection	NOUN
ajlm-2099	30	24	of	of	ADP
ajlm-2099	30	25	ancas	ancas	NOUN
ajlm-2099	30	26	is	be	AUX
ajlm-2099	30	27	vital	vital	ADJ
ajlm-2099	30	28	for	for	ADP
ajlm-2099	30	29	the	the	DET
ajlm-2099	30	30	diagnosis	diagnosis	NOUN
ajlm-2099	30	31	of	of	ADP
ajlm-2099	30	32	the	the	DET
ajlm-2099	30	33	unique	unique	ADJ
ajlm-2099	30	34	group	group	NOUN
ajlm-2099	30	35	of	of	ADP
ajlm-2099	30	36	small	small	ADJ
ajlm-2099	30	37	-	-	PUNCT
ajlm-2099	30	38	vessel	vessel	NOUN
ajlm-2099	30	39	vasculitic	vasculitic	ADJ
ajlm-2099	30	40	disorders	disorder	NOUN
ajlm-2099	30	41	named	name	VERB
ajlm-2099	30	42	aav	aav	PROPN
ajlm-2099	30	43	.	.	PUNCT
ajlm-2099	31	1	this	this	DET
ajlm-2099	31	2	group	group	NOUN
ajlm-2099	31	3	includes	include	VERB
ajlm-2099	31	4	three	three	NUM
ajlm-2099	31	5	main	main	ADJ
ajlm-2099	31	6	diseases	disease	NOUN
ajlm-2099	31	7	:	:	PUNCT
ajlm-2099	31	8	granulomatosis	granulomatosis	VERB
ajlm-2099	31	9	with	with	ADP
ajlm-2099	31	10	polyangiitis	polyangiitis	ADJ
ajlm-2099	31	11	,	,	PUNCT
ajlm-2099	31	12	microscopic	microscopic	ADJ
ajlm-2099	31	13	polyangiitis	polyangiitis	ADJ
ajlm-2099	31	14	,	,	PUNCT
ajlm-2099	31	15	and	and	CCONJ
ajlm-2099	31	16	eosinophilic	eosinophilic	ADJ
ajlm-2099	31	17	granulomatosis	granulomatosis	NOUN
ajlm-2099	31	18	with	with	ADP
ajlm-2099	31	19	polyangiitis	polyangiitis	PROPN
ajlm-2099	31	20	.	.	PUNCT
ajlm-2099	32	1	patients	patient	NOUN
ajlm-2099	32	2	with	with	ADP
ajlm-2099	32	3	granulomatosis	granulomatosis	NOUN
ajlm-2099	32	4	with	with	ADP
ajlm-2099	32	5	polyangiitis	polyangiitis	PROPN
ajlm-2099	32	6	are	be	AUX
ajlm-2099	32	7	mainly	mainly	ADV
ajlm-2099	32	8	proteinase	proteinase	ADJ
ajlm-2099	32	9	3	3	NUM
ajlm-2099	32	10	-	-	PUNCT
ajlm-2099	32	11	anca	anca	NOUN
ajlm-2099	32	12	positive	positive	NOUN
ajlm-2099	32	13	,	,	PUNCT
ajlm-2099	32	14	while	while	SCONJ
ajlm-2099	32	15	those	those	PRON
ajlm-2099	32	16	with	with	ADP
ajlm-2099	32	17	microscopic	microscopic	ADJ
ajlm-2099	32	18	polyangiitis	polyangiitis	ADJ
ajlm-2099	32	19	and	and	CCONJ
ajlm-2099	32	20	eosinophilic	eosinophilic	ADJ
ajlm-2099	32	21	granulomatosis	granulomatosis	NOUN
ajlm-2099	32	22	with	with	ADP
ajlm-2099	32	23	polyangiitis	polyangiitis	PROPN
ajlm-2099	32	24	are	be	AUX
ajlm-2099	32	25	mainly	mainly	ADV
ajlm-2099	32	26	myeloperoxidase	myeloperoxidase	NOUN
ajlm-2099	32	27	-	-	PUNCT
ajlm-2099	32	28	anca	anca	NOUN
ajlm-2099	32	29	positive.20,21	positive.20,21	NOUN
ajlm-2099	32	30	indirect	indirect	ADJ
ajlm-2099	32	31	immunofluorescence	immunofluorescence	NOUN
ajlm-2099	32	32	is	be	AUX
ajlm-2099	32	33	used	use	VERB
ajlm-2099	32	34	as	as	ADP
ajlm-2099	32	35	a	a	DET
ajlm-2099	32	36	screening	screening	NOUN
ajlm-2099	32	37	test	test	NOUN
ajlm-2099	32	38	for	for	ADP
ajlm-2099	32	39	anca	anca	NOUN
ajlm-2099	32	40	in	in	ADP
ajlm-2099	32	41	accordance	accordance	NOUN
ajlm-2099	32	42	with	with	ADP
ajlm-2099	32	43	the	the	DET
ajlm-2099	32	44	1999	1999	NUM
ajlm-2099	32	45	international	international	ADJ
ajlm-2099	32	46	recommendations	recommendation	NOUN
ajlm-2099	32	47	for	for	ADP
ajlm-2099	32	48	anca	anca	NOUN
ajlm-2099	32	49	detection.22	detection.22	NOUN
ajlm-2099	32	50	this	this	DET
ajlm-2099	32	51	guideline	guideline	NOUN
ajlm-2099	32	52	advises	advise	VERB
ajlm-2099	32	53	the	the	DET
ajlm-2099	32	54	use	use	NOUN
ajlm-2099	32	55	of	of	ADP
ajlm-2099	32	56	an	an	DET
ajlm-2099	32	57	antigen	antigen	NOUN
ajlm-2099	32	58	-	-	PUNCT
ajlm-2099	32	59	specific	specific	ADJ
ajlm-2099	32	60	assay	assay	NOUN
ajlm-2099	32	61	to	to	PART
ajlm-2099	32	62	confirm	confirm	VERB
ajlm-2099	32	63	a	a	DET
ajlm-2099	32	64	positive	positive	ADJ
ajlm-2099	32	65	iif	iif	PROPN
ajlm-2099	32	66	test	test	NOUN
ajlm-2099	32	67	.	.	PUNCT
ajlm-2099	33	1	however	however	ADV
ajlm-2099	33	2	,	,	PUNCT
ajlm-2099	33	3	the	the	DET
ajlm-2099	33	4	revised	revise	VERB
ajlm-2099	33	5	2017	2017	NUM
ajlm-2099	33	6	international	international	ADJ
ajlm-2099	33	7	consensus	consensus	NOUN
ajlm-2099	33	8	of	of	ADP
ajlm-2099	33	9	anca	anca	PROPN
ajlm-2099	33	10	testing23	testing23	PROPN
ajlm-2099	33	11	stated	state	VERB
ajlm-2099	33	12	that	that	SCONJ
ajlm-2099	33	13	the	the	DET
ajlm-2099	33	14	combined	combined	ADJ
ajlm-2099	33	15	use	use	NOUN
ajlm-2099	33	16	of	of	ADP
ajlm-2099	33	17	both	both	CCONJ
ajlm-2099	33	18	iif	iif	PROPN
ajlm-2099	33	19	and	and	CCONJ
ajlm-2099	33	20	antigen	antigen	NOUN
ajlm-2099	33	21	-	-	PUNCT
ajlm-2099	33	22	specific	specific	ADJ
ajlm-2099	33	23	immunoassays	immunoassay	NOUN
ajlm-2099	33	24	is	be	AUX
ajlm-2099	33	25	not	not	PART
ajlm-2099	33	26	necessary	necessary	ADJ
ajlm-2099	33	27	.	.	PUNCT
ajlm-2099	34	1	specifically	specifically	ADV
ajlm-2099	34	2	,	,	PUNCT
ajlm-2099	34	3	a	a	DET
ajlm-2099	34	4	high	high	ADJ
ajlm-2099	34	5	-	-	PUNCT
ajlm-2099	34	6	quality	quality	NOUN
ajlm-2099	34	7	antigen	antigen	NOUN
ajlm-2099	34	8	-	-	PUNCT
ajlm-2099	34	9	specific	specific	ADJ
ajlm-2099	34	10	immunoassay	immunoassay	NOUN
ajlm-2099	34	11	is	be	AUX
ajlm-2099	34	12	sufficient	sufficient	ADJ
ajlm-2099	34	13	and	and	CCONJ
ajlm-2099	34	14	does	do	AUX
ajlm-2099	34	15	not	not	PART
ajlm-2099	34	16	need	need	VERB
ajlm-2099	34	17	iif	iif	PROPN
ajlm-2099	34	18	confirmation.24,25	confirmation.24,25	VERB
ajlm-2099	34	19	international	international	ADJ
ajlm-2099	34	20	guidelines	guideline	NOUN
ajlm-2099	34	21	and	and	CCONJ
ajlm-2099	34	22	recommendations	recommendation	NOUN
ajlm-2099	34	23	have	have	AUX
ajlm-2099	34	24	emphasised	emphasise	VERB
ajlm-2099	34	25	the	the	DET
ajlm-2099	34	26	roles	role	NOUN
ajlm-2099	34	27	of	of	ADP
ajlm-2099	34	28	anti	anti	ADJ
ajlm-2099	34	29	-	-	ADJ
ajlm-2099	34	30	dsdna	dsdna	ADJ
ajlm-2099	34	31	and	and	CCONJ
ajlm-2099	34	32	anca	anca	NOUN
ajlm-2099	34	33	in	in	ADP
ajlm-2099	34	34	the	the	DET
ajlm-2099	34	35	diagnosis	diagnosis	NOUN
ajlm-2099	34	36	and	and	CCONJ
ajlm-2099	34	37	follow	follow	VERB
ajlm-2099	34	38	-	-	PUNCT
ajlm-2099	34	39	up	up	NOUN
ajlm-2099	34	40	of	of	ADP
ajlm-2099	34	41	autoimmune	autoimmune	ADJ
ajlm-2099	34	42	rheumatic	rheumatic	ADJ
ajlm-2099	34	43	diseases	disease	NOUN
ajlm-2099	34	44	and	and	CCONJ
ajlm-2099	34	45	vasculitic	vasculitic	ADJ
ajlm-2099	34	46	disorders.15,23	disorders.15,23	NOUN
ajlm-2099	34	47	with	with	ADP
ajlm-2099	34	48	this	this	DET
ajlm-2099	34	49	study	study	NOUN
ajlm-2099	34	50	,	,	PUNCT
ajlm-2099	34	51	therefore	therefore	ADV
ajlm-2099	34	52	,	,	PUNCT
ajlm-2099	34	53	we	we	PRON
ajlm-2099	34	54	aimed	aim	VERB
ajlm-2099	34	55	to	to	PART
ajlm-2099	34	56	assess	assess	VERB
ajlm-2099	34	57	the	the	DET
ajlm-2099	34	58	performance	performance	NOUN
ajlm-2099	34	59	of	of	ADP
ajlm-2099	34	60	the	the	DET
ajlm-2099	34	61	athena	athena	PROPN
ajlm-2099	34	62	multi	multi	PROPN
ajlm-2099	34	63	-	-	ADJ
ajlm-2099	34	64	lyte	lyte	ADJ
ajlm-2099	34	65	®	®	NOUN
ajlm-2099	34	66	test	test	NOUN
ajlm-2099	34	67	systems	system	NOUN
ajlm-2099	34	68	for	for	ADP
ajlm-2099	34	69	the	the	DET
ajlm-2099	34	70	detection	detection	NOUN
ajlm-2099	34	71	of	of	ADP
ajlm-2099	34	72	these	these	DET
ajlm-2099	34	73	antibodies	antibody	NOUN
ajlm-2099	34	74	.	.	PUNCT
ajlm-2099	35	1	methods	method	NOUN
ajlm-2099	35	2	ethical	ethical	ADJ
ajlm-2099	35	3	considerations	consideration	NOUN
ajlm-2099	35	4	ethical	ethical	ADJ
ajlm-2099	35	5	approval	approval	NOUN
ajlm-2099	35	6	for	for	ADP
ajlm-2099	35	7	this	this	DET
ajlm-2099	35	8	study	study	NOUN
ajlm-2099	35	9	was	be	AUX
ajlm-2099	35	10	obtained	obtain	VERB
ajlm-2099	35	11	from	from	ADP
ajlm-2099	35	12	the	the	DET
ajlm-2099	35	13	zagazig	zagazig	PROPN
ajlm-2099	35	14	university	university	PROPN
ajlm-2099	35	15	-	-	PUNCT
ajlm-2099	35	16	institutional	institutional	ADJ
ajlm-2099	35	17	research	research	NOUN
ajlm-2099	35	18	board	board	NOUN
ajlm-2099	35	19	(	(	PUNCT
ajlm-2099	35	20	zu	zu	NOUN
ajlm-2099	35	21	-	-	PUNCT
ajlm-2099	35	22	irb	irb	NOUN
ajlm-2099	35	23	)	)	PUNCT
ajlm-2099	35	24	(	(	PUNCT
ajlm-2099	35	25	approval	approval	NOUN
ajlm-2099	35	26	number	number	NOUN
ajlm-2099	35	27	:	:	PUNCT
ajlm-2099	35	28	5926	5926	NUM
ajlm-2099	35	29	)	)	PUNCT
ajlm-2099	35	30	.	.	PUNCT
ajlm-2099	36	1	written	write	VERB
ajlm-2099	36	2	informed	informed	ADJ
ajlm-2099	36	3	consent	consent	NOUN
ajlm-2099	36	4	was	be	AUX
ajlm-2099	36	5	obtained	obtain	VERB
ajlm-2099	36	6	from	from	ADP
ajlm-2099	36	7	participants	participant	NOUN
ajlm-2099	36	8	and	and	CCONJ
ajlm-2099	36	9	parents	parent	NOUN
ajlm-2099	36	10	or	or	CCONJ
ajlm-2099	36	11	guardians	guardian	NOUN
ajlm-2099	36	12	of	of	ADP
ajlm-2099	36	13	patients	patient	NOUN
ajlm-2099	36	14	younger	young	ADJ
ajlm-2099	36	15	than	than	ADP
ajlm-2099	36	16	18	18	NUM
ajlm-2099	36	17	years	year	NOUN
ajlm-2099	36	18	.	.	PUNCT
ajlm-2099	37	1	all	all	DET
ajlm-2099	37	2	procedures	procedure	NOUN
ajlm-2099	37	3	were	be	AUX
ajlm-2099	37	4	performed	perform	VERB
ajlm-2099	37	5	according	accord	VERB
ajlm-2099	37	6	to	to	ADP
ajlm-2099	37	7	the	the	DET
ajlm-2099	37	8	principles	principle	NOUN
ajlm-2099	37	9	of	of	ADP
ajlm-2099	37	10	the	the	DET
ajlm-2099	37	11	declaration	declaration	NOUN
ajlm-2099	37	12	of	of	ADP
ajlm-2099	37	13	helsinki.26	helsinki.26	ADJ
ajlm-2099	37	14	patients	patient	NOUN
ajlm-2099	37	15	’	'	PUNCT
ajlm-2099	37	16	files	file	NOUN
ajlm-2099	37	17	and	and	CCONJ
ajlm-2099	37	18	samples	sample	NOUN
ajlm-2099	37	19	were	be	AUX
ajlm-2099	37	20	de	de	ADJ
ajlm-2099	37	21	-	-	VERB
ajlm-2099	37	22	identified	identify	VERB
ajlm-2099	37	23	and	and	CCONJ
ajlm-2099	37	24	coded	code	VERB
ajlm-2099	37	25	,	,	PUNCT
ajlm-2099	37	26	and	and	CCONJ
ajlm-2099	37	27	all	all	DET
ajlm-2099	37	28	laboratory	laboratory	NOUN
ajlm-2099	37	29	members	member	NOUN
ajlm-2099	37	30	were	be	AUX
ajlm-2099	37	31	blinded	blind	VERB
ajlm-2099	37	32	to	to	ADP
ajlm-2099	37	33	the	the	DET
ajlm-2099	37	34	participants	participant	NOUN
ajlm-2099	37	35	’	'	PUNCT
ajlm-2099	37	36	data	datum	NOUN
ajlm-2099	37	37	.	.	PUNCT
ajlm-2099	38	1	study	study	NOUN
ajlm-2099	38	2	population	population	NOUN
ajlm-2099	38	3	this	this	DET
ajlm-2099	38	4	study	study	NOUN
ajlm-2099	38	5	was	be	AUX
ajlm-2099	38	6	conducted	conduct	VERB
ajlm-2099	38	7	in	in	ADP
ajlm-2099	38	8	the	the	DET
ajlm-2099	38	9	clinical	clinical	ADJ
ajlm-2099	38	10	pathology	pathology	NOUN
ajlm-2099	38	11	department	department	NOUN
ajlm-2099	38	12	of	of	ADP
ajlm-2099	38	13	the	the	DET
ajlm-2099	38	14	faculty	faculty	NOUN
ajlm-2099	38	15	of	of	ADP
ajlm-2099	38	16	medicine	medicine	NOUN
ajlm-2099	38	17	at	at	ADP
ajlm-2099	38	18	zagazig	zagazig	PROPN
ajlm-2099	38	19	university	university	PROPN
ajlm-2099	38	20	,	,	PUNCT
ajlm-2099	38	21	zagazig	zagazig	PROPN
ajlm-2099	38	22	,	,	PUNCT
ajlm-2099	38	23	al	al	PROPN
ajlm-2099	38	24	sharqia	sharqia	PROPN
ajlm-2099	38	25	,	,	PUNCT
ajlm-2099	38	26	egypt	egypt	PROPN
ajlm-2099	38	27	,	,	PUNCT
ajlm-2099	38	28	from	from	ADP
ajlm-2099	38	29	may	may	PROPN
ajlm-2099	38	30	2020	2020	NUM
ajlm-2099	38	31	to	to	ADP
ajlm-2099	38	32	april	april	PROPN
ajlm-2099	38	33	2022	2022	NUM
ajlm-2099	38	34	.	.	PUNCT
ajlm-2099	39	1	all	all	DET
ajlm-2099	39	2	participants	participant	NOUN
ajlm-2099	39	3	were	be	AUX
ajlm-2099	39	4	of	of	ADP
ajlm-2099	39	5	the	the	DET
ajlm-2099	39	6	same	same	ADJ
ajlm-2099	39	7	ethnicity	ethnicity	NOUN
ajlm-2099	39	8	.	.	PUNCT
ajlm-2099	40	1	the	the	DET
ajlm-2099	40	2	required	require	VERB
ajlm-2099	40	3	sample	sample	NOUN
ajlm-2099	40	4	sizes	size	NOUN
ajlm-2099	40	5	were	be	AUX
ajlm-2099	40	6	calculated	calculate	VERB
ajlm-2099	40	7	using	use	VERB
ajlm-2099	40	8	the	the	DET
ajlm-2099	40	9	openepi	openepi	PROPN
ajlm-2099	40	10	program	program	NOUN
ajlm-2099	40	11	version	version	NOUN
ajlm-2099	40	12	3	3	NUM
ajlm-2099	40	13	(	(	PUNCT
ajlm-2099	40	14	https://www.openepi.com/samplesize/sscc.htm	https://www.openepi.com/samplesize/sscc.htm	PROPN
ajlm-2099	40	15	)	)	PUNCT
ajlm-2099	40	16	at	at	ADP
ajlm-2099	40	17	95	95	NUM
ajlm-2099	40	18	%	%	NOUN
ajlm-2099	40	19	confidence	confidence	NOUN
ajlm-2099	40	20	,	,	PUNCT
ajlm-2099	40	21	90	90	NUM
ajlm-2099	40	22	%	%	NOUN
ajlm-2099	40	23	power	power	NOUN
ajlm-2099	40	24	,	,	PUNCT
ajlm-2099	40	25	and	and	CCONJ
ajlm-2099	40	26	a	a	DET
ajlm-2099	40	27	10	10	NUM
ajlm-2099	40	28	%	%	NOUN
ajlm-2099	40	29	dropout	dropout	NOUN
ajlm-2099	40	30	rate.27	rate.27	PROPN
ajlm-2099	40	31	we	we	PRON
ajlm-2099	40	32	assumed	assume	VERB
ajlm-2099	40	33	the	the	DET
ajlm-2099	40	34	anti	anti	ADJ
ajlm-2099	40	35	-	-	ADJ
ajlm-2099	40	36	dsdna	dsdna	ADJ
ajlm-2099	40	37	sensitivity	sensitivity	NOUN
ajlm-2099	40	38	in	in	ADP
ajlm-2099	40	39	sle	sle	PROPN
ajlm-2099	40	40	patients	patient	NOUN
ajlm-2099	40	41	to	to	PART
ajlm-2099	40	42	be	be	AUX
ajlm-2099	40	43	33	33	NUM
ajlm-2099	40	44	%	%	NOUN
ajlm-2099	40	45	and	and	CCONJ
ajlm-2099	40	46	that	that	SCONJ
ajlm-2099	40	47	up	up	ADP
ajlm-2099	40	48	to	to	PART
ajlm-2099	40	49	3	3	NUM
ajlm-2099	40	50	%	%	NOUN
ajlm-2099	40	51	of	of	ADP
ajlm-2099	40	52	healthy	healthy	ADJ
ajlm-2099	40	53	controls	control	NOUN
ajlm-2099	40	54	and	and	CCONJ
ajlm-2099	40	55	6	6	NUM
ajlm-2099	40	56	%	%	NOUN
ajlm-2099	40	57	of	of	ADP
ajlm-2099	40	58	diseased	diseased	ADJ
ajlm-2099	40	59	controls	control	NOUN
ajlm-2099	40	60	can	can	AUX
ajlm-2099	40	61	be	be	AUX
ajlm-2099	40	62	anti	anti	ADJ
ajlm-2099	40	63	-	-	ADJ
ajlm-2099	40	64	dsdna	dsdna	ADJ
ajlm-2099	40	65	positive.15	positive.15	NOUN
ajlm-2099	40	66	we	we	PRON
ajlm-2099	40	67	also	also	ADV
ajlm-2099	40	68	assumed	assume	VERB
ajlm-2099	40	69	an	an	DET
ajlm-2099	40	70	anca	anca	NOUN
ajlm-2099	40	71	sensitivity	sensitivity	NOUN
ajlm-2099	40	72	of	of	ADP
ajlm-2099	40	73	46	46	NUM
ajlm-2099	40	74	%	%	NOUN
ajlm-2099	40	75	in	in	ADP
ajlm-2099	40	76	vasculitis	vasculitis	ADJ
ajlm-2099	40	77	patients	patient	NOUN
ajlm-2099	40	78	and	and	CCONJ
ajlm-2099	40	79	that	that	SCONJ
ajlm-2099	40	80	up	up	ADP
ajlm-2099	40	81	to	to	PART
ajlm-2099	40	82	6	6	NUM
ajlm-2099	40	83	%	%	NOUN
ajlm-2099	40	84	of	of	ADP
ajlm-2099	40	85	healthy	healthy	ADJ
ajlm-2099	40	86	controls	control	NOUN
ajlm-2099	40	87	may	may	AUX
ajlm-2099	40	88	be	be	AUX
ajlm-2099	40	89	anca	anca	NOUN
ajlm-2099	40	90	positive.28	positive.28	NOUN
ajlm-2099	40	91	sera	sera	NOUN
ajlm-2099	40	92	for	for	ADP
ajlm-2099	40	93	anti	anti	ADJ
ajlm-2099	40	94	-	-	ADJ
ajlm-2099	40	95	dsdna	dsdna	ADJ
ajlm-2099	40	96	testing	testing	NOUN
ajlm-2099	40	97	were	be	AUX
ajlm-2099	40	98	collected	collect	VERB
ajlm-2099	40	99	from	from	ADP
ajlm-2099	40	100	170	170	NUM
ajlm-2099	40	101	subjects	subject	NOUN
ajlm-2099	40	102	,	,	PUNCT
ajlm-2099	40	103	including	include	VERB
ajlm-2099	40	104	105	105	NUM
ajlm-2099	40	105	patients	patient	NOUN
ajlm-2099	40	106	who	who	PRON
ajlm-2099	40	107	met	meet	VERB
ajlm-2099	40	108	the	the	DET
ajlm-2099	40	109	revised	revise	VERB
ajlm-2099	40	110	criteria	criterion	NOUN
ajlm-2099	40	111	(	(	PUNCT
ajlm-2099	40	112	european	european	PROPN
ajlm-2099	40	113	league	league	PROPN
ajlm-2099	40	114	against	against	ADP
ajlm-2099	40	115	rheumatism	rheumatism	NOUN
ajlm-2099	40	116	and	and	CCONJ
ajlm-2099	40	117	the	the	DET
ajlm-2099	40	118	american	american	PROPN
ajlm-2099	40	119	college	college	PROPN
ajlm-2099	40	120	of	of	ADP
ajlm-2099	40	121	rheumatology	rheumatology	NOUN
ajlm-2099	40	122	)	)	PUNCT
ajlm-2099	40	123	for	for	ADP
ajlm-2099	40	124	sle	sle	PROPN
ajlm-2099	40	125	classification18	classification18	NOUN
ajlm-2099	40	126	and	and	CCONJ
ajlm-2099	40	127	65	65	NUM
ajlm-2099	40	128	control	control	NOUN
ajlm-2099	40	129	subjects	subject	NOUN
ajlm-2099	40	130	matched	match	VERB
ajlm-2099	40	131	for	for	ADP
ajlm-2099	40	132	age	age	NOUN
ajlm-2099	40	133	and	and	CCONJ
ajlm-2099	40	134	gender	gender	NOUN
ajlm-2099	40	135	.	.	PUNCT
ajlm-2099	41	1	the	the	DET
ajlm-2099	41	2	control	control	NOUN
ajlm-2099	41	3	subjects	subject	NOUN
ajlm-2099	41	4	included	include	VERB
ajlm-2099	41	5	35	35	NUM
ajlm-2099	41	6	patients	patient	NOUN
ajlm-2099	41	7	diagnosed	diagnose	VERB
ajlm-2099	41	8	with	with	ADP
ajlm-2099	41	9	autoimmune	autoimmune	ADJ
ajlm-2099	41	10	diseases	disease	NOUN
ajlm-2099	41	11	other	other	ADJ
ajlm-2099	41	12	than	than	ADP
ajlm-2099	41	13	sle	sle	PROPN
ajlm-2099	41	14	(	(	PUNCT
ajlm-2099	41	15	diseased	diseased	ADJ
ajlm-2099	41	16	controls	control	NOUN
ajlm-2099	41	17	)	)	PUNCT
ajlm-2099	41	18	and	and	CCONJ
ajlm-2099	41	19	30	30	NUM
ajlm-2099	41	20	healthy	healthy	ADJ
ajlm-2099	41	21	participants	participant	NOUN
ajlm-2099	41	22	(	(	PUNCT
ajlm-2099	41	23	healthy	healthy	ADJ
ajlm-2099	41	24	controls	control	NOUN
ajlm-2099	41	25	)	)	PUNCT
ajlm-2099	41	26	.	.	PUNCT
ajlm-2099	42	1	sera	sera	NOUN
ajlm-2099	42	2	for	for	ADP
ajlm-2099	42	3	anca	anca	NOUN
ajlm-2099	42	4	testing	testing	NOUN
ajlm-2099	42	5	were	be	AUX
ajlm-2099	42	6	collected	collect	VERB
ajlm-2099	42	7	from	from	ADP
ajlm-2099	42	8	75	75	NUM
ajlm-2099	42	9	patients	patient	NOUN
ajlm-2099	42	10	with	with	ADP
ajlm-2099	42	11	clinically	clinically	ADV
ajlm-2099	42	12	suspected	suspect	VERB
ajlm-2099	42	13	autoimmune	autoimmune	ADJ
ajlm-2099	42	14	vasculitis	vasculitis	PROPN
ajlm-2099	42	15	(	(	PUNCT
ajlm-2099	42	16	aiv	aiv	PROPN
ajlm-2099	42	17	)	)	PUNCT
ajlm-2099	42	18	and	and	CCONJ
ajlm-2099	42	19	25	25	NUM
ajlm-2099	42	20	healthy	healthy	ADJ
ajlm-2099	42	21	volunteers	volunteer	NOUN
ajlm-2099	42	22	matched	match	VERB
ajlm-2099	42	23	for	for	ADP
ajlm-2099	42	24	age	age	NOUN
ajlm-2099	42	25	and	and	CCONJ
ajlm-2099	42	26	gender	gender	NOUN
ajlm-2099	42	27	(	(	PUNCT
ajlm-2099	42	28	control	control	NOUN
ajlm-2099	42	29	group	group	NOUN
ajlm-2099	42	30	)	)	PUNCT
ajlm-2099	42	31	.	.	PUNCT
ajlm-2099	43	1	individuals	individual	NOUN
ajlm-2099	43	2	who	who	PRON
ajlm-2099	43	3	were	be	AUX
ajlm-2099	43	4	pregnant	pregnant	ADJ
ajlm-2099	43	5	,	,	PUNCT
ajlm-2099	43	6	had	have	VERB
ajlm-2099	43	7	a	a	DET
ajlm-2099	43	8	severe	severe	ADJ
ajlm-2099	43	9	infection	infection	NOUN
ajlm-2099	43	10	or	or	CCONJ
ajlm-2099	43	11	systemic	systemic	ADJ
ajlm-2099	43	12	disease,29	disease,29	NOUN
ajlm-2099	43	13	or	or	CCONJ
ajlm-2099	43	14	refused	refuse	VERB
ajlm-2099	43	15	to	to	PART
ajlm-2099	43	16	sign	sign	VERB
ajlm-2099	43	17	the	the	DET
ajlm-2099	43	18	informed	informed	ADJ
ajlm-2099	43	19	consent	consent	NOUN
ajlm-2099	43	20	were	be	AUX
ajlm-2099	43	21	excluded	exclude	VERB
ajlm-2099	43	22	from	from	ADP
ajlm-2099	43	23	the	the	DET
ajlm-2099	43	24	study	study	NOUN
ajlm-2099	43	25	.	.	PUNCT
ajlm-2099	44	1	personal	personal	ADJ
ajlm-2099	44	2	data	datum	NOUN
ajlm-2099	44	3	(	(	PUNCT
ajlm-2099	44	4	age	age	NOUN
ajlm-2099	44	5	,	,	PUNCT
ajlm-2099	44	6	gender	gender	NOUN
ajlm-2099	44	7	,	,	PUNCT
ajlm-2099	44	8	ethnicity	ethnicity	NOUN
ajlm-2099	44	9	)	)	PUNCT
ajlm-2099	44	10	and	and	CCONJ
ajlm-2099	44	11	medical	medical	ADJ
ajlm-2099	44	12	data	datum	NOUN
ajlm-2099	44	13	were	be	AUX
ajlm-2099	44	14	collected	collect	VERB
ajlm-2099	44	15	from	from	ADP
ajlm-2099	44	16	patients	patient	NOUN
ajlm-2099	44	17	’	'	PUNCT
ajlm-2099	44	18	files	file	NOUN
ajlm-2099	44	19	retrieved	retrieve	VERB
ajlm-2099	44	20	from	from	ADP
ajlm-2099	44	21	the	the	DET
ajlm-2099	44	22	rheumatology	rheumatology	NOUN
ajlm-2099	44	23	department	department	NOUN
ajlm-2099	44	24	after	after	ADP
ajlm-2099	44	25	obtaining	obtain	VERB
ajlm-2099	44	26	the	the	DET
ajlm-2099	44	27	required	required	ADJ
ajlm-2099	44	28	permissions	permission	NOUN
ajlm-2099	44	29	.	.	PUNCT
ajlm-2099	45	1	for	for	ADP
ajlm-2099	45	2	the	the	DET
ajlm-2099	45	3	diseased	diseased	ADJ
ajlm-2099	45	4	control	control	NOUN
ajlm-2099	45	5	group	group	NOUN
ajlm-2099	45	6	,	,	PUNCT
ajlm-2099	45	7	the	the	DET
ajlm-2099	45	8	disease	disease	NOUN
ajlm-2099	45	9	diagnosis	diagnosis	NOUN
ajlm-2099	45	10	was	be	AUX
ajlm-2099	45	11	confirmed	confirm	VERB
ajlm-2099	45	12	clinically	clinically	ADV
ajlm-2099	45	13	and	and	CCONJ
ajlm-2099	45	14	by	by	ADP
ajlm-2099	45	15	the	the	DET
ajlm-2099	45	16	presence	presence	NOUN
ajlm-2099	45	17	of	of	ADP
ajlm-2099	45	18	specific	specific	ADJ
ajlm-2099	45	19	autoantibodies	autoantibody	NOUN
ajlm-2099	45	20	.	.	PUNCT
ajlm-2099	46	1	serum	serum	NOUN
ajlm-2099	46	2	rheumatoid	rheumatoid	NOUN
ajlm-2099	46	3	factor	factor	NOUN
ajlm-2099	46	4	and	and	CCONJ
ajlm-2099	46	5	anti	anti	ADJ
ajlm-2099	46	6	-	-	ADJ
ajlm-2099	46	7	ccp	ccp	PROPN
ajlm-2099	46	8	measured	measure	VERB
ajlm-2099	46	9	using	use	VERB
ajlm-2099	46	10	the	the	DET
ajlm-2099	46	11	cobas	cobas	ADJ
ajlm-2099	46	12	6000	6000	NUM
ajlm-2099	46	13	autoanalyzer	autoanalyzer	NOUN
ajlm-2099	46	14	(	(	PUNCT
ajlm-2099	46	15	roche	roche	NOUN
ajlm-2099	46	16	diagnostics	diagnostic	NOUN
ajlm-2099	46	17	,	,	PUNCT
ajlm-2099	46	18	forrenstrasse	forrenstrasse	NOUN
ajlm-2099	46	19	,	,	PUNCT
ajlm-2099	46	20	rotkreuz	rotkreuz	PROPN
ajlm-2099	46	21	,	,	PUNCT
ajlm-2099	46	22	switzerland	switzerland	PROPN
ajlm-2099	46	23	)	)	PUNCT
ajlm-2099	46	24	were	be	AUX
ajlm-2099	46	25	used	use	VERB
ajlm-2099	46	26	to	to	PART
ajlm-2099	46	27	confirm	confirm	VERB
ajlm-2099	46	28	rheumatoid	rheumatoid	VERB
ajlm-2099	46	29	arthritis	arthritis	NOUN
ajlm-2099	46	30	.	.	PUNCT
ajlm-2099	47	1	using	use	VERB
ajlm-2099	47	2	the	the	DET
ajlm-2099	47	3	anti	anti	ADJ
ajlm-2099	47	4	-	-	ADJ
ajlm-2099	47	5	nuclear	nuclear	ADJ
ajlm-2099	47	6	antibodies	antibody	NOUN
ajlm-2099	47	7	profile	profile	VERB
ajlm-2099	47	8	3	3	NUM
ajlm-2099	47	9	immunoglobulin	immunoglobulin	NOUN
ajlm-2099	47	10	g	g	PROPN
ajlm-2099	47	11	(	(	PUNCT
ajlm-2099	47	12	igg	igg	PROPN
ajlm-2099	47	13	)	)	PUNCT
ajlm-2099	47	14	euroline	euroline	NOUN
ajlm-2099	47	15	immunoblot	immunoblot	NOUN
ajlm-2099	47	16	assay	assay	PROPN
ajlm-2099	47	17	(	(	PUNCT
ajlm-2099	47	18	euroimmun	euroimmun	NOUN
ajlm-2099	47	19	,	,	PUNCT
ajlm-2099	47	20	seekamp	seekamp	NOUN
ajlm-2099	47	21	,	,	PUNCT
ajlm-2099	47	22	lübeck	lübeck	PROPN
ajlm-2099	47	23	,	,	PUNCT
ajlm-2099	47	24	germany	germany	PROPN
ajlm-2099	47	25	)	)	PUNCT
ajlm-2099	47	26	,	,	PUNCT
ajlm-2099	47	27	we	we	PRON
ajlm-2099	47	28	measured	measure	VERB
ajlm-2099	47	29	anti	anti	ADJ
ajlm-2099	47	30	-	-	ADJ
ajlm-2099	47	31	sjögren’s	sjögren’s	NOUN
ajlm-2099	47	32	-	-	PUNCT
ajlm-2099	47	33	syndrome	syndrome	NOUN
ajlm-2099	47	34	-	-	PUNCT
ajlm-2099	47	35	related	relate	VERB
ajlm-2099	47	36	antigen	antigen	NOUN
ajlm-2099	47	37	a	a	DET
ajlm-2099	47	38	and	and	CCONJ
ajlm-2099	47	39	anti	anti	ADJ
ajlm-2099	47	40	-	-	ADJ
ajlm-2099	47	41	sjögren’s	sjögren’s	NOUN
ajlm-2099	47	42	-	-	PUNCT
ajlm-2099	47	43	syndrome	syndrome	NOUN
ajlm-2099	47	44	-	-	PUNCT
ajlm-2099	47	45	related	relate	VERB
ajlm-2099	47	46	antigen	antigen	NOUN
ajlm-2099	47	47	b	b	NOUN
ajlm-2099	47	48	for	for	ADP
ajlm-2099	47	49	primary	primary	ADJ
ajlm-2099	47	50	sjögrens	sjögren	NOUN
ajlm-2099	47	51	’	’	PART
ajlm-2099	47	52	syndrome	syndrome	NOUN
ajlm-2099	47	53	diagnosis	diagnosis	NOUN
ajlm-2099	47	54	,	,	PUNCT
ajlm-2099	47	55	anti	anti	ADJ
ajlm-2099	47	56	-	-	ADJ
ajlm-2099	47	57	scl70	scl70	ADJ
ajlm-2099	47	58	for	for	ADP
ajlm-2099	47	59	systemic	systemic	ADJ
ajlm-2099	47	60	sclerosis	sclerosis	NOUN
ajlm-2099	47	61	diagnosis	diagnosis	NOUN
ajlm-2099	47	62	,	,	PUNCT
ajlm-2099	47	63	and	and	CCONJ
ajlm-2099	47	64	anti	anti	ADJ
ajlm-2099	47	65	-	-	ADJ
ajlm-2099	47	66	jo1	jo1	NOUN
ajlm-2099	47	67	and	and	CCONJ
ajlm-2099	47	68	anti	anti	ADJ
ajlm-2099	47	69	-	-	ADJ
ajlm-2099	47	70	pm	pm	ADJ
ajlm-2099	47	71	/	/	SYM
ajlm-2099	47	72	scl100	scl100	NOUN
ajlm-2099	47	73	for	for	ADP
ajlm-2099	47	74	polymyositis	polymyositis	NOUN
ajlm-2099	47	75	diagnosis	diagnosis	NOUN
ajlm-2099	47	76	.	.	PUNCT
ajlm-2099	48	1	sample	sample	NOUN
ajlm-2099	48	2	collection	collection	NOUN
ajlm-2099	48	3	two	two	NUM
ajlm-2099	48	4	millilitres	millilitre	NOUN
ajlm-2099	48	5	of	of	ADP
ajlm-2099	48	6	whole	whole	ADJ
ajlm-2099	48	7	blood	blood	NOUN
ajlm-2099	48	8	were	be	AUX
ajlm-2099	48	9	collected	collect	VERB
ajlm-2099	48	10	from	from	ADP
ajlm-2099	48	11	each	each	DET
ajlm-2099	48	12	patient	patient	NOUN
ajlm-2099	48	13	at	at	ADP
ajlm-2099	48	14	the	the	DET
ajlm-2099	48	15	time	time	NOUN
ajlm-2099	48	16	of	of	ADP
ajlm-2099	48	17	diagnosis	diagnosis	NOUN
ajlm-2099	48	18	.	.	PUNCT
ajlm-2099	49	1	the	the	DET
ajlm-2099	49	2	blood	blood	NOUN
ajlm-2099	49	3	samples	sample	NOUN
ajlm-2099	49	4	were	be	AUX
ajlm-2099	49	5	left	leave	VERB
ajlm-2099	49	6	to	to	PART
ajlm-2099	49	7	clot	clot	VERB
ajlm-2099	49	8	at	at	ADP
ajlm-2099	49	9	room	room	NOUN
ajlm-2099	49	10	temperature	temperature	NOUN
ajlm-2099	49	11	for	for	ADP
ajlm-2099	49	12	15	15	NUM
ajlm-2099	49	13	min	min	NOUN
ajlm-2099	49	14	–	–	PUNCT
ajlm-2099	49	15	30	30	NUM
ajlm-2099	49	16	min	min	NOUN
ajlm-2099	49	17	and	and	CCONJ
ajlm-2099	49	18	then	then	ADV
ajlm-2099	49	19	centrifuged	centrifuge	VERB
ajlm-2099	49	20	at	at	ADP
ajlm-2099	49	21	1000−2000	1000−2000	NUM
ajlm-2099	49	22	×	×	NOUN
ajlm-2099	49	23	g	g	NOUN
ajlm-2099	49	24	for	for	ADP
ajlm-2099	49	25	10	10	NUM
ajlm-2099	49	26	min	min	NOUN
ajlm-2099	49	27	.	.	PROPN
ajlm-2099	49	28	sera	sera	PROPN
ajlm-2099	49	29	were	be	AUX
ajlm-2099	49	30	separated	separate	VERB
ajlm-2099	49	31	and	and	CCONJ
ajlm-2099	49	32	stored	store	VERB
ajlm-2099	49	33	at	at	ADP
ajlm-2099	49	34	−80	−80	PROPN
ajlm-2099	49	35	°	°	ADP
ajlm-2099	49	36	c	c	NOUN
ajlm-2099	49	37	prior	prior	ADV
ajlm-2099	49	38	to	to	ADP
ajlm-2099	49	39	use	use	NOUN
ajlm-2099	49	40	.	.	PUNCT
ajlm-2099	50	1	multiplex	multiplex	PROPN
ajlm-2099	50	2	microbead	microbead	PROPN
ajlm-2099	50	3	-	-	PUNCT
ajlm-2099	50	4	based	base	VERB
ajlm-2099	50	5	immunoassay	immunoassay	PROPN
ajlm-2099	50	6	the	the	DET
ajlm-2099	50	7	athena	athena	PROPN
ajlm-2099	50	8	multi	multi	PROPN
ajlm-2099	50	9	-	-	PROPN
ajlm-2099	50	10	lyte	lyte	ADJ
ajlm-2099	50	11	ana	ana	PROPN
ajlm-2099	50	12	-	-	PUNCT
ajlm-2099	50	13	ii	ii	PROPN
ajlm-2099	50	14	plus	plus	CCONJ
ajlm-2099	50	15	test	test	NOUN
ajlm-2099	50	16	system	system	NOUN
ajlm-2099	50	17	(	(	PUNCT
ajlm-2099	50	18	zeus	zeus	PROPN
ajlm-2099	50	19	scientific	scientific	PROPN
ajlm-2099	50	20	,	,	PUNCT
ajlm-2099	50	21	evans	evans	PROPN
ajlm-2099	50	22	way	way	PROPN
ajlm-2099	50	23	,	,	PUNCT
ajlm-2099	50	24	branchburg	branchburg	PROPN
ajlm-2099	50	25	,	,	PUNCT
ajlm-2099	50	26	new	new	PROPN
ajlm-2099	50	27	jersey	jersey	PROPN
ajlm-2099	50	28	,	,	PUNCT
ajlm-2099	50	29	united	united	PROPN
ajlm-2099	50	30	states	states	PROPN
ajlm-2099	50	31	)	)	PUNCT
ajlm-2099	50	32	was	be	AUX
ajlm-2099	50	33	used	use	VERB
ajlm-2099	50	34	for	for	ADP
ajlm-2099	50	35	the	the	DET
ajlm-2099	50	36	quantitative	quantitative	ADJ
ajlm-2099	50	37	detection	detection	NOUN
ajlm-2099	50	38	of	of	ADP
ajlm-2099	50	39	igg	igg	NOUN
ajlm-2099	50	40	-	-	PUNCT
ajlm-2099	50	41	class	class	NOUN
ajlm-2099	50	42	anti	anti	ADJ
ajlm-2099	50	43	-	-	ADJ
ajlm-2099	50	44	dsdna	dsdna	ADJ
ajlm-2099	50	45	,	,	PUNCT
ajlm-2099	50	46	the	the	DET
ajlm-2099	50	47	qualitative	qualitative	ADJ
ajlm-2099	50	48	detection	detection	NOUN
ajlm-2099	50	49	of	of	ADP
ajlm-2099	50	50	igg	igg	NOUN
ajlm-2099	50	51	-	-	PUNCT
ajlm-2099	50	52	class	class	NOUN
ajlm-2099	50	53	anti	anti	ADJ
ajlm-2099	50	54	-	-	ADJ
ajlm-2099	50	55	nuclear	nuclear	ADJ
ajlm-2099	50	56	antibodies	antibody	NOUN
ajlm-2099	50	57	,	,	PUNCT
ajlm-2099	50	58	and	and	CCONJ
ajlm-2099	50	59	the	the	DET
ajlm-2099	50	60	semi	semi	ADJ
ajlm-2099	50	61	-	-	ADJ
ajlm-2099	50	62	quantitative	quantitative	ADJ
ajlm-2099	50	63	detection	detection	NOUN
ajlm-2099	50	64	of	of	ADP
ajlm-2099	50	65	igg	igg	PROPN
ajlm-2099	50	66	-	-	PUNCT
ajlm-2099	50	67	class	class	NOUN
ajlm-2099	50	68	antibodies	antibodie	VERB
ajlm-2099	50	69	specific	specific	ADJ
ajlm-2099	50	70	for	for	ADP
ajlm-2099	50	71	eight	eight	NUM
ajlm-2099	50	72	different	different	ADJ
ajlm-2099	50	73	nuclear	nuclear	ADJ
ajlm-2099	50	74	antigens	antigen	NOUN
ajlm-2099	50	75	(	(	PUNCT
ajlm-2099	50	76	sjögren’s	sjögren’s	NOUN
ajlm-2099	50	77	-	-	PUNCT
ajlm-2099	50	78	syndrome	syndrome	NOUN
ajlm-2099	50	79	-	-	PUNCT
ajlm-2099	50	80	related	relate	VERB
ajlm-2099	50	81	antigen	antigen	NOUN
ajlm-2099	50	82	a	a	PRON
ajlm-2099	50	83	,	,	PUNCT
ajlm-2099	50	84	sjögren’s	sjögren’s	NOUN
ajlm-2099	50	85	-	-	PUNCT
ajlm-2099	50	86	syndrome	syndrome	NOUN
ajlm-2099	50	87	-	-	PUNCT
ajlm-2099	50	88	related	relate	VERB
ajlm-2099	50	89	antigen	antigen	ADJ
ajlm-2099	50	90	b	b	NOUN
ajlm-2099	50	91	,	,	PUNCT
ajlm-2099	50	92	sm	sm	PROPN
ajlm-2099	50	93	,	,	PUNCT
ajlm-2099	50	94	rnp	rnp	PROPN
ajlm-2099	50	95	,	,	PUNCT
ajlm-2099	50	96	scl-70	scl-70	PROPN
ajlm-2099	50	97	,	,	PUNCT
ajlm-2099	50	98	jo-1	jo-1	PROPN
ajlm-2099	50	99	,	,	PUNCT
ajlm-2099	50	100	centromere	centromere	NOUN
ajlm-2099	50	101	b	b	NOUN
ajlm-2099	50	102	,	,	PUNCT
ajlm-2099	50	103	and	and	CCONJ
ajlm-2099	50	104	histone	histone	NOUN
ajlm-2099	50	105	)	)	PUNCT
ajlm-2099	50	106	in	in	ADP
ajlm-2099	50	107	the	the	DET
ajlm-2099	50	108	sera	sera	NOUN
ajlm-2099	50	109	of	of	ADP
ajlm-2099	50	110	enrolled	enrol	VERB
ajlm-2099	50	111	subjects	subject	NOUN
ajlm-2099	50	112	.	.	PUNCT
ajlm-2099	51	1	the	the	DET
ajlm-2099	51	2	athena	athena	PROPN
ajlm-2099	51	3	multi	multi	PROPN
ajlm-2099	51	4	-	-	ADJ
ajlm-2099	51	5	lyte	lyte	ADJ
ajlm-2099	51	6	aiv	aiv	PROPN
ajlm-2099	51	7	plus	plus	CCONJ
ajlm-2099	51	8	test	test	NOUN
ajlm-2099	51	9	system	system	NOUN
ajlm-2099	51	10	(	(	PUNCT
ajlm-2099	51	11	zeus	zeus	PROPN
ajlm-2099	51	12	scientific	scientific	PROPN
ajlm-2099	51	13	,	,	PUNCT
ajlm-2099	51	14	evans	evans	PROPN
ajlm-2099	51	15	way	way	PROPN
ajlm-2099	51	16	,	,	PUNCT
ajlm-2099	51	17	branchburg	branchburg	PROPN
ajlm-2099	51	18	,	,	PUNCT
ajlm-2099	51	19	new	new	PROPN
ajlm-2099	51	20	jersey	jersey	PROPN
ajlm-2099	51	21	,	,	PUNCT
ajlm-2099	51	22	united	united	PROPN
ajlm-2099	51	23	states	states	PROPN
ajlm-2099	51	24	)	)	PUNCT
ajlm-2099	51	25	was	be	AUX
ajlm-2099	51	26	used	use	VERB
ajlm-2099	51	27	for	for	ADP
ajlm-2099	51	28	the	the	DET
ajlm-2099	51	29	semi	semi	ADJ
ajlm-2099	51	30	-	-	ADJ
ajlm-2099	51	31	quantitative	quantitative	ADJ
ajlm-2099	51	32	and	and	CCONJ
ajlm-2099	51	33	qualitative	qualitative	ADJ
ajlm-2099	51	34	detection	detection	NOUN
ajlm-2099	51	35	of	of	ADP
ajlm-2099	51	36	igg	igg	PROPN
ajlm-2099	51	37	-	-	PUNCT
ajlm-2099	51	38	class	class	NOUN
ajlm-2099	51	39	antibodies	antibodie	VERB
ajlm-2099	51	40	specific	specific	ADJ
ajlm-2099	51	41	for	for	ADP
ajlm-2099	51	42	three	three	NUM
ajlm-2099	51	43	analytes	analyte	NOUN
ajlm-2099	51	44	(	(	PUNCT
ajlm-2099	51	45	myeloperoxidase	myeloperoxidase	NOUN
ajlm-2099	51	46	,	,	PUNCT
ajlm-2099	51	47	proteinase	proteinase	NOUN
ajlm-2099	51	48	3	3	NUM
ajlm-2099	51	49	,	,	PUNCT
ajlm-2099	51	50	and	and	CCONJ
ajlm-2099	51	51	glomerular	glomerular	ADJ
ajlm-2099	51	52	basement	basement	NOUN
ajlm-2099	51	53	membrane	membrane	NOUN
ajlm-2099	51	54	)	)	PUNCT
ajlm-2099	51	55	in	in	ADP
ajlm-2099	51	56	the	the	DET
ajlm-2099	51	57	sera	sera	NOUN
ajlm-2099	51	58	of	of	ADP
ajlm-2099	51	59	enrolled	enrol	VERB
ajlm-2099	51	60	subjects	subject	NOUN
ajlm-2099	51	61	.	.	PUNCT
ajlm-2099	52	1	results	result	NOUN
ajlm-2099	52	2	>	>	X
ajlm-2099	52	3	120	120	NUM
ajlm-2099	52	4	international	international	ADJ
ajlm-2099	52	5	units	unit	NOUN
ajlm-2099	52	6	/	/	SYM
ajlm-2099	52	7	ml	ml	NOUN
ajlm-2099	52	8	were	be	AUX
ajlm-2099	52	9	considered	consider	VERB
ajlm-2099	52	10	positive	positive	ADJ
ajlm-2099	52	11	.	.	PUNCT
ajlm-2099	53	1	the	the	DET
ajlm-2099	53	2	microsphere	microsphere	NOUN
ajlm-2099	53	3	suspension	suspension	NOUN
ajlm-2099	53	4	was	be	AUX
ajlm-2099	53	5	prepared	prepare	VERB
ajlm-2099	53	6	according	accord	VERB
ajlm-2099	53	7	to	to	ADP
ajlm-2099	53	8	the	the	DET
ajlm-2099	53	9	manufacturer	manufacturer	NOUN
ajlm-2099	53	10	’s	’s	PART
ajlm-2099	53	11	instructions	instruction	NOUN
ajlm-2099	53	12	and	and	CCONJ
ajlm-2099	53	13	analysed	analyse	VERB
ajlm-2099	53	14	using	use	VERB
ajlm-2099	53	15	the	the	DET
ajlm-2099	53	16	luminex200	luminex200	PROPN
ajlm-2099	53	17	platform	platform	NOUN
ajlm-2099	53	18	(	(	PUNCT
ajlm-2099	53	19	a	a	DET
ajlm-2099	53	20	diasorin	diasorin	NOUN
ajlm-2099	53	21	company	company	NOUN
ajlm-2099	53	22	,	,	PUNCT
ajlm-2099	53	23	technology	technology	NOUN
ajlm-2099	53	24	boulevard	boulevard	NOUN
ajlm-2099	53	25	,	,	PUNCT
ajlm-2099	53	26	austin	austin	PROPN
ajlm-2099	53	27	,	,	PUNCT
ajlm-2099	53	28	texas	texas	PROPN
ajlm-2099	53	29	,	,	PUNCT
ajlm-2099	53	30	united	united	PROPN
ajlm-2099	53	31	states	states	PROPN
ajlm-2099	53	32	)	)	PUNCT
ajlm-2099	53	33	.	.	PUNCT
ajlm-2099	54	1	all	all	DET
ajlm-2099	54	2	samples	sample	NOUN
ajlm-2099	54	3	were	be	AUX
ajlm-2099	54	4	run	run	VERB
ajlm-2099	54	5	in	in	ADP
ajlm-2099	54	6	duplicate	duplicate	NOUN
ajlm-2099	54	7	.	.	PUNCT
ajlm-2099	55	1	indirect	indirect	ADJ
ajlm-2099	55	2	immunofluorescence	immunofluorescence	NOUN
ajlm-2099	55	3	assay	assay	VERB
ajlm-2099	55	4	anti	anti	ADJ
ajlm-2099	55	5	-	-	ADJ
ajlm-2099	55	6	dsdna	dsdna	ADJ
ajlm-2099	55	7	was	be	AUX
ajlm-2099	55	8	detected	detect	VERB
ajlm-2099	55	9	via	via	ADP
ajlm-2099	55	10	iif	iif	PROPN
ajlm-2099	55	11	using	use	VERB
ajlm-2099	55	12	nova	nova	PROPN
ajlm-2099	55	13	lite	lite	PROPN
ajlm-2099	55	14	®	®	PROPN
ajlm-2099	55	15	dsdna	dsdna	PROPN
ajlm-2099	55	16	c.	c.	PROPN
ajlm-2099	55	17	luciliae	luciliae	PROPN
ajlm-2099	55	18	kits	kits	PROPN
ajlm-2099	55	19	(	(	PUNCT
ajlm-2099	55	20	inova	inova	PROPN
ajlm-2099	55	21	diagnostics	diagnostics	PROPN
ajlm-2099	55	22	,	,	PUNCT
ajlm-2099	55	23	inc	inc	PROPN
ajlm-2099	55	24	.	.	PROPN
ajlm-2099	55	25	,	,	PUNCT
ajlm-2099	55	26	san	san	PROPN
ajlm-2099	55	27	diego	diego	PROPN
ajlm-2099	55	28	,	,	PUNCT
ajlm-2099	55	29	california	california	PROPN
ajlm-2099	55	30	,	,	PUNCT
ajlm-2099	55	31	united	united	PROPN
ajlm-2099	55	32	states	states	PROPN
ajlm-2099	55	33	)	)	PUNCT
ajlm-2099	55	34	.	.	PUNCT
ajlm-2099	56	1	the	the	DET
ajlm-2099	56	2	screening	screening	NOUN
ajlm-2099	56	3	was	be	AUX
ajlm-2099	56	4	performed	perform	VERB
ajlm-2099	56	5	at	at	ADP
ajlm-2099	56	6	a	a	DET
ajlm-2099	56	7	serum	serum	NOUN
ajlm-2099	56	8	dilution	dilution	NOUN
ajlm-2099	56	9	of	of	ADP
ajlm-2099	56	10	1/10	1/10	NUM
ajlm-2099	56	11	,	,	PUNCT
ajlm-2099	56	12	after	after	ADP
ajlm-2099	56	13	which	which	PRON
ajlm-2099	56	14	positive	positive	ADJ
ajlm-2099	56	15	samples	sample	NOUN
ajlm-2099	56	16	were	be	AUX
ajlm-2099	56	17	diluted	dilute	VERB
ajlm-2099	56	18	in	in	ADP
ajlm-2099	56	19	the	the	DET
ajlm-2099	56	20	range	range	NOUN
ajlm-2099	56	21	of	of	ADP
ajlm-2099	56	22	1/20	1/20	NUM
ajlm-2099	56	23	to	to	ADP
ajlm-2099	56	24	1/640	1/640	NUM
ajlm-2099	56	25	for	for	ADP
ajlm-2099	56	26	anti	anti	ADJ
ajlm-2099	56	27	-	-	ADJ
ajlm-2099	56	28	dsdna	dsdna	ADJ
ajlm-2099	56	29	titre	titre	NOUN
ajlm-2099	56	30	determination	determination	NOUN
ajlm-2099	56	31	.	.	PUNCT
ajlm-2099	57	1	anti	anti	ADJ
ajlm-2099	57	2	-	-	ADJ
ajlm-2099	57	3	neutrophil	neutrophil	ADJ
ajlm-2099	57	4	cytoplasmic	cytoplasmic	ADJ
ajlm-2099	57	5	antibody	antibody	NOUN
ajlm-2099	57	6	was	be	AUX
ajlm-2099	57	7	detected	detect	VERB
ajlm-2099	57	8	via	via	ADP
ajlm-2099	57	9	iif	iif	PROPN
ajlm-2099	57	10	using	use	VERB
ajlm-2099	57	11	nova	nova	PROPN
ajlm-2099	57	12	lite	lite	PROPN
ajlm-2099	57	13	®	®	PROPN
ajlm-2099	57	14	anca	anca	NOUN
ajlm-2099	57	15	anti	anti	ADJ
ajlm-2099	57	16	-	-	ADJ
ajlm-2099	57	17	neutrophil	neutrophil	ADJ
ajlm-2099	57	18	cytoplasmic	cytoplasmic	ADJ
ajlm-2099	57	19	autoantibody	autoantibody	ADJ
ajlm-2099	57	20	kits	kit	NOUN
ajlm-2099	57	21	(	(	PUNCT
ajlm-2099	57	22	inova	inova	PROPN
ajlm-2099	57	23	diagnostics	diagnostics	PROPN
ajlm-2099	57	24	,	,	PUNCT
ajlm-2099	57	25	inc	inc	PROPN
ajlm-2099	57	26	.	.	PROPN
ajlm-2099	57	27	,	,	PUNCT
ajlm-2099	57	28	san	san	PROPN
ajlm-2099	57	29	diego	diego	PROPN
ajlm-2099	57	30	,	,	PUNCT
ajlm-2099	57	31	california	california	PROPN
ajlm-2099	57	32	,	,	PUNCT
ajlm-2099	57	33	united	united	PROPN
ajlm-2099	57	34	states	states	PROPN
ajlm-2099	57	35	)	)	PUNCT
ajlm-2099	57	36	.	.	PUNCT
ajlm-2099	58	1	the	the	DET
ajlm-2099	58	2	screening	screening	NOUN
ajlm-2099	58	3	was	be	AUX
ajlm-2099	58	4	performed	perform	VERB
ajlm-2099	58	5	at	at	ADP
ajlm-2099	58	6	a	a	DET
ajlm-2099	58	7	serum	serum	NOUN
ajlm-2099	58	8	dilution	dilution	NOUN
ajlm-2099	58	9	of	of	ADP
ajlm-2099	58	10	1/20	1/20	NUM
ajlm-2099	58	11	.	.	PUNCT
ajlm-2099	59	1	both	both	DET
ajlm-2099	59	2	tests	test	NOUN
ajlm-2099	59	3	were	be	AUX
ajlm-2099	59	4	performed	perform	VERB
ajlm-2099	59	5	according	accord	VERB
ajlm-2099	59	6	to	to	ADP
ajlm-2099	59	7	the	the	DET
ajlm-2099	59	8	manufacturer	manufacturer	NOUN
ajlm-2099	59	9	’s	’s	PART
ajlm-2099	59	10	instructions	instruction	NOUN
ajlm-2099	59	11	.	.	PUNCT
ajlm-2099	60	1	positive	positive	ADJ
ajlm-2099	60	2	anti	anti	ADJ
ajlm-2099	60	3	-	-	ADJ
ajlm-2099	60	4	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	60	5	appears	appear	VERB
ajlm-2099	60	6	as	as	ADP
ajlm-2099	60	7	perinuclear	perinuclear	ADJ
ajlm-2099	60	8	staining	stain	VERB
ajlm-2099	60	9	(	(	PUNCT
ajlm-2099	60	10	p	p	NOUN
ajlm-2099	60	11	-	-	PUNCT
ajlm-2099	60	12	anca	anca	NOUN
ajlm-2099	60	13	)	)	PUNCT
ajlm-2099	60	14	while	while	SCONJ
ajlm-2099	60	15	positive	positive	ADJ
ajlm-2099	60	16	anti	anti	ADJ
ajlm-2099	60	17	-	-	ADJ
ajlm-2099	60	18	proteinase	proteinase	ADJ
ajlm-2099	60	19	3	3	NUM
ajlm-2099	60	20	appears	appear	VERB
ajlm-2099	60	21	as	as	SCONJ
ajlm-2099	60	22	cytoplasmic	cytoplasmic	ADJ
ajlm-2099	60	23	staining	stain	VERB
ajlm-2099	60	24	(	(	PUNCT
ajlm-2099	60	25	c	c	X
ajlm-2099	60	26	-	-	PUNCT
ajlm-2099	60	27	anca).30	anca).30	VERB
ajlm-2099	60	28	enzyme	enzyme	NOUN
ajlm-2099	60	29	-	-	PUNCT
ajlm-2099	60	30	linked	link	VERB
ajlm-2099	60	31	immunosorbent	immunosorbent	NOUN
ajlm-2099	60	32	assay	assay	NOUN
ajlm-2099	60	33	for	for	ADP
ajlm-2099	60	34	anti	anti	ADJ
ajlm-2099	60	35	-	-	ADJ
ajlm-2099	60	36	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	60	37	and	and	CCONJ
ajlm-2099	60	38	anti	anti	ADJ
ajlm-2099	60	39	-	-	ADJ
ajlm-2099	60	40	proteinase	proteinase	ADJ
ajlm-2099	60	41	3	3	NUM
ajlm-2099	60	42	the	the	DET
ajlm-2099	60	43	orgentec	orgentec	ADJ
ajlm-2099	60	44	anti	anti	ADJ
ajlm-2099	60	45	-	-	ADJ
ajlm-2099	60	46	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	60	47	(	(	PUNCT
ajlm-2099	60	48	p	p	NOUN
ajlm-2099	60	49	-	-	PUNCT
ajlm-2099	60	50	anca	anca	NOUN
ajlm-2099	60	51	)	)	PUNCT
ajlm-2099	60	52	and	and	CCONJ
ajlm-2099	60	53	anti	anti	ADJ
ajlm-2099	60	54	-	-	ADJ
ajlm-2099	60	55	proteinase	proteinase	ADJ
ajlm-2099	60	56	3	3	NUM
ajlm-2099	60	57	(	(	PUNCT
ajlm-2099	60	58	c	c	NOUN
ajlm-2099	60	59	-	-	PUNCT
ajlm-2099	60	60	anca	anca	NOUN
ajlm-2099	60	61	)	)	PUNCT
ajlm-2099	60	62	elisa	elisa	PROPN
ajlm-2099	60	63	kits	kit	NOUN
ajlm-2099	60	64	(	(	PUNCT
ajlm-2099	60	65	orgentec	orgentec	ADJ
ajlm-2099	60	66	diagnostika	diagnostika	NOUN
ajlm-2099	60	67	gmbh	gmbh	NOUN
ajlm-2099	60	68	,	,	PUNCT
ajlm-2099	60	69	mainz	mainz	PROPN
ajlm-2099	60	70	,	,	PUNCT
ajlm-2099	60	71	germany	germany	PROPN
ajlm-2099	60	72	)	)	PUNCT
ajlm-2099	60	73	were	be	AUX
ajlm-2099	60	74	used	use	VERB
ajlm-2099	60	75	for	for	ADP
ajlm-2099	60	76	the	the	DET
ajlm-2099	60	77	quantitative	quantitative	ADJ
ajlm-2099	60	78	measurement	measurement	NOUN
ajlm-2099	60	79	of	of	ADP
ajlm-2099	60	80	igg	igg	PROPN
ajlm-2099	60	81	-	-	PUNCT
ajlm-2099	60	82	class	class	NOUN
ajlm-2099	60	83	autoantibodies	autoantibody	NOUN
ajlm-2099	60	84	specific	specific	ADJ
ajlm-2099	60	85	for	for	ADP
ajlm-2099	60	86	myeloperoxidase	myeloperoxidase	NOUN
ajlm-2099	60	87	and	and	CCONJ
ajlm-2099	60	88	proteinase	proteinase	NOUN
ajlm-2099	60	89	3	3	NUM
ajlm-2099	60	90	.	.	PUNCT
ajlm-2099	60	91	results	result	NOUN
ajlm-2099	60	92	≥	≥	NUM
ajlm-2099	60	93	5	5	NUM
ajlm-2099	60	94	iu	iu	ADP
ajlm-2099	60	95	/	/	SYM
ajlm-2099	60	96	ml	ml	NOUN
ajlm-2099	60	97	were	be	AUX
ajlm-2099	60	98	considered	consider	VERB
ajlm-2099	60	99	positive	positive	ADJ
ajlm-2099	60	100	.	.	PUNCT
ajlm-2099	61	1	all	all	DET
ajlm-2099	61	2	samples	sample	NOUN
ajlm-2099	61	3	were	be	AUX
ajlm-2099	61	4	run	run	VERB
ajlm-2099	61	5	in	in	ADP
ajlm-2099	61	6	duplicate	duplicate	NOUN
ajlm-2099	61	7	.	.	PUNCT
ajlm-2099	62	1	we	we	PRON
ajlm-2099	62	2	performed	perform	VERB
ajlm-2099	62	3	the	the	DET
ajlm-2099	62	4	assays	assay	NOUN
ajlm-2099	62	5	and	and	CCONJ
ajlm-2099	62	6	calculated	calculate	VERB
ajlm-2099	62	7	the	the	DET
ajlm-2099	62	8	results	result	NOUN
ajlm-2099	62	9	according	accord	VERB
ajlm-2099	62	10	to	to	ADP
ajlm-2099	62	11	the	the	DET
ajlm-2099	62	12	manufacturer	manufacturer	NOUN
ajlm-2099	62	13	’s	’s	PART
ajlm-2099	62	14	instructions	instruction	NOUN
ajlm-2099	62	15	.	.	PUNCT
ajlm-2099	63	1	data	datum	NOUN
ajlm-2099	63	2	analysis	analysis	NOUN
ajlm-2099	63	3	the	the	DET
ajlm-2099	63	4	spss	spss	PROPN
ajlm-2099	63	5	®	®	NOUN
ajlm-2099	63	6	20.0	20.0	NUM
ajlm-2099	63	7	software	software	NOUN
ajlm-2099	63	8	package	package	NOUN
ajlm-2099	63	9	(	(	PUNCT
ajlm-2099	63	10	ibm	ibm	PROPN
ajlm-2099	63	11	corporation	corporation	PROPN
ajlm-2099	63	12	,	,	PUNCT
ajlm-2099	63	13	armonk	armonk	PROPN
ajlm-2099	63	14	,	,	PUNCT
ajlm-2099	63	15	new	new	PROPN
ajlm-2099	63	16	york	york	PROPN
ajlm-2099	63	17	,	,	PUNCT
ajlm-2099	63	18	united	united	PROPN
ajlm-2099	63	19	states	states	PROPN
ajlm-2099	63	20	)	)	PUNCT
ajlm-2099	63	21	was	be	AUX
ajlm-2099	63	22	used	use	VERB
ajlm-2099	63	23	for	for	ADP
ajlm-2099	63	24	data	data	NOUN
ajlm-2099	63	25	processing	processing	NOUN
ajlm-2099	63	26	and	and	CCONJ
ajlm-2099	63	27	analysis	analysis	NOUN
ajlm-2099	63	28	.	.	PUNCT
ajlm-2099	64	1	the	the	DET
ajlm-2099	64	2	overall	overall	ADJ
ajlm-2099	64	3	detection	detection	NOUN
ajlm-2099	64	4	results	result	NOUN
ajlm-2099	64	5	are	be	AUX
ajlm-2099	64	6	expressed	express	VERB
ajlm-2099	64	7	as	as	ADP
ajlm-2099	64	8	percentages	percentage	NOUN
ajlm-2099	64	9	of	of	ADP
ajlm-2099	64	10	the	the	DET
ajlm-2099	64	11	total	total	ADJ
ajlm-2099	64	12	number	number	NOUN
ajlm-2099	64	13	of	of	ADP
ajlm-2099	64	14	samples	sample	NOUN
ajlm-2099	64	15	.	.	PUNCT
ajlm-2099	65	1	agreement	agreement	NOUN
ajlm-2099	65	2	between	between	ADP
ajlm-2099	65	3	different	different	ADJ
ajlm-2099	65	4	assays	assay	NOUN
ajlm-2099	65	5	was	be	AUX
ajlm-2099	65	6	assessed	assess	VERB
ajlm-2099	65	7	using	use	VERB
ajlm-2099	65	8	cohen	cohen	PROPN
ajlm-2099	65	9	’s	’s	PART
ajlm-2099	65	10	kappa	kappa	PROPN
ajlm-2099	65	11	(	(	PUNCT
ajlm-2099	65	12	κ	κ	NOUN
ajlm-2099	65	13	)	)	PUNCT
ajlm-2099	65	14	coefficient	coefficient	NOUN
ajlm-2099	65	15	,	,	PUNCT
ajlm-2099	65	16	with	with	ADP
ajlm-2099	65	17	the	the	DET
ajlm-2099	65	18	following	follow	VERB
ajlm-2099	65	19	levels	level	NOUN
ajlm-2099	65	20	of	of	ADP
ajlm-2099	65	21	agreement	agreement	NOUN
ajlm-2099	65	22	:	:	PUNCT
ajlm-2099	65	23	0.01–0.2	0.01–0.2	NUM
ajlm-2099	65	24	=	=	PUNCT
ajlm-2099	65	25	slight	slight	ADJ
ajlm-2099	65	26	agreement	agreement	NOUN
ajlm-2099	65	27	,	,	PUNCT
ajlm-2099	65	28	0.21–0.4	0.21–0.4	NUM
ajlm-2099	65	29	=	=	ADJ
ajlm-2099	65	30	fair	fair	ADJ
ajlm-2099	65	31	agreement	agreement	NOUN
ajlm-2099	65	32	,	,	PUNCT
ajlm-2099	65	33	0.41–0.61	0.41–0.61	NUM
ajlm-2099	65	34	=	=	SYM
ajlm-2099	65	35	moderate	moderate	ADJ
ajlm-2099	65	36	agreement	agreement	NOUN
ajlm-2099	65	37	,	,	PUNCT
ajlm-2099	65	38	0.61–0.8	0.61–0.8	NUM
ajlm-2099	65	39	=	=	PUNCT
ajlm-2099	65	40	substantial	substantial	ADJ
ajlm-2099	65	41	agreement	agreement	NOUN
ajlm-2099	65	42	,	,	PUNCT
ajlm-2099	65	43	and	and	CCONJ
ajlm-2099	65	44	0.81–1	0.81–1	X
ajlm-2099	65	45	=	=	PUNCT
ajlm-2099	65	46	almost	almost	ADV
ajlm-2099	65	47	perfect	perfect	ADJ
ajlm-2099	65	48	or	or	CCONJ
ajlm-2099	65	49	perfect	perfect	ADJ
ajlm-2099	65	50	agreement	agreement	NOUN
ajlm-2099	65	51	.	.	PUNCT
ajlm-2099	66	1	receiver	receiver	ADJ
ajlm-2099	66	2	operating	operate	VERB
ajlm-2099	66	3	characteristic	characteristic	ADJ
ajlm-2099	66	4	curves	curve	NOUN
ajlm-2099	66	5	were	be	AUX
ajlm-2099	66	6	constructed	construct	VERB
ajlm-2099	66	7	,	,	PUNCT
ajlm-2099	66	8	and	and	CCONJ
ajlm-2099	66	9	the	the	DET
ajlm-2099	66	10	areas	area	NOUN
ajlm-2099	66	11	under	under	ADP
ajlm-2099	66	12	the	the	DET
ajlm-2099	66	13	curves	curve	NOUN
ajlm-2099	66	14	were	be	AUX
ajlm-2099	66	15	calculated	calculate	VERB
ajlm-2099	66	16	at	at	ADP
ajlm-2099	66	17	95	95	NUM
ajlm-2099	66	18	%	%	NOUN
ajlm-2099	66	19	confidence	confidence	NOUN
ajlm-2099	66	20	intervals	interval	NOUN
ajlm-2099	66	21	.	.	PUNCT
ajlm-2099	67	1	the	the	DET
ajlm-2099	67	2	t	t	NOUN
ajlm-2099	67	3	-	-	PUNCT
ajlm-2099	67	4	test	test	NOUN
ajlm-2099	67	5	and	and	CCONJ
ajlm-2099	67	6	one	one	NUM
ajlm-2099	67	7	-	-	PUNCT
ajlm-2099	67	8	way	way	NOUN
ajlm-2099	67	9	analysis	analysis	NOUN
ajlm-2099	67	10	of	of	ADP
ajlm-2099	67	11	variance	variance	NOUN
ajlm-2099	67	12	with	with	ADP
ajlm-2099	67	13	post	post	X
ajlm-2099	67	14	hoc	hoc	X
ajlm-2099	67	15	tests	test	NOUN
ajlm-2099	67	16	were	be	AUX
ajlm-2099	67	17	used	use	VERB
ajlm-2099	67	18	to	to	PART
ajlm-2099	67	19	compare	compare	VERB
ajlm-2099	67	20	ages	age	NOUN
ajlm-2099	67	21	,	,	PUNCT
ajlm-2099	67	22	and	and	CCONJ
ajlm-2099	67	23	the	the	DET
ajlm-2099	67	24	chi	chi	ADJ
ajlm-2099	67	25	-	-	PUNCT
ajlm-2099	67	26	square	square	ADJ
ajlm-2099	67	27	test	test	NOUN
ajlm-2099	67	28	was	be	AUX
ajlm-2099	67	29	used	use	VERB
ajlm-2099	67	30	to	to	PART
ajlm-2099	67	31	compare	compare	VERB
ajlm-2099	67	32	frequencies	frequency	NOUN
ajlm-2099	67	33	.	.	PUNCT
ajlm-2099	68	1	the	the	DET
ajlm-2099	68	2	spearman	spearman	NOUN
ajlm-2099	68	3	correlation	correlation	NOUN
ajlm-2099	68	4	coefficient	coefficient	NOUN
ajlm-2099	68	5	test	test	NOUN
ajlm-2099	68	6	(	(	PUNCT
ajlm-2099	68	7	r	r	NOUN
ajlm-2099	68	8	)	)	PUNCT
ajlm-2099	68	9	was	be	AUX
ajlm-2099	68	10	performed	perform	VERB
ajlm-2099	68	11	to	to	PART
ajlm-2099	68	12	examine	examine	VERB
ajlm-2099	68	13	the	the	DET
ajlm-2099	68	14	correlation	correlation	NOUN
ajlm-2099	68	15	between	between	ADP
ajlm-2099	68	16	anti	anti	ADJ
ajlm-2099	68	17	-	-	ADJ
ajlm-2099	68	18	dsdna	dsdna	ADJ
ajlm-2099	68	19	concentrations	concentration	NOUN
ajlm-2099	68	20	measured	measure	VERB
ajlm-2099	68	21	by	by	ADP
ajlm-2099	68	22	athena	athena	PROPN
ajlm-2099	68	23	multi	multi	PROPN
ajlm-2099	68	24	-	-	ADJ
ajlm-2099	68	25	lyte	lyte	ADJ
ajlm-2099	68	26	®	®	PROPN
ajlm-2099	68	27	ana	ana	PROPN
ajlm-2099	68	28	-	-	PUNCT
ajlm-2099	68	29	ii	ii	PROPN
ajlm-2099	68	30	(	(	PUNCT
ajlm-2099	68	31	continuous	continuous	ADJ
ajlm-2099	68	32	variable	variable	NOUN
ajlm-2099	68	33	)	)	PUNCT
ajlm-2099	68	34	and	and	CCONJ
ajlm-2099	68	35	anti	anti	ADJ
ajlm-2099	68	36	-	-	ADJ
ajlm-2099	68	37	dsdna	dsdna	ADJ
ajlm-2099	68	38	titres	titre	NOUN
ajlm-2099	68	39	estimated	estimate	VERB
ajlm-2099	68	40	by	by	ADP
ajlm-2099	68	41	iif	iif	PROPN
ajlm-2099	68	42	(	(	PUNCT
ajlm-2099	68	43	ordinal	ordinal	ADJ
ajlm-2099	68	44	variable).31	variable).31	PROPN
ajlm-2099	68	45	results	result	NOUN
ajlm-2099	68	46	were	be	AUX
ajlm-2099	68	47	considered	consider	VERB
ajlm-2099	68	48	significant	significant	ADJ
ajlm-2099	68	49	at	at	ADP
ajlm-2099	68	50	a	a	DET
ajlm-2099	68	51	p	p	NOUN
ajlm-2099	68	52	-	-	PUNCT
ajlm-2099	68	53	value	value	NOUN
ajlm-2099	68	54	<	<	X
ajlm-2099	68	55	0.05	0.05	NUM
ajlm-2099	68	56	.	.	PUNCT
ajlm-2099	69	1	sensitivity	sensitivity	NOUN
ajlm-2099	69	2	,	,	PUNCT
ajlm-2099	69	3	specificity	specificity	NOUN
ajlm-2099	69	4	,	,	PUNCT
ajlm-2099	69	5	accuracy	accuracy	NOUN
ajlm-2099	69	6	,	,	PUNCT
ajlm-2099	69	7	and	and	CCONJ
ajlm-2099	69	8	positive	positive	ADJ
ajlm-2099	69	9	and	and	CCONJ
ajlm-2099	69	10	negative	negative	ADJ
ajlm-2099	69	11	predictive	predictive	ADJ
ajlm-2099	69	12	values	value	NOUN
ajlm-2099	69	13	were	be	AUX
ajlm-2099	69	14	calculated	calculate	VERB
ajlm-2099	69	15	using	use	VERB
ajlm-2099	69	16	medcalc	medcalc	NOUN
ajlm-2099	69	17	(	(	PUNCT
ajlm-2099	69	18	https://www.medcalc.org/	https://www.medcalc.org/	NOUN
ajlm-2099	69	19	)	)	PUNCT
ajlm-2099	69	20	(	(	PUNCT
ajlm-2099	69	21	medcalc	medcalc	PROPN
ajlm-2099	69	22	software	software	PROPN
ajlm-2099	69	23	ltd	ltd	PROPN
ajlm-2099	69	24	,	,	PUNCT
ajlm-2099	69	25	acacialaan	acacialaan	ADV
ajlm-2099	69	26	,	,	PUNCT
ajlm-2099	69	27	ostend	ostend	PROPN
ajlm-2099	69	28	,	,	PUNCT
ajlm-2099	69	29	belgium).32	belgium).32	VERB
ajlm-2099	69	30	in	in	ADP
ajlm-2099	69	31	addition	addition	NOUN
ajlm-2099	69	32	to	to	ADP
ajlm-2099	69	33	the	the	DET
ajlm-2099	69	34	clinical	clinical	ADJ
ajlm-2099	69	35	and	and	CCONJ
ajlm-2099	69	36	analytical	analytical	ADJ
ajlm-2099	69	37	performance	performance	NOUN
ajlm-2099	69	38	evaluations	evaluation	NOUN
ajlm-2099	69	39	conducted	conduct	VERB
ajlm-2099	69	40	,	,	PUNCT
ajlm-2099	69	41	we	we	PRON
ajlm-2099	69	42	compared	compare	VERB
ajlm-2099	69	43	the	the	DET
ajlm-2099	69	44	general	general	ADJ
ajlm-2099	69	45	characteristics	characteristic	NOUN
ajlm-2099	69	46	of	of	ADP
ajlm-2099	69	47	the	the	DET
ajlm-2099	69	48	assays	assay	NOUN
ajlm-2099	69	49	used	use	VERB
ajlm-2099	69	50	,	,	PUNCT
ajlm-2099	69	51	including	include	VERB
ajlm-2099	69	52	time	time	NOUN
ajlm-2099	69	53	taken	take	VERB
ajlm-2099	69	54	for	for	ADP
ajlm-2099	69	55	the	the	DET
ajlm-2099	69	56	run	run	NOUN
ajlm-2099	69	57	,	,	PUNCT
ajlm-2099	69	58	estimated	estimate	VERB
ajlm-2099	69	59	cost	cost	NOUN
ajlm-2099	69	60	per	per	ADP
ajlm-2099	69	61	test	test	NOUN
ajlm-2099	69	62	,	,	PUNCT
ajlm-2099	69	63	and	and	CCONJ
ajlm-2099	69	64	the	the	DET
ajlm-2099	69	65	technical	technical	ADJ
ajlm-2099	69	66	experience	experience	NOUN
ajlm-2099	69	67	required	require	VERB
ajlm-2099	69	68	.	.	PUNCT
ajlm-2099	70	1	results	result	NOUN
ajlm-2099	70	2	general	general	ADJ
ajlm-2099	70	3	characteristics	characteristic	NOUN
ajlm-2099	70	4	of	of	ADP
ajlm-2099	70	5	patients	patient	NOUN
ajlm-2099	70	6	anti	anti	ADJ
ajlm-2099	70	7	-	-	ADJ
ajlm-2099	70	8	dsdna	dsdna	ADJ
ajlm-2099	70	9	antibodies	antibody	NOUN
ajlm-2099	70	10	were	be	AUX
ajlm-2099	70	11	studied	study	VERB
ajlm-2099	70	12	in	in	ADP
ajlm-2099	70	13	105	105	NUM
ajlm-2099	70	14	sle	sle	PROPN
ajlm-2099	70	15	patients	patient	NOUN
ajlm-2099	70	16	and	and	CCONJ
ajlm-2099	70	17	participants	participant	NOUN
ajlm-2099	70	18	in	in	ADP
ajlm-2099	70	19	control	control	NOUN
ajlm-2099	70	20	groups	group	NOUN
ajlm-2099	70	21	(	(	PUNCT
ajlm-2099	70	22	30	30	NUM
ajlm-2099	70	23	healthy	healthy	ADJ
ajlm-2099	70	24	participants	participant	NOUN
ajlm-2099	70	25	and	and	CCONJ
ajlm-2099	70	26	35	35	NUM
ajlm-2099	70	27	patients	patient	NOUN
ajlm-2099	70	28	with	with	ADP
ajlm-2099	70	29	autoimmune	autoimmune	ADJ
ajlm-2099	70	30	diseases	disease	NOUN
ajlm-2099	70	31	other	other	ADJ
ajlm-2099	70	32	than	than	ADP
ajlm-2099	70	33	sle	sle	PROPN
ajlm-2099	70	34	)	)	PUNCT
ajlm-2099	70	35	.	.	PUNCT
ajlm-2099	71	1	among	among	ADP
ajlm-2099	71	2	patients	patient	NOUN
ajlm-2099	71	3	with	with	ADP
ajlm-2099	71	4	other	other	ADJ
ajlm-2099	71	5	autoimmune	autoimmune	ADJ
ajlm-2099	71	6	diseases	disease	NOUN
ajlm-2099	71	7	,	,	PUNCT
ajlm-2099	71	8	18	18	NUM
ajlm-2099	71	9	had	have	VERB
ajlm-2099	71	10	systemic	systemic	ADJ
ajlm-2099	71	11	sclerosis	sclerosis	NOUN
ajlm-2099	71	12	,	,	PUNCT
ajlm-2099	71	13	15	15	NUM
ajlm-2099	71	14	had	have	VERB
ajlm-2099	71	15	rheumatoid	rheumatoid	NOUN
ajlm-2099	71	16	arthritis	arthritis	NOUN
ajlm-2099	71	17	,	,	PUNCT
ajlm-2099	71	18	one	one	NUM
ajlm-2099	71	19	had	have	VERB
ajlm-2099	71	20	polymyositis	polymyositis	NOUN
ajlm-2099	71	21	,	,	PUNCT
ajlm-2099	71	22	and	and	CCONJ
ajlm-2099	71	23	one	one	NUM
ajlm-2099	71	24	had	have	VERB
ajlm-2099	71	25	primary	primary	ADJ
ajlm-2099	71	26	sjögren	sjögren	NOUN
ajlm-2099	71	27	syndrome	syndrome	NOUN
ajlm-2099	71	28	.	.	PUNCT
ajlm-2099	72	1	within	within	ADP
ajlm-2099	72	2	the	the	DET
ajlm-2099	72	3	anca	anca	NOUN
ajlm-2099	72	4	group	group	NOUN
ajlm-2099	72	5	,	,	PUNCT
ajlm-2099	72	6	we	we	PRON
ajlm-2099	72	7	examined	examine	VERB
ajlm-2099	72	8	75	75	NUM
ajlm-2099	72	9	patients	patient	NOUN
ajlm-2099	72	10	with	with	ADP
ajlm-2099	72	11	aiv	aiv	PROPN
ajlm-2099	72	12	and	and	CCONJ
ajlm-2099	72	13	25	25	NUM
ajlm-2099	72	14	healthy	healthy	ADJ
ajlm-2099	72	15	participants	participant	NOUN
ajlm-2099	72	16	matched	match	VERB
ajlm-2099	72	17	for	for	ADP
ajlm-2099	72	18	age	age	NOUN
ajlm-2099	72	19	and	and	CCONJ
ajlm-2099	72	20	gender	gender	NOUN
ajlm-2099	72	21	.	.	PUNCT
ajlm-2099	73	1	systemic	systemic	ADJ
ajlm-2099	73	2	lupus	lupus	PROPN
ajlm-2099	73	3	erythematosus	erythematosus	PROPN
ajlm-2099	73	4	patients	patient	NOUN
ajlm-2099	73	5	’	'	PUNCT
ajlm-2099	73	6	ages	age	NOUN
ajlm-2099	73	7	ranged	range	VERB
ajlm-2099	73	8	from	from	ADP
ajlm-2099	73	9	5	5	NUM
ajlm-2099	73	10	to	to	PART
ajlm-2099	73	11	60	60	NUM
ajlm-2099	73	12	years	year	NOUN
ajlm-2099	73	13	(	(	PUNCT
ajlm-2099	73	14	mean	mean	PROPN
ajlm-2099	73	15	±	±	NUM
ajlm-2099	73	16	standard	standard	ADJ
ajlm-2099	73	17	deviation	deviation	NOUN
ajlm-2099	73	18	:	:	PUNCT
ajlm-2099	73	19	32.4	32.4	NUM
ajlm-2099	73	20	±	±	NUM
ajlm-2099	73	21	12.8	12.8	NUM
ajlm-2099	73	22	years	year	NOUN
ajlm-2099	73	23	)	)	PUNCT
ajlm-2099	73	24	,	,	PUNCT
ajlm-2099	73	25	and	and	CCONJ
ajlm-2099	73	26	80	80	NUM
ajlm-2099	73	27	(	(	PUNCT
ajlm-2099	73	28	76.1	76.1	NUM
ajlm-2099	73	29	%	%	NOUN
ajlm-2099	73	30	)	)	PUNCT
ajlm-2099	73	31	of	of	ADP
ajlm-2099	73	32	them	they	PRON
ajlm-2099	73	33	were	be	AUX
ajlm-2099	73	34	women	woman	NOUN
ajlm-2099	73	35	(	(	PUNCT
ajlm-2099	73	36	table	table	NOUN
ajlm-2099	73	37	1	1	NUM
ajlm-2099	73	38	)	)	PUNCT
ajlm-2099	73	39	.	.	PUNCT
ajlm-2099	74	1	the	the	DET
ajlm-2099	74	2	ages	age	NOUN
ajlm-2099	74	3	of	of	ADP
ajlm-2099	74	4	the	the	DET
ajlm-2099	74	5	aiv	aiv	NOUN
ajlm-2099	74	6	patients	patient	NOUN
ajlm-2099	74	7	ranged	range	VERB
ajlm-2099	74	8	from	from	ADP
ajlm-2099	74	9	14	14	NUM
ajlm-2099	74	10	to	to	PART
ajlm-2099	74	11	77	77	NUM
ajlm-2099	74	12	years	year	NOUN
ajlm-2099	74	13	(	(	PUNCT
ajlm-2099	74	14	mean	mean	PROPN
ajlm-2099	74	15	±	±	NUM
ajlm-2099	74	16	standard	standard	ADJ
ajlm-2099	74	17	deviation	deviation	NOUN
ajlm-2099	74	18	:	:	PUNCT
ajlm-2099	74	19	38.4	38.4	NUM
ajlm-2099	74	20	±	±	NUM
ajlm-2099	74	21	15.7	15.7	NUM
ajlm-2099	74	22	years	year	NOUN
ajlm-2099	74	23	)	)	PUNCT
ajlm-2099	74	24	,	,	PUNCT
ajlm-2099	74	25	and	and	CCONJ
ajlm-2099	74	26	50	50	NUM
ajlm-2099	74	27	(	(	PUNCT
ajlm-2099	74	28	66.7	66.7	NUM
ajlm-2099	74	29	%	%	NOUN
ajlm-2099	74	30	)	)	PUNCT
ajlm-2099	74	31	of	of	ADP
ajlm-2099	74	32	them	they	PRON
ajlm-2099	74	33	were	be	AUX
ajlm-2099	74	34	women	woman	NOUN
ajlm-2099	74	35	.	.	PUNCT
ajlm-2099	75	1	table	table	NOUN
ajlm-2099	75	2	1	1	NUM
ajlm-2099	75	3	:	:	PUNCT
ajlm-2099	75	4	 	 	SPACE
ajlm-2099	75	5	demographic	demographic	ADJ
ajlm-2099	75	6	characteristics	characteristic	NOUN
ajlm-2099	75	7	of	of	ADP
ajlm-2099	75	8	sle	sle	PROPN
ajlm-2099	75	9	patients	patient	NOUN
ajlm-2099	75	10	and	and	CCONJ
ajlm-2099	75	11	control	control	VERB
ajlm-2099	75	12	subjects	subject	NOUN
ajlm-2099	75	13	at	at	ADP
ajlm-2099	75	14	the	the	DET
ajlm-2099	75	15	zagazig	zagazig	PROPN
ajlm-2099	75	16	university	university	PROPN
ajlm-2099	75	17	hospitals	hospital	NOUN
ajlm-2099	75	18	,	,	PUNCT
ajlm-2099	75	19	zagazig	zagazig	PROPN
ajlm-2099	75	20	,	,	PUNCT
ajlm-2099	75	21	al	al	PROPN
ajlm-2099	75	22	sharqia	sharqia	PROPN
ajlm-2099	75	23	,	,	PUNCT
ajlm-2099	75	24	egypt	egypt	PROPN
ajlm-2099	75	25	,	,	PUNCT
ajlm-2099	75	26	may	may	PROPN
ajlm-2099	75	27	2020	2020	NUM
ajlm-2099	75	28	–	–	PUNCT
ajlm-2099	75	29	april	april	PROPN
ajlm-2099	75	30	2022	2022	NUM
ajlm-2099	75	31	.	.	PUNCT
ajlm-2099	76	1	the	the	DET
ajlm-2099	76	2	most	most	ADV
ajlm-2099	76	3	common	common	ADJ
ajlm-2099	76	4	symptom	symptom	NOUN
ajlm-2099	76	5	observed	observe	VERB
ajlm-2099	76	6	in	in	ADP
ajlm-2099	76	7	the	the	DET
ajlm-2099	76	8	sle	sle	PROPN
ajlm-2099	76	9	group	group	NOUN
ajlm-2099	76	10	was	be	AUX
ajlm-2099	76	11	skin	skin	NOUN
ajlm-2099	76	12	manifestations	manifestation	NOUN
ajlm-2099	76	13	(	(	PUNCT
ajlm-2099	76	14	86.7	86.7	NUM
ajlm-2099	76	15	%	%	NOUN
ajlm-2099	76	16	;	;	PUNCT
ajlm-2099	76	17	91/105	91/105	NUM
ajlm-2099	76	18	)	)	PUNCT
ajlm-2099	76	19	in	in	ADP
ajlm-2099	76	20	the	the	DET
ajlm-2099	76	21	form	form	NOUN
ajlm-2099	76	22	of	of	ADP
ajlm-2099	76	23	photosensitivity	photosensitivity	NOUN
ajlm-2099	76	24	,	,	PUNCT
ajlm-2099	76	25	malar	malar	ADJ
ajlm-2099	76	26	,	,	PUNCT
ajlm-2099	76	27	or	or	CCONJ
ajlm-2099	76	28	discoid	discoid	VERB
ajlm-2099	76	29	rash	rash	NOUN
ajlm-2099	76	30	(	(	PUNCT
ajlm-2099	76	31	table	table	NOUN
ajlm-2099	76	32	2	2	NUM
ajlm-2099	76	33	)	)	PUNCT
ajlm-2099	76	34	.	.	PUNCT
ajlm-2099	77	1	articular	articular	ADJ
ajlm-2099	77	2	manifestations	manifestation	NOUN
ajlm-2099	77	3	in	in	ADP
ajlm-2099	77	4	the	the	DET
ajlm-2099	77	5	form	form	NOUN
ajlm-2099	77	6	of	of	ADP
ajlm-2099	77	7	arthritis	arthritis	NOUN
ajlm-2099	77	8	and	and	CCONJ
ajlm-2099	77	9	arthralgia	arthralgia	NOUN
ajlm-2099	77	10	were	be	AUX
ajlm-2099	77	11	observed	observe	VERB
ajlm-2099	77	12	in	in	ADP
ajlm-2099	77	13	82.8	82.8	NUM
ajlm-2099	77	14	%	%	NOUN
ajlm-2099	77	15	(	(	PUNCT
ajlm-2099	77	16	87/105	87/105	NUM
ajlm-2099	77	17	)	)	PUNCT
ajlm-2099	77	18	of	of	ADP
ajlm-2099	77	19	patients	patient	NOUN
ajlm-2099	77	20	,	,	PUNCT
ajlm-2099	77	21	while	while	SCONJ
ajlm-2099	77	22	75.2	75.2	NUM
ajlm-2099	77	23	%	%	NOUN
ajlm-2099	77	24	(	(	PUNCT
ajlm-2099	77	25	79/105	79/105	NOUN
ajlm-2099	77	26	)	)	PUNCT
ajlm-2099	77	27	of	of	ADP
ajlm-2099	77	28	patients	patient	NOUN
ajlm-2099	77	29	had	have	VERB
ajlm-2099	77	30	nephritis	nephritis	NOUN
ajlm-2099	77	31	.	.	PUNCT
ajlm-2099	78	1	autoimmune	autoimmune	PROPN
ajlm-2099	78	2	vasculitis	vasculitis	PROPN
ajlm-2099	78	3	patients	patient	NOUN
ajlm-2099	78	4	presented	present	VERB
ajlm-2099	78	5	mainly	mainly	ADV
ajlm-2099	78	6	with	with	ADP
ajlm-2099	78	7	constitutional	constitutional	ADJ
ajlm-2099	78	8	symptoms	symptom	NOUN
ajlm-2099	78	9	(	(	PUNCT
ajlm-2099	78	10	80.0	80.0	NUM
ajlm-2099	78	11	%	%	NOUN
ajlm-2099	78	12	;	;	PUNCT
ajlm-2099	78	13	60/75	60/75	NUM
ajlm-2099	78	14	)	)	PUNCT
ajlm-2099	78	15	and	and	CCONJ
ajlm-2099	78	16	skin	skin	NOUN
ajlm-2099	78	17	manifestations	manifestation	NOUN
ajlm-2099	78	18	(	(	PUNCT
ajlm-2099	78	19	57.3	57.3	NUM
ajlm-2099	78	20	%	%	NOUN
ajlm-2099	78	21	;	;	PUNCT
ajlm-2099	78	22	43/75	43/75	NUM
ajlm-2099	78	23	)	)	PUNCT
ajlm-2099	78	24	in	in	ADP
ajlm-2099	78	25	the	the	DET
ajlm-2099	78	26	form	form	NOUN
ajlm-2099	78	27	of	of	ADP
ajlm-2099	78	28	skin	skin	NOUN
ajlm-2099	78	29	ulcerations	ulceration	NOUN
ajlm-2099	78	30	and	and	CCONJ
ajlm-2099	78	31	palpable	palpable	ADJ
ajlm-2099	78	32	purpura	purpura	NOUN
ajlm-2099	78	33	.	.	PUNCT
ajlm-2099	79	1	the	the	DET
ajlm-2099	79	2	lungs	lung	NOUN
ajlm-2099	79	3	(	(	PUNCT
ajlm-2099	79	4	66.7	66.7	NUM
ajlm-2099	79	5	%	%	NOUN
ajlm-2099	79	6	;	;	PUNCT
ajlm-2099	79	7	50/75	50/75	NUM
ajlm-2099	79	8	)	)	PUNCT
ajlm-2099	79	9	and	and	CCONJ
ajlm-2099	79	10	cardiovascular	cardiovascular	ADJ
ajlm-2099	79	11	system	system	NOUN
ajlm-2099	79	12	(	(	PUNCT
ajlm-2099	79	13	56.0	56.0	NUM
ajlm-2099	79	14	%	%	NOUN
ajlm-2099	79	15	;	;	PUNCT
ajlm-2099	79	16	42/75	42/75	NUM
ajlm-2099	79	17	)	)	PUNCT
ajlm-2099	79	18	were	be	AUX
ajlm-2099	79	19	the	the	DET
ajlm-2099	79	20	most	most	ADV
ajlm-2099	79	21	frequently	frequently	ADV
ajlm-2099	79	22	affected	affect	VERB
ajlm-2099	79	23	organs	organ	NOUN
ajlm-2099	79	24	in	in	ADP
ajlm-2099	79	25	these	these	DET
ajlm-2099	79	26	patients	patient	NOUN
ajlm-2099	79	27	.	.	PUNCT
ajlm-2099	80	1	anti	anti	ADJ
ajlm-2099	80	2	-	-	ADJ
ajlm-2099	80	3	nuclear	nuclear	ADJ
ajlm-2099	80	4	antibodies	antibody	NOUN
ajlm-2099	80	5	were	be	AUX
ajlm-2099	80	6	detected	detect	VERB
ajlm-2099	80	7	in	in	ADP
ajlm-2099	80	8	all	all	DET
ajlm-2099	80	9	sle	sle	PROPN
ajlm-2099	80	10	patients	patient	NOUN
ajlm-2099	80	11	(	(	PUNCT
ajlm-2099	80	12	100	100	NUM
ajlm-2099	80	13	%	%	NOUN
ajlm-2099	80	14	;	;	PUNCT
ajlm-2099	80	15	105/105	105/105	NUM
ajlm-2099	80	16	)	)	PUNCT
ajlm-2099	80	17	and	and	CCONJ
ajlm-2099	80	18	77.1	77.1	NUM
ajlm-2099	80	19	%	%	NOUN
ajlm-2099	80	20	(	(	PUNCT
ajlm-2099	80	21	27/35	27/35	NUM
ajlm-2099	80	22	)	)	PUNCT
ajlm-2099	80	23	of	of	ADP
ajlm-2099	80	24	the	the	DET
ajlm-2099	80	25	diseased	diseased	ADJ
ajlm-2099	80	26	control	control	NOUN
ajlm-2099	80	27	group	group	NOUN
ajlm-2099	80	28	.	.	PUNCT
ajlm-2099	81	1	other	other	ADJ
ajlm-2099	81	2	autoantibodies	autoantibody	NOUN
ajlm-2099	81	3	were	be	AUX
ajlm-2099	81	4	detected	detect	VERB
ajlm-2099	81	5	in	in	ADP
ajlm-2099	81	6	both	both	DET
ajlm-2099	81	7	groups	group	NOUN
ajlm-2099	81	8	with	with	ADP
ajlm-2099	81	9	variable	variable	ADJ
ajlm-2099	81	10	frequencies	frequency	NOUN
ajlm-2099	81	11	.	.	PUNCT
ajlm-2099	82	1	table	table	NOUN
ajlm-2099	82	2	2	2	NUM
ajlm-2099	82	3	:	:	PUNCT
ajlm-2099	82	4	 	 	SPACE
ajlm-2099	82	5	clinical	clinical	ADJ
ajlm-2099	82	6	manifestations	manifestation	NOUN
ajlm-2099	82	7	and	and	CCONJ
ajlm-2099	82	8	serological	serological	ADJ
ajlm-2099	82	9	findings	finding	NOUN
ajlm-2099	82	10	of	of	ADP
ajlm-2099	82	11	sle	sle	PROPN
ajlm-2099	82	12	patients	patient	NOUN
ajlm-2099	82	13	,	,	PUNCT
ajlm-2099	82	14	aiv	aiv	NOUN
ajlm-2099	82	15	patients	patient	NOUN
ajlm-2099	82	16	,	,	PUNCT
ajlm-2099	82	17	and	and	CCONJ
ajlm-2099	82	18	diseased	diseased	ADJ
ajlm-2099	82	19	controls	control	NOUN
ajlm-2099	82	20	,	,	PUNCT
ajlm-2099	82	21	zagazig	zagazig	PROPN
ajlm-2099	82	22	university	university	NOUN
ajlm-2099	82	23	hospitals	hospital	NOUN
ajlm-2099	82	24	,	,	PUNCT
ajlm-2099	82	25	zagazig	zagazig	PROPN
ajlm-2099	82	26	,	,	PUNCT
ajlm-2099	82	27	al	al	PROPN
ajlm-2099	82	28	sharqia	sharqia	PROPN
ajlm-2099	82	29	,	,	PUNCT
ajlm-2099	82	30	egypt	egypt	PROPN
ajlm-2099	82	31	,	,	PUNCT
ajlm-2099	82	32	may	may	PROPN
ajlm-2099	82	33	2020	2020	NUM
ajlm-2099	82	34	–	–	PUNCT
ajlm-2099	82	35	april	april	PROPN
ajlm-2099	82	36	2022	2022	NUM
ajlm-2099	82	37	.	.	PUNCT
ajlm-2099	83	1	anti	anti	ADJ
ajlm-2099	83	2	-	-	ADJ
ajlm-2099	83	3	double	double	ADJ
ajlm-2099	83	4	-	-	PUNCT
ajlm-2099	83	5	stranded	strand	VERB
ajlm-2099	83	6	dna	dna	NOUN
ajlm-2099	83	7	testing	testing	NOUN
ajlm-2099	83	8	by	by	ADP
ajlm-2099	83	9	iif	iif	PROPN
ajlm-2099	83	10	and	and	CCONJ
ajlm-2099	83	11	athena	athena	PROPN
ajlm-2099	83	12	multi	multi	PROPN
ajlm-2099	83	13	-	-	PROPN
ajlm-2099	83	14	lyte	lyte	ADJ
ajlm-2099	83	15	ana	ana	PROPN
ajlm-2099	83	16	-	-	PUNCT
ajlm-2099	83	17	ii	ii	PROPN
ajlm-2099	83	18	test	test	NOUN
ajlm-2099	83	19	overall	overall	ADJ
ajlm-2099	83	20	,	,	PUNCT
ajlm-2099	83	21	38.1	38.1	NUM
ajlm-2099	83	22	%	%	NOUN
ajlm-2099	83	23	(	(	PUNCT
ajlm-2099	83	24	40/105	40/105	NUM
ajlm-2099	83	25	)	)	PUNCT
ajlm-2099	83	26	of	of	ADP
ajlm-2099	83	27	sle	sle	PROPN
ajlm-2099	83	28	patients	patient	NOUN
ajlm-2099	83	29	were	be	AUX
ajlm-2099	83	30	positive	positive	ADJ
ajlm-2099	83	31	for	for	ADP
ajlm-2099	83	32	anti	anti	ADJ
ajlm-2099	83	33	-	-	ADJ
ajlm-2099	83	34	dsdna	dsdna	ADJ
ajlm-2099	83	35	by	by	ADP
ajlm-2099	83	36	iif	iif	PROPN
ajlm-2099	83	37	or	or	CCONJ
ajlm-2099	83	38	athena	athena	PROPN
ajlm-2099	83	39	multi	multi	PROPN
ajlm-2099	83	40	-	-	ADJ
ajlm-2099	83	41	lyte	lyte	ADJ
ajlm-2099	83	42	®	®	PROPN
ajlm-2099	83	43	ana	ana	PROPN
ajlm-2099	83	44	-	-	PUNCT
ajlm-2099	83	45	ii	ii	PROPN
ajlm-2099	83	46	.	.	PUNCT
ajlm-2099	84	1	additionally	additionally	ADV
ajlm-2099	84	2	,	,	PUNCT
ajlm-2099	84	3	athena	athena	PROPN
ajlm-2099	84	4	multi	multi	PROPN
ajlm-2099	84	5	-	-	ADJ
ajlm-2099	84	6	lyte	lyte	ADJ
ajlm-2099	84	7	®	®	PROPN
ajlm-2099	84	8	ana	ana	PROPN
ajlm-2099	84	9	-	-	PUNCT
ajlm-2099	84	10	ii	ii	PROPN
ajlm-2099	84	11	yielded	yield	VERB
ajlm-2099	84	12	equivocal	equivocal	ADJ
ajlm-2099	84	13	results	result	NOUN
ajlm-2099	84	14	for	for	ADP
ajlm-2099	84	15	9.5	9.5	NUM
ajlm-2099	84	16	%	%	NOUN
ajlm-2099	84	17	(	(	PUNCT
ajlm-2099	84	18	10/105	10/105	NUM
ajlm-2099	84	19	)	)	PUNCT
ajlm-2099	84	20	of	of	ADP
ajlm-2099	84	21	samples	sample	NOUN
ajlm-2099	84	22	(	(	PUNCT
ajlm-2099	84	23	anti	anti	ADJ
ajlm-2099	84	24	-	-	ADJ
ajlm-2099	84	25	dsdna	dsdna	ADJ
ajlm-2099	84	26	100	100	NUM
ajlm-2099	84	27	iu	iu	NOUN
ajlm-2099	84	28	/	/	SYM
ajlm-2099	84	29	ml	ml	NOUN
ajlm-2099	84	30	–	–	PUNCT
ajlm-2099	84	31	120	120	NUM
ajlm-2099	84	32	iu	iu	NOUN
ajlm-2099	84	33	/	/	SYM
ajlm-2099	84	34	ml	ml	NOUN
ajlm-2099	84	35	)	)	PUNCT
ajlm-2099	84	36	.	.	PUNCT
ajlm-2099	85	1	all	all	DET
ajlm-2099	85	2	healthy	healthy	ADJ
ajlm-2099	85	3	controls	control	NOUN
ajlm-2099	85	4	were	be	AUX
ajlm-2099	85	5	negative	negative	ADJ
ajlm-2099	85	6	for	for	ADP
ajlm-2099	85	7	anti	anti	ADJ
ajlm-2099	85	8	-	-	ADJ
ajlm-2099	85	9	dsdna	dsdna	ADJ
ajlm-2099	85	10	using	use	VERB
ajlm-2099	85	11	both	both	CCONJ
ajlm-2099	85	12	iif	iif	PROPN
ajlm-2099	85	13	and	and	CCONJ
ajlm-2099	85	14	athena	athena	PROPN
ajlm-2099	85	15	multi	multi	PROPN
ajlm-2099	85	16	-	-	ADJ
ajlm-2099	85	17	lyte	lyte	ADJ
ajlm-2099	85	18	®	®	PROPN
ajlm-2099	85	19	ana	ana	PROPN
ajlm-2099	85	20	-	-	PUNCT
ajlm-2099	85	21	ii	ii	PROPN
ajlm-2099	85	22	.	.	PUNCT
ajlm-2099	86	1	one	one	NUM
ajlm-2099	86	2	patient	patient	NOUN
ajlm-2099	86	3	with	with	ADP
ajlm-2099	86	4	rheumatoid	rheumatoid	NOUN
ajlm-2099	86	5	arthritis	arthritis	NOUN
ajlm-2099	86	6	had	have	VERB
ajlm-2099	86	7	positive	positive	ADJ
ajlm-2099	86	8	anti	anti	ADJ
ajlm-2099	86	9	-	-	ADJ
ajlm-2099	86	10	dsdna	dsdna	ADJ
ajlm-2099	86	11	results	result	NOUN
ajlm-2099	86	12	with	with	ADP
ajlm-2099	86	13	iif	iif	PROPN
ajlm-2099	86	14	,	,	PUNCT
ajlm-2099	86	15	and	and	CCONJ
ajlm-2099	86	16	another	another	DET
ajlm-2099	86	17	one	one	NOUN
ajlm-2099	86	18	had	have	VERB
ajlm-2099	86	19	positive	positive	ADJ
ajlm-2099	86	20	results	result	NOUN
ajlm-2099	86	21	with	with	ADP
ajlm-2099	86	22	both	both	DET
ajlm-2099	86	23	methods	method	NOUN
ajlm-2099	86	24	.	.	PUNCT
ajlm-2099	87	1	there	there	PRON
ajlm-2099	87	2	was	be	VERB
ajlm-2099	87	3	a	a	DET
ajlm-2099	87	4	moderate	moderate	ADJ
ajlm-2099	87	5	correlation	correlation	NOUN
ajlm-2099	87	6	between	between	ADP
ajlm-2099	87	7	the	the	DET
ajlm-2099	87	8	anti	anti	ADJ
ajlm-2099	87	9	-	-	ADJ
ajlm-2099	87	10	dsdna	dsdna	ADJ
ajlm-2099	87	11	concentrations	concentration	NOUN
ajlm-2099	87	12	measured	measure	VERB
ajlm-2099	87	13	using	use	VERB
ajlm-2099	87	14	athena	athena	PROPN
ajlm-2099	87	15	multi	multi	PROPN
ajlm-2099	87	16	-	-	PROPN
ajlm-2099	87	17	lyte	lyte	ADJ
ajlm-2099	87	18	ana	ana	PROPN
ajlm-2099	87	19	-	-	PUNCT
ajlm-2099	87	20	ii	ii	PROPN
ajlm-2099	87	21	and	and	CCONJ
ajlm-2099	87	22	the	the	DET
ajlm-2099	87	23	anti	anti	ADJ
ajlm-2099	87	24	-	-	ADJ
ajlm-2099	87	25	dsdna	dsdna	ADJ
ajlm-2099	87	26	titres	titre	NOUN
ajlm-2099	87	27	estimated	estimate	VERB
ajlm-2099	87	28	using	use	VERB
ajlm-2099	87	29	iif	iif	PROPN
ajlm-2099	87	30	(	(	PUNCT
ajlm-2099	87	31	r	r	NOUN
ajlm-2099	87	32	=	=	SYM
ajlm-2099	87	33	0.55	0.55	NUM
ajlm-2099	87	34	,	,	PUNCT
ajlm-2099	87	35	p	p	X
ajlm-2099	87	36	<	<	X
ajlm-2099	87	37	0.001	0.001	NUM
ajlm-2099	87	38	)	)	PUNCT
ajlm-2099	87	39	.	.	PUNCT
ajlm-2099	88	1	the	the	DET
ajlm-2099	88	2	athena	athena	PROPN
ajlm-2099	88	3	multi	multi	PROPN
ajlm-2099	88	4	-	-	ADJ
ajlm-2099	88	5	lyte	lyte	ADJ
ajlm-2099	88	6	®	®	PROPN
ajlm-2099	88	7	ana	ana	PROPN
ajlm-2099	88	8	-	-	PUNCT
ajlm-2099	88	9	ii	ii	PROPN
ajlm-2099	88	10	and	and	CCONJ
ajlm-2099	88	11	iif	iif	PROPN
ajlm-2099	88	12	results	result	NOUN
ajlm-2099	88	13	exhibited	exhibit	VERB
ajlm-2099	88	14	substantial	substantial	ADJ
ajlm-2099	88	15	agreement	agreement	NOUN
ajlm-2099	88	16	with	with	ADP
ajlm-2099	88	17	respect	respect	NOUN
ajlm-2099	88	18	to	to	ADP
ajlm-2099	88	19	anti	anti	ADJ
ajlm-2099	88	20	-	-	ADJ
ajlm-2099	88	21	dsdna	dsdna	ADJ
ajlm-2099	88	22	testing	testing	NOUN
ajlm-2099	88	23	(	(	PUNCT
ajlm-2099	88	24	κ	κ	X
ajlm-2099	88	25	=	=	SYM
ajlm-2099	88	26	0.66	0.66	NUM
ajlm-2099	88	27	,	,	PUNCT
ajlm-2099	88	28	95	95	NUM
ajlm-2099	88	29	%	%	NOUN
ajlm-2099	88	30	confidence	confidence	NOUN
ajlm-2099	88	31	intervals	interval	NOUN
ajlm-2099	88	32	:	:	PUNCT
ajlm-2099	88	33	0.53–0.79	0.53–0.79	NOUN
ajlm-2099	88	34	,	,	PUNCT
ajlm-2099	88	35	percent	percent	NOUN
ajlm-2099	88	36	agreement	agreement	NOUN
ajlm-2099	88	37	:	:	PUNCT
ajlm-2099	88	38	87.6	87.6	NUM
ajlm-2099	88	39	%	%	NOUN
ajlm-2099	88	40	,	,	PUNCT
ajlm-2099	88	41	p	p	X
ajlm-2099	88	42	<	<	X
ajlm-2099	88	43	0.001	0.001	NUM
ajlm-2099	88	44	)	)	PUNCT
ajlm-2099	88	45	.	.	PUNCT
ajlm-2099	89	1	at	at	ADP
ajlm-2099	89	2	the	the	DET
ajlm-2099	89	3	manufacturer	manufacturer	NOUN
ajlm-2099	89	4	’s	’s	PART
ajlm-2099	89	5	cut	cut	NOUN
ajlm-2099	89	6	-	-	PUNCT
ajlm-2099	89	7	off	off	NOUN
ajlm-2099	89	8	(	(	PUNCT
ajlm-2099	89	9	120	120	NUM
ajlm-2099	89	10	iu	iu	NOUN
ajlm-2099	89	11	/	/	SYM
ajlm-2099	89	12	ml	ml	NOUN
ajlm-2099	89	13	)	)	PUNCT
ajlm-2099	89	14	,	,	PUNCT
ajlm-2099	89	15	the	the	DET
ajlm-2099	89	16	sensitivity	sensitivity	NOUN
ajlm-2099	89	17	of	of	ADP
ajlm-2099	89	18	athena	athena	PROPN
ajlm-2099	89	19	multi	multi	PROPN
ajlm-2099	89	20	-	-	PROPN
ajlm-2099	89	21	lyte	lyte	ADJ
ajlm-2099	89	22	ana	ana	PROPN
ajlm-2099	89	23	-	-	PUNCT
ajlm-2099	89	24	ii	ii	PROPN
ajlm-2099	89	25	for	for	ADP
ajlm-2099	89	26	sle	sle	PROPN
ajlm-2099	89	27	diagnosis	diagnosis	NOUN
ajlm-2099	89	28	was	be	AUX
ajlm-2099	89	29	38.1	38.1	NUM
ajlm-2099	89	30	%	%	NOUN
ajlm-2099	89	31	,	,	PUNCT
ajlm-2099	89	32	and	and	CCONJ
ajlm-2099	89	33	the	the	DET
ajlm-2099	89	34	specificity	specificity	NOUN
ajlm-2099	89	35	was	be	AUX
ajlm-2099	89	36	98.5	98.5	NUM
ajlm-2099	89	37	%	%	NOUN
ajlm-2099	89	38	(	(	PUNCT
ajlm-2099	89	39	online	online	ADJ
ajlm-2099	89	40	supplementary	supplementary	ADJ
ajlm-2099	89	41	table	table	NOUN
ajlm-2099	89	42	1	1	NUM
ajlm-2099	89	43	,	,	PUNCT
ajlm-2099	89	44	figure	figure	NOUN
ajlm-2099	89	45	1	1	NUM
ajlm-2099	89	46	)	)	PUNCT
ajlm-2099	89	47	.	.	PUNCT
ajlm-2099	90	1	the	the	DET
ajlm-2099	90	2	best	good	ADJ
ajlm-2099	90	3	youden	youden	PROPN
ajlm-2099	90	4	’s	’s	PART
ajlm-2099	90	5	index	index	NOUN
ajlm-2099	90	6	was	be	AUX
ajlm-2099	90	7	obtained	obtain	VERB
ajlm-2099	90	8	when	when	SCONJ
ajlm-2099	90	9	the	the	DET
ajlm-2099	90	10	cut	cut	NOUN
ajlm-2099	90	11	-	-	PUNCT
ajlm-2099	90	12	off	off	NOUN
ajlm-2099	90	13	was	be	AUX
ajlm-2099	90	14	lowered	lower	VERB
ajlm-2099	90	15	to	to	ADP
ajlm-2099	90	16	109	109	NUM
ajlm-2099	90	17	iu	iu	NOUN
ajlm-2099	90	18	/	/	SYM
ajlm-2099	90	19	ml	ml	NOUN
ajlm-2099	90	20	,	,	PUNCT
ajlm-2099	90	21	at	at	ADP
ajlm-2099	90	22	which	which	PRON
ajlm-2099	90	23	the	the	DET
ajlm-2099	90	24	sensitivity	sensitivity	NOUN
ajlm-2099	90	25	increased	increase	VERB
ajlm-2099	90	26	to	to	ADP
ajlm-2099	90	27	46.7	46.7	NUM
ajlm-2099	90	28	%	%	NOUN
ajlm-2099	90	29	and	and	CCONJ
ajlm-2099	90	30	the	the	DET
ajlm-2099	90	31	specificity	specificity	NOUN
ajlm-2099	90	32	decreased	decrease	VERB
ajlm-2099	90	33	to	to	ADP
ajlm-2099	90	34	96.9	96.9	NUM
ajlm-2099	90	35	%	%	NOUN
ajlm-2099	90	36	.	.	PUNCT
ajlm-2099	91	1	full	full	ADJ
ajlm-2099	91	2	(	(	PUNCT
ajlm-2099	91	3	100	100	NUM
ajlm-2099	91	4	%	%	NOUN
ajlm-2099	91	5	)	)	PUNCT
ajlm-2099	91	6	specificity	specificity	NOUN
ajlm-2099	91	7	was	be	AUX
ajlm-2099	91	8	reached	reach	VERB
ajlm-2099	91	9	by	by	ADP
ajlm-2099	91	10	increasing	increase	VERB
ajlm-2099	91	11	the	the	DET
ajlm-2099	91	12	cut	cut	NOUN
ajlm-2099	91	13	-	-	PUNCT
ajlm-2099	91	14	off	off	NOUN
ajlm-2099	91	15	to	to	ADP
ajlm-2099	91	16	134	134	NUM
ajlm-2099	91	17	iu	iu	NOUN
ajlm-2099	91	18	/	/	SYM
ajlm-2099	91	19	ml	ml	NOUN
ajlm-2099	91	20	,	,	PUNCT
ajlm-2099	91	21	but	but	CCONJ
ajlm-2099	91	22	this	this	PRON
ajlm-2099	91	23	caused	cause	VERB
ajlm-2099	91	24	the	the	DET
ajlm-2099	91	25	sensitivity	sensitivity	NOUN
ajlm-2099	91	26	to	to	PART
ajlm-2099	91	27	decrease	decrease	VERB
ajlm-2099	91	28	to	to	ADP
ajlm-2099	91	29	37.1	37.1	NUM
ajlm-2099	91	30	%	%	NOUN
ajlm-2099	91	31	.	.	PUNCT
ajlm-2099	92	1	for	for	ADP
ajlm-2099	92	2	iif	iif	PROPN
ajlm-2099	92	3	,	,	PUNCT
ajlm-2099	92	4	the	the	DET
ajlm-2099	92	5	sensitivity	sensitivity	NOUN
ajlm-2099	92	6	was	be	AUX
ajlm-2099	92	7	38.1	38.1	NUM
ajlm-2099	92	8	%	%	NOUN
ajlm-2099	92	9	and	and	CCONJ
ajlm-2099	92	10	the	the	DET
ajlm-2099	92	11	specificity	specificity	NOUN
ajlm-2099	92	12	was	be	AUX
ajlm-2099	92	13	96.9	96.9	NUM
ajlm-2099	92	14	%	%	NOUN
ajlm-2099	92	15	.	.	PUNCT
ajlm-2099	93	1	however	however	ADV
ajlm-2099	93	2	,	,	PUNCT
ajlm-2099	93	3	the	the	DET
ajlm-2099	93	4	combination	combination	NOUN
ajlm-2099	93	5	of	of	ADP
ajlm-2099	93	6	both	both	DET
ajlm-2099	93	7	methods	method	NOUN
ajlm-2099	93	8	at	at	ADP
ajlm-2099	93	9	the	the	DET
ajlm-2099	93	10	manufacturer	manufacturer	NOUN
ajlm-2099	93	11	’s	’s	PART
ajlm-2099	93	12	cut	cut	NOUN
ajlm-2099	93	13	-	-	PUNCT
ajlm-2099	93	14	off	off	NOUN
ajlm-2099	93	15	(	(	PUNCT
ajlm-2099	93	16	120	120	NUM
ajlm-2099	93	17	iu	iu	NOUN
ajlm-2099	93	18	/	/	SYM
ajlm-2099	93	19	ml	ml	VERB
ajlm-2099	93	20	)	)	PUNCT
ajlm-2099	93	21	increased	increase	VERB
ajlm-2099	93	22	the	the	DET
ajlm-2099	93	23	sensitivity	sensitivity	NOUN
ajlm-2099	93	24	to	to	ADP
ajlm-2099	93	25	47.6	47.6	NUM
ajlm-2099	93	26	%	%	NOUN
ajlm-2099	93	27	and	and	CCONJ
ajlm-2099	93	28	the	the	DET
ajlm-2099	93	29	specificity	specificity	NOUN
ajlm-2099	93	30	to	to	ADP
ajlm-2099	93	31	96.9	96.9	NUM
ajlm-2099	93	32	%	%	NOUN
ajlm-2099	93	33	.	.	PUNCT
ajlm-2099	94	1	figure	figure	VERB
ajlm-2099	94	2	1	1	NUM
ajlm-2099	94	3	:	:	PUNCT
ajlm-2099	94	4	receiver	receiver	ADJ
ajlm-2099	94	5	operating	operate	VERB
ajlm-2099	94	6	characteristic	characteristic	ADJ
ajlm-2099	94	7	curves	curve	NOUN
ajlm-2099	94	8	showing	show	VERB
ajlm-2099	94	9	the	the	DET
ajlm-2099	94	10	clinical	clinical	ADJ
ajlm-2099	94	11	performance	performance	NOUN
ajlm-2099	94	12	of	of	ADP
ajlm-2099	94	13	iif	iif	PROPN
ajlm-2099	94	14	and	and	CCONJ
ajlm-2099	94	15	athena	athena	PROPN
ajlm-2099	94	16	multi	multi	PROPN
ajlm-2099	94	17	-	-	PROPN
ajlm-2099	94	18	lyte	lyte	ADJ
ajlm-2099	94	19	ana	ana	PROPN
ajlm-2099	94	20	-	-	PUNCT
ajlm-2099	94	21	ii	ii	PROPN
ajlm-2099	94	22	when	when	SCONJ
ajlm-2099	94	23	conducted	conduct	VERB
ajlm-2099	94	24	separately	separately	ADV
ajlm-2099	94	25	and	and	CCONJ
ajlm-2099	94	26	in	in	ADP
ajlm-2099	94	27	combination	combination	NOUN
ajlm-2099	94	28	for	for	ADP
ajlm-2099	94	29	the	the	DET
ajlm-2099	94	30	diagnosis	diagnosis	NOUN
ajlm-2099	94	31	of	of	ADP
ajlm-2099	94	32	sle	sle	NOUN
ajlm-2099	94	33	among	among	ADP
ajlm-2099	94	34	patients	patient	NOUN
ajlm-2099	94	35	attending	attend	VERB
ajlm-2099	94	36	zagazig	zagazig	PROPN
ajlm-2099	94	37	university	university	NOUN
ajlm-2099	94	38	hospitals	hospital	NOUN
ajlm-2099	94	39	,	,	PUNCT
ajlm-2099	94	40	zagazig	zagazig	PROPN
ajlm-2099	94	41	,	,	PUNCT
ajlm-2099	94	42	al	al	PROPN
ajlm-2099	94	43	sharqia	sharqia	PROPN
ajlm-2099	94	44	,	,	PUNCT
ajlm-2099	94	45	egypt	egypt	PROPN
ajlm-2099	94	46	,	,	PUNCT
ajlm-2099	94	47	between	between	ADP
ajlm-2099	94	48	may	may	PROPN
ajlm-2099	94	49	2020	2020	NUM
ajlm-2099	94	50	and	and	CCONJ
ajlm-2099	94	51	april	april	PROPN
ajlm-2099	94	52	2022	2022	NUM
ajlm-2099	94	53	.	.	PUNCT
ajlm-2099	95	1	the	the	DET
ajlm-2099	95	2	european	european	PROPN
ajlm-2099	95	3	league	league	PROPN
ajlm-2099	95	4	against	against	ADP
ajlm-2099	95	5	rheumatism	rheumatism	NOUN
ajlm-2099	95	6	and	and	CCONJ
ajlm-2099	95	7	the	the	DET
ajlm-2099	95	8	american	american	PROPN
ajlm-2099	95	9	college	college	PROPN
ajlm-2099	95	10	of	of	ADP
ajlm-2099	95	11	rheumatology	rheumatology	NOUN
ajlm-2099	95	12	criteria	criterion	NOUN
ajlm-2099	95	13	was	be	AUX
ajlm-2099	95	14	used	use	VERB
ajlm-2099	95	15	as	as	ADP
ajlm-2099	95	16	the	the	DET
ajlm-2099	95	17	gold	gold	NOUN
ajlm-2099	95	18	standard	standard	NOUN
ajlm-2099	95	19	.	.	PUNCT
ajlm-2099	96	1	to	to	PART
ajlm-2099	96	2	determine	determine	VERB
ajlm-2099	96	3	its	its	PRON
ajlm-2099	96	4	analytical	analytical	ADJ
ajlm-2099	96	5	performance	performance	NOUN
ajlm-2099	96	6	,	,	PUNCT
ajlm-2099	96	7	we	we	PRON
ajlm-2099	96	8	compared	compare	VERB
ajlm-2099	96	9	the	the	DET
ajlm-2099	96	10	results	result	NOUN
ajlm-2099	96	11	of	of	ADP
ajlm-2099	96	12	athena	athena	PROPN
ajlm-2099	96	13	multi	multi	PROPN
ajlm-2099	96	14	-	-	ADJ
ajlm-2099	96	15	lyte	lyte	ADJ
ajlm-2099	96	16	®	®	PROPN
ajlm-2099	96	17	ana	ana	PROPN
ajlm-2099	96	18	-	-	PUNCT
ajlm-2099	96	19	ii	ii	PROPN
ajlm-2099	96	20	to	to	ADP
ajlm-2099	96	21	those	those	PRON
ajlm-2099	96	22	of	of	ADP
ajlm-2099	96	23	iif	iif	PROPN
ajlm-2099	96	24	,	,	PUNCT
ajlm-2099	96	25	the	the	DET
ajlm-2099	96	26	gold	gold	NOUN
ajlm-2099	96	27	-	-	PUNCT
ajlm-2099	96	28	standard	standard	NOUN
ajlm-2099	96	29	method	method	NOUN
ajlm-2099	96	30	.	.	PUNCT
ajlm-2099	97	1	athena	athena	PROPN
ajlm-2099	97	2	multi	multi	PROPN
ajlm-2099	97	3	-	-	ADJ
ajlm-2099	97	4	lyte	lyte	ADJ
ajlm-2099	97	5	®	®	PROPN
ajlm-2099	97	6	ana	ana	PROPN
ajlm-2099	97	7	-	-	PUNCT
ajlm-2099	97	8	ii	ii	PROPN
ajlm-2099	97	9	had	have	VERB
ajlm-2099	97	10	a	a	DET
ajlm-2099	97	11	sensitivity	sensitivity	NOUN
ajlm-2099	97	12	of	of	ADP
ajlm-2099	97	13	73.8	73.8	NUM
ajlm-2099	97	14	%	%	NOUN
ajlm-2099	97	15	(	(	PUNCT
ajlm-2099	97	16	95	95	NUM
ajlm-2099	97	17	%	%	NOUN
ajlm-2099	97	18	confidence	confidence	NOUN
ajlm-2099	97	19	intervals	interval	NOUN
ajlm-2099	97	20	:	:	PUNCT
ajlm-2099	97	21	57.96	57.96	NUM
ajlm-2099	97	22	%	%	NOUN
ajlm-2099	97	23	–	–	PUNCT
ajlm-2099	97	24	86.14	86.14	NUM
ajlm-2099	97	25	%	%	NOUN
ajlm-2099	97	26	)	)	PUNCT
ajlm-2099	97	27	,	,	PUNCT
ajlm-2099	97	28	a	a	DET
ajlm-2099	97	29	specificity	specificity	NOUN
ajlm-2099	97	30	of	of	ADP
ajlm-2099	97	31	92.19	92.19	NUM
ajlm-2099	97	32	%	%	NOUN
ajlm-2099	97	33	(	(	PUNCT
ajlm-2099	97	34	86.10	86.10	NUM
ajlm-2099	97	35	%	%	NOUN
ajlm-2099	97	36	–	–	PUNCT
ajlm-2099	97	37	96.19	96.19	NUM
ajlm-2099	97	38	%	%	NOUN
ajlm-2099	97	39	)	)	PUNCT
ajlm-2099	97	40	,	,	PUNCT
ajlm-2099	97	41	a	a	DET
ajlm-2099	97	42	positive	positive	ADJ
ajlm-2099	97	43	predictive	predictive	ADJ
ajlm-2099	97	44	value	value	NOUN
ajlm-2099	97	45	of	of	ADP
ajlm-2099	97	46	75.61	75.61	NUM
ajlm-2099	97	47	%	%	NOUN
ajlm-2099	97	48	(	(	PUNCT
ajlm-2099	97	49	62.47	62.47	NUM
ajlm-2099	97	50	%	%	NOUN
ajlm-2099	97	51	–	–	PUNCT
ajlm-2099	97	52	85.24	85.24	NUM
ajlm-2099	97	53	%	%	NOUN
ajlm-2099	97	54	)	)	PUNCT
ajlm-2099	97	55	,	,	PUNCT
ajlm-2099	97	56	a	a	DET
ajlm-2099	97	57	negative	negative	ADJ
ajlm-2099	97	58	predictive	predictive	ADJ
ajlm-2099	97	59	value	value	NOUN
ajlm-2099	97	60	of	of	ADP
ajlm-2099	97	61	91.47	91.47	NUM
ajlm-2099	97	62	%	%	NOUN
ajlm-2099	97	63	(	(	PUNCT
ajlm-2099	97	64	86.56	86.56	NUM
ajlm-2099	97	65	%	%	NOUN
ajlm-2099	97	66	–	–	PUNCT
ajlm-2099	97	67	94.70	94.70	NUM
ajlm-2099	97	68	%	%	NOUN
ajlm-2099	97	69	)	)	PUNCT
ajlm-2099	97	70	,	,	PUNCT
ajlm-2099	97	71	an	an	DET
ajlm-2099	97	72	accuracy	accuracy	NOUN
ajlm-2099	97	73	of	of	ADP
ajlm-2099	97	74	87.65	87.65	NUM
ajlm-2099	97	75	%	%	NOUN
ajlm-2099	97	76	(	(	PUNCT
ajlm-2099	97	77	81.74	81.74	NUM
ajlm-2099	97	78	%	%	NOUN
ajlm-2099	97	79	–	–	PUNCT
ajlm-2099	97	80	92.19	92.19	NUM
ajlm-2099	97	81	%	%	NOUN
ajlm-2099	97	82	)	)	PUNCT
ajlm-2099	97	83	,	,	PUNCT
ajlm-2099	97	84	and	and	CCONJ
ajlm-2099	97	85	an	an	DET
ajlm-2099	97	86	area	area	NOUN
ajlm-2099	97	87	under	under	ADP
ajlm-2099	97	88	the	the	DET
ajlm-2099	97	89	curves	curve	NOUN
ajlm-2099	97	90	of	of	ADP
ajlm-2099	97	91	0.830	0.830	NUM
ajlm-2099	97	92	(	(	PUNCT
ajlm-2099	97	93	0.746–0.914	0.746–0.914	NUM
ajlm-2099	97	94	)	)	PUNCT
ajlm-2099	97	95	(	(	PUNCT
ajlm-2099	97	96	figure	figure	NOUN
ajlm-2099	97	97	2	2	NUM
ajlm-2099	97	98	)	)	PUNCT
ajlm-2099	97	99	.	.	PUNCT
ajlm-2099	98	1	figure	figure	VERB
ajlm-2099	98	2	2	2	NUM
ajlm-2099	98	3	:	:	PUNCT
ajlm-2099	98	4	receiver	receiver	ADJ
ajlm-2099	98	5	operating	operate	VERB
ajlm-2099	98	6	characteristic	characteristic	ADJ
ajlm-2099	98	7	curve	curve	NOUN
ajlm-2099	98	8	showing	show	VERB
ajlm-2099	98	9	the	the	DET
ajlm-2099	98	10	analytical	analytical	ADJ
ajlm-2099	98	11	performance	performance	NOUN
ajlm-2099	98	12	of	of	ADP
ajlm-2099	98	13	athena	athena	PROPN
ajlm-2099	98	14	multi	multi	PROPN
ajlm-2099	98	15	-	-	PROPN
ajlm-2099	98	16	lyte	lyte	ADJ
ajlm-2099	98	17	ana	ana	PROPN
ajlm-2099	98	18	-	-	PUNCT
ajlm-2099	98	19	ii	ii	PROPN
ajlm-2099	98	20	in	in	ADP
ajlm-2099	98	21	the	the	DET
ajlm-2099	98	22	detection	detection	NOUN
ajlm-2099	98	23	of	of	ADP
ajlm-2099	98	24	anti	anti	ADJ
ajlm-2099	98	25	-	-	ADJ
ajlm-2099	98	26	double	double	ADJ
ajlm-2099	98	27	-	-	PUNCT
ajlm-2099	98	28	stranded	strand	VERB
ajlm-2099	98	29	dna	dna	NOUN
ajlm-2099	98	30	among	among	ADP
ajlm-2099	98	31	patients	patient	NOUN
ajlm-2099	98	32	with	with	ADP
ajlm-2099	98	33	sle	sle	PROPN
ajlm-2099	98	34	attending	attend	VERB
ajlm-2099	98	35	zagazig	zagazig	PROPN
ajlm-2099	98	36	university	university	NOUN
ajlm-2099	98	37	hospitals	hospital	NOUN
ajlm-2099	98	38	,	,	PUNCT
ajlm-2099	98	39	zagazig	zagazig	PROPN
ajlm-2099	98	40	,	,	PUNCT
ajlm-2099	98	41	al	al	PROPN
ajlm-2099	98	42	sharqia	sharqia	PROPN
ajlm-2099	98	43	,	,	PUNCT
ajlm-2099	98	44	egypt	egypt	PROPN
ajlm-2099	98	45	,	,	PUNCT
ajlm-2099	98	46	between	between	ADP
ajlm-2099	98	47	may	may	PROPN
ajlm-2099	98	48	2020	2020	NUM
ajlm-2099	98	49	and	and	CCONJ
ajlm-2099	98	50	april	april	PROPN
ajlm-2099	98	51	2022	2022	NUM
ajlm-2099	98	52	.	.	PUNCT
ajlm-2099	99	1	indirect	indirect	ADJ
ajlm-2099	99	2	immunofluorescence	immunofluorescence	NOUN
ajlm-2099	99	3	was	be	AUX
ajlm-2099	99	4	used	use	VERB
ajlm-2099	99	5	as	as	ADP
ajlm-2099	99	6	the	the	DET
ajlm-2099	99	7	gold	gold	NOUN
ajlm-2099	99	8	standard	standard	NOUN
ajlm-2099	99	9	.	.	PUNCT
ajlm-2099	100	1	anti	anti	ADJ
ajlm-2099	100	2	-	-	ADJ
ajlm-2099	100	3	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	100	4	and	and	CCONJ
ajlm-2099	100	5	anti	anti	ADJ
ajlm-2099	100	6	-	-	ADJ
ajlm-2099	100	7	proteinase	proteinase	ADJ
ajlm-2099	100	8	3	3	NUM
ajlm-2099	100	9	analyses	analysis	NOUN
ajlm-2099	100	10	using	use	VERB
ajlm-2099	100	11	iif	iif	PROPN
ajlm-2099	100	12	,	,	PUNCT
ajlm-2099	100	13	athena	athena	PROPN
ajlm-2099	100	14	multi	multi	PROPN
ajlm-2099	100	15	-	-	ADJ
ajlm-2099	100	16	lyte	lyte	ADJ
ajlm-2099	100	17	®	®	NOUN
ajlm-2099	100	18	iif	iif	NOUN
ajlm-2099	100	19	,	,	PUNCT
ajlm-2099	100	20	and	and	CCONJ
ajlm-2099	100	21	elisa	elisa	VERB
ajlm-2099	100	22	overall	overall	ADV
ajlm-2099	100	23	,	,	PUNCT
ajlm-2099	100	24	62.7	62.7	NUM
ajlm-2099	100	25	%	%	NOUN
ajlm-2099	100	26	(	(	PUNCT
ajlm-2099	100	27	47/75	47/75	NUM
ajlm-2099	100	28	)	)	PUNCT
ajlm-2099	100	29	and	and	CCONJ
ajlm-2099	100	30	14.7	14.7	NUM
ajlm-2099	100	31	%	%	NOUN
ajlm-2099	100	32	(	(	PUNCT
ajlm-2099	100	33	11/75	11/75	NUM
ajlm-2099	100	34	)	)	PUNCT
ajlm-2099	100	35	of	of	ADP
ajlm-2099	100	36	patients	patient	NOUN
ajlm-2099	100	37	tested	test	VERB
ajlm-2099	100	38	positive	positive	ADJ
ajlm-2099	100	39	for	for	ADP
ajlm-2099	100	40	p	p	NOUN
ajlm-2099	100	41	-	-	PUNCT
ajlm-2099	100	42	anca	anca	NOUN
ajlm-2099	100	43	and	and	CCONJ
ajlm-2099	100	44	c	c	NOUN
ajlm-2099	100	45	-	-	PUNCT
ajlm-2099	100	46	anca	anca	NOUN
ajlm-2099	100	47	by	by	ADP
ajlm-2099	100	48	iif	iif	PROPN
ajlm-2099	100	49	,	,	PUNCT
ajlm-2099	100	50	while	while	SCONJ
ajlm-2099	100	51	only	only	ADV
ajlm-2099	100	52	40.0	40.0	NUM
ajlm-2099	100	53	%	%	NOUN
ajlm-2099	100	54	(	(	PUNCT
ajlm-2099	100	55	30/75	30/75	NUM
ajlm-2099	100	56	)	)	PUNCT
ajlm-2099	100	57	and	and	CCONJ
ajlm-2099	100	58	14.7	14.7	NUM
ajlm-2099	100	59	%	%	NOUN
ajlm-2099	100	60	(	(	PUNCT
ajlm-2099	100	61	11/75	11/75	NUM
ajlm-2099	100	62	)	)	PUNCT
ajlm-2099	100	63	tested	test	VERB
ajlm-2099	100	64	positive	positive	ADJ
ajlm-2099	100	65	for	for	ADP
ajlm-2099	100	66	anti	anti	ADJ
ajlm-2099	100	67	-	-	ADJ
ajlm-2099	100	68	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	100	69	and	and	CCONJ
ajlm-2099	100	70	anti	anti	ADJ
ajlm-2099	100	71	-	-	ADJ
ajlm-2099	100	72	proteinase	proteinase	ADJ
ajlm-2099	100	73	3	3	NUM
ajlm-2099	100	74	by	by	ADP
ajlm-2099	100	75	athena	athena	PROPN
ajlm-2099	100	76	multi	multi	PROPN
ajlm-2099	100	77	-	-	PROPN
ajlm-2099	100	78	lyte	lyte	ADJ
ajlm-2099	100	79	aiv	aiv	NOUN
ajlm-2099	100	80	.	.	PUNCT
ajlm-2099	101	1	using	use	VERB
ajlm-2099	101	2	the	the	DET
ajlm-2099	101	3	elisa	elisa	NOUN
ajlm-2099	101	4	method	method	NOUN
ajlm-2099	101	5	,	,	PUNCT
ajlm-2099	101	6	32.0	32.0	NUM
ajlm-2099	101	7	%	%	NOUN
ajlm-2099	101	8	(	(	PUNCT
ajlm-2099	101	9	24/75	24/75	NUM
ajlm-2099	101	10	)	)	PUNCT
ajlm-2099	101	11	of	of	ADP
ajlm-2099	101	12	patients	patient	NOUN
ajlm-2099	101	13	were	be	AUX
ajlm-2099	101	14	positive	positive	ADJ
ajlm-2099	101	15	for	for	ADP
ajlm-2099	101	16	ani	ani	NOUN
ajlm-2099	101	17	-	-	PUNCT
ajlm-2099	101	18	myeloperoxidase	myeloperoxidase	NOUN
ajlm-2099	101	19	,	,	PUNCT
ajlm-2099	101	20	and	and	CCONJ
ajlm-2099	101	21	28.0	28.0	NUM
ajlm-2099	101	22	%	%	NOUN
ajlm-2099	101	23	(	(	PUNCT
ajlm-2099	101	24	21/75	21/75	NUM
ajlm-2099	101	25	)	)	PUNCT
ajlm-2099	101	26	were	be	AUX
ajlm-2099	101	27	positive	positive	ADJ
ajlm-2099	101	28	for	for	ADP
ajlm-2099	101	29	anti	anti	ADJ
ajlm-2099	101	30	-	-	ADJ
ajlm-2099	101	31	proteinase	proteinase	ADJ
ajlm-2099	101	32	3	3	NUM
ajlm-2099	101	33	.	.	PUNCT
ajlm-2099	102	1	all	all	DET
ajlm-2099	102	2	healthy	healthy	ADJ
ajlm-2099	102	3	volunteers	volunteer	NOUN
ajlm-2099	102	4	were	be	AUX
ajlm-2099	102	5	negative	negative	ADJ
ajlm-2099	102	6	for	for	ADP
ajlm-2099	102	7	anti	anti	ADJ
ajlm-2099	102	8	-	-	ADJ
ajlm-2099	102	9	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	102	10	and	and	CCONJ
ajlm-2099	102	11	anti	anti	ADJ
ajlm-2099	102	12	-	-	ADJ
ajlm-2099	102	13	proteinase	proteinase	ADJ
ajlm-2099	102	14	3	3	NUM
ajlm-2099	102	15	using	use	VERB
ajlm-2099	102	16	all	all	DET
ajlm-2099	102	17	three	three	NUM
ajlm-2099	102	18	methods	method	NOUN
ajlm-2099	102	19	.	.	PUNCT
ajlm-2099	103	1	all	all	DET
ajlm-2099	103	2	subjects	subject	NOUN
ajlm-2099	103	3	were	be	AUX
ajlm-2099	103	4	negative	negative	ADJ
ajlm-2099	103	5	for	for	ADP
ajlm-2099	103	6	anti	anti	ADJ
ajlm-2099	103	7	-	-	ADJ
ajlm-2099	103	8	glomerular	glomerular	ADJ
ajlm-2099	103	9	basement	basement	NOUN
ajlm-2099	103	10	membrane	membrane	NOUN
ajlm-2099	103	11	.	.	PUNCT
ajlm-2099	104	1	regarding	regard	VERB
ajlm-2099	104	2	the	the	DET
ajlm-2099	104	3	results	result	NOUN
ajlm-2099	104	4	of	of	ADP
ajlm-2099	104	5	anti	anti	ADJ
ajlm-2099	104	6	-	-	ADJ
ajlm-2099	104	7	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	104	8	testing	testing	NOUN
ajlm-2099	104	9	,	,	PUNCT
ajlm-2099	104	10	we	we	PRON
ajlm-2099	104	11	observed	observe	VERB
ajlm-2099	104	12	a	a	DET
ajlm-2099	104	13	substantial	substantial	ADJ
ajlm-2099	104	14	agreement	agreement	NOUN
ajlm-2099	104	15	between	between	ADP
ajlm-2099	104	16	iif	iif	PROPN
ajlm-2099	104	17	and	and	CCONJ
ajlm-2099	104	18	athena	athena	PROPN
ajlm-2099	104	19	multi	multi	PROPN
ajlm-2099	104	20	-	-	ADJ
ajlm-2099	104	21	lyte	lyte	ADJ
ajlm-2099	104	22	aiv	aiv	NOUN
ajlm-2099	104	23	(	(	PUNCT
ajlm-2099	104	24	κ	κ	X
ajlm-2099	104	25	=	=	NOUN
ajlm-2099	104	26	0.653	0.653	NUM
ajlm-2099	104	27	)	)	PUNCT
ajlm-2099	104	28	,	,	PUNCT
ajlm-2099	104	29	a	a	DET
ajlm-2099	104	30	moderate	moderate	ADJ
ajlm-2099	104	31	agreement	agreement	NOUN
ajlm-2099	104	32	between	between	ADP
ajlm-2099	104	33	iif	iif	PROPN
ajlm-2099	104	34	and	and	CCONJ
ajlm-2099	104	35	elisa	elisa	PROPN
ajlm-2099	104	36	(	(	PUNCT
ajlm-2099	104	37	κ	κ	NOUN
ajlm-2099	104	38	=	=	NOUN
ajlm-2099	104	39	0.525	0.525	NUM
ajlm-2099	104	40	)	)	PUNCT
ajlm-2099	104	41	,	,	PUNCT
ajlm-2099	104	42	and	and	CCONJ
ajlm-2099	104	43	an	an	DET
ajlm-2099	104	44	almost	almost	ADV
ajlm-2099	104	45	perfect	perfect	ADJ
ajlm-2099	104	46	agreement	agreement	NOUN
ajlm-2099	104	47	between	between	ADP
ajlm-2099	104	48	athena	athena	PROPN
ajlm-2099	104	49	multi	multi	PROPN
ajlm-2099	104	50	-	-	ADJ
ajlm-2099	104	51	lyte	lyte	ADJ
ajlm-2099	104	52	aiv	aiv	NOUN
ajlm-2099	104	53	and	and	CCONJ
ajlm-2099	104	54	elisa	elisa	PROPN
ajlm-2099	104	55	(	(	PUNCT
ajlm-2099	104	56	κ	κ	X
ajlm-2099	104	57	=	=	VERB
ajlm-2099	104	58	0.853	0.853	NUM
ajlm-2099	104	59	)	)	PUNCT
ajlm-2099	104	60	(	(	PUNCT
ajlm-2099	104	61	table	table	NOUN
ajlm-2099	104	62	3	3	NUM
ajlm-2099	104	63	)	)	PUNCT
ajlm-2099	104	64	.	.	PUNCT
ajlm-2099	105	1	for	for	ADP
ajlm-2099	105	2	anti	anti	ADJ
ajlm-2099	105	3	-	-	ADJ
ajlm-2099	105	4	proteinase	proteinase	ADJ
ajlm-2099	105	5	3	3	NUM
ajlm-2099	105	6	testing	testing	NOUN
ajlm-2099	105	7	,	,	PUNCT
ajlm-2099	105	8	there	there	PRON
ajlm-2099	105	9	was	be	VERB
ajlm-2099	105	10	a	a	DET
ajlm-2099	105	11	perfect	perfect	ADJ
ajlm-2099	105	12	agreement	agreement	NOUN
ajlm-2099	105	13	between	between	ADP
ajlm-2099	105	14	athena	athena	PROPN
ajlm-2099	105	15	multi	multi	PROPN
ajlm-2099	105	16	-	-	ADJ
ajlm-2099	105	17	lyte	lyte	ADJ
ajlm-2099	105	18	aiv	aiv	NOUN
ajlm-2099	105	19	and	and	CCONJ
ajlm-2099	105	20	iif	iif	PROPN
ajlm-2099	105	21	(	(	PUNCT
ajlm-2099	105	22	κ	κ	NOUN
ajlm-2099	105	23	=	=	NOUN
ajlm-2099	105	24	1	1	NUM
ajlm-2099	105	25	)	)	PUNCT
ajlm-2099	105	26	,	,	PUNCT
ajlm-2099	105	27	and	and	CCONJ
ajlm-2099	105	28	a	a	DET
ajlm-2099	105	29	substantial	substantial	ADJ
ajlm-2099	105	30	agreement	agreement	NOUN
ajlm-2099	105	31	between	between	ADP
ajlm-2099	105	32	elisa	elisa	NOUN
ajlm-2099	105	33	and	and	CCONJ
ajlm-2099	105	34	both	both	CCONJ
ajlm-2099	105	35	iif	iif	PROPN
ajlm-2099	105	36	and	and	CCONJ
ajlm-2099	105	37	athena	athena	PROPN
ajlm-2099	105	38	multi	multi	PROPN
ajlm-2099	105	39	-	-	ADJ
ajlm-2099	105	40	lyte	lyte	ADJ
ajlm-2099	105	41	aiv	aiv	NOUN
ajlm-2099	105	42	(	(	PUNCT
ajlm-2099	105	43	κ	κ	X
ajlm-2099	105	44	=	=	PROPN
ajlm-2099	105	45	0.635	0.635	NUM
ajlm-2099	105	46	)	)	PUNCT
ajlm-2099	105	47	.	.	PUNCT
ajlm-2099	106	1	moreover	moreover	ADV
ajlm-2099	106	2	,	,	PUNCT
ajlm-2099	106	3	the	the	DET
ajlm-2099	106	4	elisa	elisa	NOUN
ajlm-2099	106	5	results	result	NOUN
ajlm-2099	106	6	were	be	AUX
ajlm-2099	106	7	highly	highly	ADV
ajlm-2099	106	8	correlated	correlate	VERB
ajlm-2099	106	9	with	with	ADP
ajlm-2099	106	10	the	the	DET
ajlm-2099	106	11	athena	athena	PROPN
ajlm-2099	106	12	multi	multi	PROPN
ajlm-2099	106	13	-	-	ADJ
ajlm-2099	106	14	lyte	lyte	ADJ
ajlm-2099	106	15	aiv	aiv	NOUN
ajlm-2099	106	16	results	result	NOUN
ajlm-2099	106	17	for	for	ADP
ajlm-2099	106	18	the	the	DET
ajlm-2099	106	19	analyses	analysis	NOUN
ajlm-2099	106	20	of	of	ADP
ajlm-2099	106	21	both	both	CCONJ
ajlm-2099	106	22	anti	anti	ADJ
ajlm-2099	106	23	-	-	ADJ
ajlm-2099	106	24	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	106	25	(	(	PUNCT
ajlm-2099	106	26	r	r	NOUN
ajlm-2099	106	27	=	=	PUNCT
ajlm-2099	106	28	0.606	0.606	NUM
ajlm-2099	106	29	,	,	PUNCT
ajlm-2099	106	30	p	p	X
ajlm-2099	106	31	<	<	X
ajlm-2099	106	32	0.001	0.001	NUM
ajlm-2099	106	33	)	)	PUNCT
ajlm-2099	106	34	and	and	CCONJ
ajlm-2099	106	35	anti	anti	ADJ
ajlm-2099	106	36	-	-	ADJ
ajlm-2099	106	37	proteinase	proteinase	ADJ
ajlm-2099	106	38	3	3	NUM
ajlm-2099	106	39	(	(	PUNCT
ajlm-2099	106	40	r	r	NOUN
ajlm-2099	106	41	=	=	SYM
ajlm-2099	106	42	0.363	0.363	NUM
ajlm-2099	106	43	,	,	PUNCT
ajlm-2099	106	44	p	p	X
ajlm-2099	106	45	=	=	NOUN
ajlm-2099	106	46	0.006	0.006	NUM
ajlm-2099	106	47	)	)	PUNCT
ajlm-2099	106	48	.	.	PUNCT
ajlm-2099	107	1	table	table	NOUN
ajlm-2099	107	2	3	3	NUM
ajlm-2099	107	3	:	:	PUNCT
ajlm-2099	107	4	 	 	SPACE
ajlm-2099	107	5	agreement	agreement	NOUN
ajlm-2099	107	6	between	between	ADP
ajlm-2099	107	7	the	the	DET
ajlm-2099	107	8	studied	study	VERB
ajlm-2099	107	9	methods	method	NOUN
ajlm-2099	107	10	(	(	PUNCT
ajlm-2099	107	11	athena	athena	PROPN
ajlm-2099	107	12	multi	multi	PROPN
ajlm-2099	107	13	-	-	ADJ
ajlm-2099	107	14	lyte	lyte	ADJ
ajlm-2099	107	15	aiv	aiv	PROPN
ajlm-2099	107	16	,	,	PUNCT
ajlm-2099	107	17	iif	iif	PROPN
ajlm-2099	107	18	,	,	PUNCT
ajlm-2099	107	19	and	and	CCONJ
ajlm-2099	107	20	elisa	elisa	NOUN
ajlm-2099	107	21	)	)	PUNCT
ajlm-2099	107	22	for	for	ADP
ajlm-2099	107	23	anca	anca	NOUN
ajlm-2099	107	24	detection	detection	NOUN
ajlm-2099	107	25	among	among	ADP
ajlm-2099	107	26	aiv	aiv	NOUN
ajlm-2099	107	27	patients	patient	NOUN
ajlm-2099	107	28	attending	attend	VERB
ajlm-2099	107	29	zagazig	zagazig	PROPN
ajlm-2099	107	30	university	university	NOUN
ajlm-2099	107	31	hospitals	hospital	NOUN
ajlm-2099	107	32	,	,	PUNCT
ajlm-2099	107	33	zagazig	zagazig	PROPN
ajlm-2099	107	34	,	,	PUNCT
ajlm-2099	107	35	al	al	PROPN
ajlm-2099	107	36	sharqia	sharqia	PROPN
ajlm-2099	107	37	,	,	PUNCT
ajlm-2099	107	38	egypt	egypt	PROPN
ajlm-2099	107	39	,	,	PUNCT
ajlm-2099	107	40	between	between	ADP
ajlm-2099	107	41	may	may	PROPN
ajlm-2099	107	42	2020	2020	NUM
ajlm-2099	107	43	and	and	CCONJ
ajlm-2099	107	44	april	april	PROPN
ajlm-2099	107	45	2022	2022	NUM
ajlm-2099	107	46	.	.	PUNCT
ajlm-2099	108	1	the	the	DET
ajlm-2099	108	2	clinical	clinical	ADJ
ajlm-2099	108	3	performances	performance	NOUN
ajlm-2099	108	4	of	of	ADP
ajlm-2099	108	5	the	the	DET
ajlm-2099	108	6	anti	anti	ADJ
ajlm-2099	108	7	-	-	ADJ
ajlm-2099	108	8	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	108	9	and	and	CCONJ
ajlm-2099	108	10	anti	anti	ADJ
ajlm-2099	108	11	-	-	ADJ
ajlm-2099	108	12	proteinase	proteinase	ADJ
ajlm-2099	108	13	3	3	NUM
ajlm-2099	108	14	detection	detection	NOUN
ajlm-2099	108	15	methods	method	NOUN
ajlm-2099	108	16	could	could	AUX
ajlm-2099	108	17	not	not	PART
ajlm-2099	108	18	be	be	AUX
ajlm-2099	108	19	assessed	assess	VERB
ajlm-2099	108	20	because	because	SCONJ
ajlm-2099	108	21	a	a	DET
ajlm-2099	108	22	definitive	definitive	ADJ
ajlm-2099	108	23	diagnosis	diagnosis	NOUN
ajlm-2099	108	24	of	of	ADP
ajlm-2099	108	25	aiv	aiv	NOUN
ajlm-2099	108	26	relies	relie	NOUN
ajlm-2099	108	27	on	on	ADP
ajlm-2099	108	28	histopathology	histopathology	NOUN
ajlm-2099	108	29	,	,	PUNCT
ajlm-2099	108	30	which	which	PRON
ajlm-2099	108	31	was	be	AUX
ajlm-2099	108	32	not	not	PART
ajlm-2099	108	33	performed	perform	VERB
ajlm-2099	108	34	routinely	routinely	ADV
ajlm-2099	108	35	for	for	ADP
ajlm-2099	108	36	all	all	DET
ajlm-2099	108	37	patients	patient	NOUN
ajlm-2099	108	38	.	.	PUNCT
ajlm-2099	109	1	however	however	ADV
ajlm-2099	109	2	,	,	PUNCT
ajlm-2099	109	3	we	we	PRON
ajlm-2099	109	4	assessed	assess	VERB
ajlm-2099	109	5	the	the	DET
ajlm-2099	109	6	analytical	analytical	ADJ
ajlm-2099	109	7	performances	performance	NOUN
ajlm-2099	109	8	of	of	ADP
ajlm-2099	109	9	athena	athena	PROPN
ajlm-2099	109	10	multi	multi	PROPN
ajlm-2099	109	11	-	-	ADJ
ajlm-2099	109	12	lyte	lyte	ADJ
ajlm-2099	109	13	aiv	aiv	NOUN
ajlm-2099	109	14	and	and	CCONJ
ajlm-2099	109	15	elisa	elisa	PROPN
ajlm-2099	109	16	versus	versus	X
ajlm-2099	109	17	iif	iif	PROPN
ajlm-2099	109	18	,	,	PUNCT
ajlm-2099	109	19	the	the	DET
ajlm-2099	109	20	gold	gold	NOUN
ajlm-2099	109	21	-	-	PUNCT
ajlm-2099	109	22	standard	standard	NOUN
ajlm-2099	109	23	method	method	NOUN
ajlm-2099	109	24	.	.	PUNCT
ajlm-2099	110	1	for	for	ADP
ajlm-2099	110	2	anti	anti	ADJ
ajlm-2099	110	3	-	-	ADJ
ajlm-2099	110	4	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	110	5	,	,	PUNCT
ajlm-2099	110	6	athena	athena	PROPN
ajlm-2099	110	7	multi	multi	PROPN
ajlm-2099	110	8	-	-	ADJ
ajlm-2099	110	9	lyte	lyte	ADJ
ajlm-2099	110	10	aiv	aiv	NOUN
ajlm-2099	110	11	had	have	VERB
ajlm-2099	110	12	a	a	DET
ajlm-2099	110	13	higher	high	ADJ
ajlm-2099	110	14	sensitivity	sensitivity	NOUN
ajlm-2099	110	15	than	than	ADP
ajlm-2099	110	16	elisa	elisa	NOUN
ajlm-2099	110	17	(	(	PUNCT
ajlm-2099	110	18	63.8	63.8	NUM
ajlm-2099	110	19	%	%	NOUN
ajlm-2099	110	20	vs	vs	ADP
ajlm-2099	110	21	51.6	51.6	NUM
ajlm-2099	110	22	%	%	NOUN
ajlm-2099	110	23	)	)	PUNCT
ajlm-2099	110	24	,	,	PUNCT
ajlm-2099	110	25	while	while	SCONJ
ajlm-2099	110	26	both	both	DET
ajlm-2099	110	27	tests	test	NOUN
ajlm-2099	110	28	had	have	VERB
ajlm-2099	110	29	a	a	DET
ajlm-2099	110	30	specificity	specificity	NOUN
ajlm-2099	110	31	of	of	ADP
ajlm-2099	110	32	100	100	NUM
ajlm-2099	110	33	%	%	NOUN
ajlm-2099	110	34	(	(	PUNCT
ajlm-2099	110	35	online	online	ADJ
ajlm-2099	110	36	supplementary	supplementary	ADJ
ajlm-2099	110	37	table	table	NOUN
ajlm-2099	110	38	2	2	NUM
ajlm-2099	110	39	)	)	PUNCT
ajlm-2099	110	40	.	.	PUNCT
ajlm-2099	111	1	for	for	ADP
ajlm-2099	111	2	anti	anti	ADJ
ajlm-2099	111	3	-	-	ADJ
ajlm-2099	111	4	proteinase	proteinase	ADJ
ajlm-2099	111	5	3	3	NUM
ajlm-2099	111	6	,	,	PUNCT
ajlm-2099	111	7	both	both	DET
ajlm-2099	111	8	methods	method	NOUN
ajlm-2099	111	9	had	have	VERB
ajlm-2099	111	10	a	a	DET
ajlm-2099	111	11	sensitivity	sensitivity	NOUN
ajlm-2099	111	12	of	of	ADP
ajlm-2099	111	13	100	100	NUM
ajlm-2099	111	14	%	%	NOUN
ajlm-2099	111	15	,	,	PUNCT
ajlm-2099	111	16	while	while	SCONJ
ajlm-2099	111	17	athena	athena	PROPN
ajlm-2099	111	18	multi	multi	PROPN
ajlm-2099	111	19	-	-	ADJ
ajlm-2099	111	20	lyte	lyte	ADJ
ajlm-2099	111	21	aiv	aiv	NOUN
ajlm-2099	111	22	had	have	VERB
ajlm-2099	111	23	a	a	DET
ajlm-2099	111	24	higher	high	ADJ
ajlm-2099	111	25	specificity	specificity	NOUN
ajlm-2099	111	26	than	than	ADP
ajlm-2099	111	27	elisa	elisa	NOUN
ajlm-2099	111	28	(	(	PUNCT
ajlm-2099	111	29	100	100	NUM
ajlm-2099	111	30	%	%	NOUN
ajlm-2099	111	31	vs	vs	ADP
ajlm-2099	111	32	88.8	88.8	NUM
ajlm-2099	111	33	%	%	NOUN
ajlm-2099	111	34	)	)	PUNCT
ajlm-2099	111	35	.	.	PUNCT
ajlm-2099	112	1	a	a	DET
ajlm-2099	112	2	comparison	comparison	NOUN
ajlm-2099	112	3	of	of	ADP
ajlm-2099	112	4	the	the	DET
ajlm-2099	112	5	general	general	ADJ
ajlm-2099	112	6	characteristics	characteristic	NOUN
ajlm-2099	112	7	of	of	ADP
ajlm-2099	112	8	the	the	DET
ajlm-2099	112	9	methods	method	NOUN
ajlm-2099	112	10	used	use	VERB
ajlm-2099	112	11	showed	show	VERB
ajlm-2099	112	12	that	that	SCONJ
ajlm-2099	112	13	iif	iif	PROPN
ajlm-2099	112	14	had	have	VERB
ajlm-2099	112	15	the	the	DET
ajlm-2099	112	16	highest	high	ADJ
ajlm-2099	112	17	estimated	estimate	VERB
ajlm-2099	112	18	cost	cost	NOUN
ajlm-2099	112	19	(	(	PUNCT
ajlm-2099	112	20	240.00	240.00	NUM
ajlm-2099	112	21	egyptian	egyptian	ADJ
ajlm-2099	112	22	pounds	pound	NOUN
ajlm-2099	113	1	[	[	X
ajlm-2099	113	2	egp	egp	X
ajlm-2099	113	3	]	]	X
ajlm-2099	113	4	)	)	PUNCT
ajlm-2099	113	5	for	for	ADP
ajlm-2099	113	6	anti	anti	ADJ
ajlm-2099	113	7	-	-	ADJ
ajlm-2099	113	8	dsdna	dsdna	ADJ
ajlm-2099	113	9	testing	testing	NOUN
ajlm-2099	113	10	as	as	SCONJ
ajlm-2099	113	11	further	further	ADJ
ajlm-2099	113	12	dilutions	dilution	NOUN
ajlm-2099	113	13	were	be	AUX
ajlm-2099	113	14	required	require	VERB
ajlm-2099	113	15	to	to	PART
ajlm-2099	113	16	obtain	obtain	VERB
ajlm-2099	113	17	the	the	DET
ajlm-2099	113	18	antibody	antibody	NOUN
ajlm-2099	113	19	titre	titre	NOUN
ajlm-2099	113	20	using	use	VERB
ajlm-2099	113	21	iif	iif	PROPN
ajlm-2099	113	22	(	(	PUNCT
ajlm-2099	113	23	table	table	NOUN
ajlm-2099	113	24	4	4	NUM
ajlm-2099	113	25	)	)	PUNCT
ajlm-2099	113	26	.	.	PUNCT
ajlm-2099	114	1	however	however	ADV
ajlm-2099	114	2	,	,	PUNCT
ajlm-2099	114	3	for	for	ADP
ajlm-2099	114	4	anca	anca	PROPN
ajlm-2099	114	5	testing	testing	NOUN
ajlm-2099	114	6	,	,	PUNCT
ajlm-2099	114	7	elisa	elisa	PROPN
ajlm-2099	114	8	had	have	VERB
ajlm-2099	114	9	the	the	DET
ajlm-2099	114	10	highest	high	ADJ
ajlm-2099	114	11	cost	cost	NOUN
ajlm-2099	114	12	(	(	PUNCT
ajlm-2099	114	13	200.00	200.00	NUM
ajlm-2099	114	14	egp	egp	NOUN
ajlm-2099	114	15	)	)	PUNCT
ajlm-2099	114	16	and	and	CCONJ
ajlm-2099	114	17	time	time	NOUN
ajlm-2099	114	18	consumption	consumption	NOUN
ajlm-2099	114	19	(	(	PUNCT
ajlm-2099	114	20	180	180	NUM
ajlm-2099	114	21	min	min	NOUN
ajlm-2099	114	22	)	)	PUNCT
ajlm-2099	114	23	due	due	ADP
ajlm-2099	114	24	to	to	ADP
ajlm-2099	114	25	the	the	DET
ajlm-2099	114	26	need	need	NOUN
ajlm-2099	114	27	for	for	ADP
ajlm-2099	114	28	two	two	NUM
ajlm-2099	114	29	separate	separate	ADJ
ajlm-2099	114	30	kits	kit	NOUN
ajlm-2099	114	31	to	to	PART
ajlm-2099	114	32	obtain	obtain	VERB
ajlm-2099	114	33	antigen	antigen	ADV
ajlm-2099	114	34	-	-	PUNCT
ajlm-2099	114	35	specific	specific	ADJ
ajlm-2099	114	36	identification	identification	NOUN
ajlm-2099	114	37	of	of	ADP
ajlm-2099	114	38	anti	anti	ADJ
ajlm-2099	114	39	-	-	ADJ
ajlm-2099	114	40	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	114	41	and	and	CCONJ
ajlm-2099	114	42	anti	anti	ADJ
ajlm-2099	114	43	-	-	ADJ
ajlm-2099	114	44	proteinase	proteinase	ADJ
ajlm-2099	114	45	3	3	NUM
ajlm-2099	114	46	.	.	PUNCT
ajlm-2099	115	1	in	in	ADP
ajlm-2099	115	2	addition	addition	NOUN
ajlm-2099	115	3	to	to	ADP
ajlm-2099	115	4	being	be	AUX
ajlm-2099	115	5	a	a	DET
ajlm-2099	115	6	quantitative	quantitative	NOUN
ajlm-2099	115	7	rather	rather	ADV
ajlm-2099	115	8	than	than	ADP
ajlm-2099	115	9	semi	semi	ADJ
ajlm-2099	115	10	-	-	ADJ
ajlm-2099	115	11	quantitative	quantitative	ADJ
ajlm-2099	115	12	assay	assay	NOUN
ajlm-2099	115	13	,	,	PUNCT
ajlm-2099	115	14	the	the	PRON
ajlm-2099	115	15	athena	athena	PROPN
ajlm-2099	115	16	multi	multi	PROPN
ajlm-2099	115	17	-	-	PROPN
ajlm-2099	115	18	lyte	lyte	PROPN
ajlm-2099	115	19	also	also	ADV
ajlm-2099	115	20	required	require	VERB
ajlm-2099	115	21	the	the	DET
ajlm-2099	115	22	least	least	ADJ
ajlm-2099	115	23	amount	amount	NOUN
ajlm-2099	115	24	of	of	ADP
ajlm-2099	115	25	technical	technical	ADJ
ajlm-2099	115	26	expertise	expertise	NOUN
ajlm-2099	115	27	(	(	PUNCT
ajlm-2099	115	28	a	a	DET
ajlm-2099	115	29	bachelor	bachelor	NOUN
ajlm-2099	115	30	’s	’s	PART
ajlm-2099	115	31	degree	degree	NOUN
ajlm-2099	115	32	in	in	ADP
ajlm-2099	115	33	clinical	clinical	ADJ
ajlm-2099	115	34	laboratory	laboratory	NOUN
ajlm-2099	115	35	science	science	NOUN
ajlm-2099	115	36	)	)	PUNCT
ajlm-2099	115	37	,	,	PUNCT
ajlm-2099	115	38	was	be	AUX
ajlm-2099	115	39	the	the	DET
ajlm-2099	115	40	least	least	ADJ
ajlm-2099	115	41	time	time	NOUN
ajlm-2099	115	42	-	-	PUNCT
ajlm-2099	115	43	consuming	consume	VERB
ajlm-2099	115	44	(	(	PUNCT
ajlm-2099	115	45	90	90	NUM
ajlm-2099	115	46	min	min	NOUN
ajlm-2099	115	47	)	)	PUNCT
ajlm-2099	115	48	,	,	PUNCT
ajlm-2099	115	49	and	and	CCONJ
ajlm-2099	115	50	had	have	VERB
ajlm-2099	115	51	intermediate	intermediate	ADJ
ajlm-2099	115	52	costs	cost	NOUN
ajlm-2099	115	53	(	(	PUNCT
ajlm-2099	115	54	120.00	120.00	NUM
ajlm-2099	115	55	egp	egp	NOUN
ajlm-2099	115	56	)	)	PUNCT
ajlm-2099	115	57	.	.	PUNCT
ajlm-2099	116	1	table	table	NOUN
ajlm-2099	116	2	4	4	NUM
ajlm-2099	116	3	:	:	PUNCT
ajlm-2099	116	4	 	 	SPACE
ajlm-2099	116	5	comparison	comparison	NOUN
ajlm-2099	116	6	of	of	ADP
ajlm-2099	116	7	the	the	DET
ajlm-2099	116	8	general	general	ADJ
ajlm-2099	116	9	characteristics	characteristic	NOUN
ajlm-2099	116	10	of	of	ADP
ajlm-2099	116	11	athena	athena	PROPN
ajlm-2099	116	12	multi	multi	PROPN
ajlm-2099	116	13	-	-	PROPN
ajlm-2099	116	14	lyte	lyte	PROPN
ajlm-2099	116	15	,	,	PUNCT
ajlm-2099	116	16	iif	iif	PROPN
ajlm-2099	116	17	,	,	PUNCT
ajlm-2099	116	18	and	and	CCONJ
ajlm-2099	116	19	elisa	elisa	NOUN
ajlm-2099	116	20	used	use	VERB
ajlm-2099	116	21	for	for	ADP
ajlm-2099	116	22	anti	anti	ADJ
ajlm-2099	116	23	-	-	ADJ
ajlm-2099	116	24	dsdna	dsdna	ADJ
ajlm-2099	116	25	and	and	CCONJ
ajlm-2099	116	26	anca	anca	NOUN
ajlm-2099	116	27	detection	detection	NOUN
ajlm-2099	116	28	among	among	ADP
ajlm-2099	116	29	sle	sle	PROPN
ajlm-2099	116	30	and	and	CCONJ
ajlm-2099	116	31	aiv	aiv	NOUN
ajlm-2099	116	32	patients	patient	NOUN
ajlm-2099	116	33	attending	attend	VERB
ajlm-2099	116	34	zagazig	zagazig	PROPN
ajlm-2099	116	35	university	university	NOUN
ajlm-2099	116	36	hospitals	hospital	NOUN
ajlm-2099	116	37	,	,	PUNCT
ajlm-2099	116	38	zagazig	zagazig	PROPN
ajlm-2099	116	39	,	,	PUNCT
ajlm-2099	116	40	al	al	PROPN
ajlm-2099	116	41	sharqia	sharqia	PROPN
ajlm-2099	116	42	,	,	PUNCT
ajlm-2099	116	43	egypt	egypt	PROPN
ajlm-2099	116	44	,	,	PUNCT
ajlm-2099	116	45	between	between	ADP
ajlm-2099	116	46	may	may	PROPN
ajlm-2099	116	47	2020	2020	NUM
ajlm-2099	116	48	and	and	CCONJ
ajlm-2099	116	49	april	april	PROPN
ajlm-2099	116	50	2022	2022	NUM
ajlm-2099	116	51	.	.	PUNCT
ajlm-2099	117	1	discussion	discussion	NOUN
ajlm-2099	117	2	this	this	DET
ajlm-2099	117	3	work	work	NOUN
ajlm-2099	117	4	was	be	AUX
ajlm-2099	117	5	designed	design	VERB
ajlm-2099	117	6	to	to	PART
ajlm-2099	117	7	evaluate	evaluate	VERB
ajlm-2099	117	8	the	the	DET
ajlm-2099	117	9	performance	performance	NOUN
ajlm-2099	117	10	of	of	ADP
ajlm-2099	117	11	two	two	NUM
ajlm-2099	117	12	commercially	commercially	ADV
ajlm-2099	117	13	available	available	ADJ
ajlm-2099	117	14	multiplex	multiplex	PROPN
ajlm-2099	117	15	bead	bead	NOUN
ajlm-2099	117	16	-	-	PUNCT
ajlm-2099	117	17	based	base	VERB
ajlm-2099	117	18	flow	flow	NOUN
ajlm-2099	117	19	cytometric	cytometric	ADJ
ajlm-2099	117	20	assays	assay	NOUN
ajlm-2099	117	21	,	,	PUNCT
ajlm-2099	117	22	the	the	DET
ajlm-2099	117	23	athena	athena	PROPN
ajlm-2099	117	24	multi	multi	PROPN
ajlm-2099	117	25	-	-	PROPN
ajlm-2099	117	26	lyte	lyte	ADJ
ajlm-2099	117	27	ana	ana	PROPN
ajlm-2099	117	28	-	-	PUNCT
ajlm-2099	117	29	ii	ii	PROPN
ajlm-2099	117	30	and	and	CCONJ
ajlm-2099	117	31	athena	athena	PROPN
ajlm-2099	117	32	multi	multi	PROPN
ajlm-2099	117	33	-	-	ADJ
ajlm-2099	117	34	lyte	lyte	ADJ
ajlm-2099	117	35	aiv	aiv	NOUN
ajlm-2099	117	36	systems	system	NOUN
ajlm-2099	117	37	,	,	PUNCT
ajlm-2099	117	38	for	for	ADP
ajlm-2099	117	39	the	the	DET
ajlm-2099	117	40	detection	detection	NOUN
ajlm-2099	117	41	of	of	ADP
ajlm-2099	117	42	anti	anti	ADJ
ajlm-2099	117	43	-	-	ADJ
ajlm-2099	117	44	dsdna	dsdna	ADJ
ajlm-2099	117	45	and	and	CCONJ
ajlm-2099	117	46	ancas	anca	NOUN
ajlm-2099	117	47	.	.	PUNCT
ajlm-2099	118	1	the	the	DET
ajlm-2099	118	2	multiplex	multiplex	PROPN
ajlm-2099	118	3	assays	assay	NOUN
ajlm-2099	118	4	had	have	VERB
ajlm-2099	118	5	reasonable	reasonable	ADJ
ajlm-2099	118	6	performance	performance	NOUN
ajlm-2099	118	7	compared	compare	VERB
ajlm-2099	118	8	with	with	ADP
ajlm-2099	118	9	traditional	traditional	ADJ
ajlm-2099	118	10	methods	method	NOUN
ajlm-2099	118	11	used	use	VERB
ajlm-2099	118	12	for	for	ADP
ajlm-2099	118	13	the	the	DET
ajlm-2099	118	14	detection	detection	NOUN
ajlm-2099	118	15	of	of	ADP
ajlm-2099	118	16	autoantibodies	autoantibody	NOUN
ajlm-2099	118	17	.	.	PUNCT
ajlm-2099	119	1	for	for	ADP
ajlm-2099	119	2	the	the	DET
ajlm-2099	119	3	detection	detection	NOUN
ajlm-2099	119	4	of	of	ADP
ajlm-2099	119	5	anti	anti	ADJ
ajlm-2099	119	6	-	-	ADJ
ajlm-2099	119	7	dsdna	dsdna	ADJ
ajlm-2099	119	8	,	,	PUNCT
ajlm-2099	119	9	our	our	PRON
ajlm-2099	119	10	data	datum	NOUN
ajlm-2099	119	11	demonstrated	demonstrate	VERB
ajlm-2099	119	12	a	a	DET
ajlm-2099	119	13	substantial	substantial	ADJ
ajlm-2099	119	14	agreement	agreement	NOUN
ajlm-2099	119	15	between	between	ADP
ajlm-2099	119	16	the	the	DET
ajlm-2099	119	17	athena	athena	PROPN
ajlm-2099	119	18	multi	multi	PROPN
ajlm-2099	119	19	-	-	ADJ
ajlm-2099	119	20	lyte	lyte	ADJ
ajlm-2099	119	21	test	test	NOUN
ajlm-2099	119	22	system	system	NOUN
ajlm-2099	119	23	and	and	CCONJ
ajlm-2099	119	24	iif	iif	PROPN
ajlm-2099	119	25	.	.	PUNCT
ajlm-2099	120	1	however	however	ADV
ajlm-2099	120	2	,	,	PUNCT
ajlm-2099	120	3	we	we	PRON
ajlm-2099	120	4	observed	observe	VERB
ajlm-2099	120	5	a	a	DET
ajlm-2099	120	6	highly	highly	ADV
ajlm-2099	120	7	significant	significant	ADJ
ajlm-2099	120	8	correlation	correlation	NOUN
ajlm-2099	120	9	between	between	ADP
ajlm-2099	120	10	anti	anti	ADJ
ajlm-2099	120	11	-	-	ADJ
ajlm-2099	120	12	dsdna	dsdna	ADJ
ajlm-2099	120	13	concentration	concentration	NOUN
ajlm-2099	120	14	by	by	ADP
ajlm-2099	120	15	athena	athena	PROPN
ajlm-2099	120	16	multi	multi	PROPN
ajlm-2099	120	17	-	-	ADJ
ajlm-2099	120	18	lyte	lyte	ADJ
ajlm-2099	120	19	test	test	NOUN
ajlm-2099	120	20	system	system	NOUN
ajlm-2099	120	21	and	and	CCONJ
ajlm-2099	120	22	iif	iif	X
ajlm-2099	120	23	antibody	antibody	NOUN
ajlm-2099	120	24	titre	titre	NOUN
ajlm-2099	120	25	.	.	PUNCT
ajlm-2099	121	1	our	our	PRON
ajlm-2099	121	2	findings	finding	NOUN
ajlm-2099	121	3	are	be	AUX
ajlm-2099	121	4	in	in	ADP
ajlm-2099	121	5	concordance	concordance	NOUN
ajlm-2099	121	6	with	with	ADP
ajlm-2099	121	7	the	the	DET
ajlm-2099	121	8	results	result	NOUN
ajlm-2099	121	9	of	of	ADP
ajlm-2099	121	10	previous	previous	ADJ
ajlm-2099	121	11	studies	study	NOUN
ajlm-2099	121	12	conducted	conduct	VERB
ajlm-2099	121	13	in	in	ADP
ajlm-2099	121	14	canada	canada	PROPN
ajlm-2099	121	15	in	in	ADP
ajlm-2099	121	16	201033	201033	NUM
ajlm-2099	121	17	and	and	CCONJ
ajlm-2099	121	18	2013,34	2013,34	NUM
ajlm-2099	121	19	and	and	CCONJ
ajlm-2099	121	20	in	in	ADP
ajlm-2099	121	21	italy	italy	PROPN
ajlm-2099	121	22	in	in	ADP
ajlm-2099	121	23	2018.15	2018.15	NUM
ajlm-2099	121	24	these	these	DET
ajlm-2099	121	25	studies	study	NOUN
ajlm-2099	121	26	used	use	VERB
ajlm-2099	121	27	a	a	DET
ajlm-2099	121	28	device	device	NOUN
ajlm-2099	121	29	from	from	ADP
ajlm-2099	121	30	a	a	DET
ajlm-2099	121	31	different	different	ADJ
ajlm-2099	121	32	manufacturer	manufacturer	NOUN
ajlm-2099	121	33	(	(	PUNCT
ajlm-2099	121	34	bioplex	bioplex	NOUN
ajlm-2099	121	35	2200	2200	NUM
ajlm-2099	121	36	,	,	PUNCT
ajlm-2099	121	37	bio	bio	PROPN
ajlm-2099	121	38	-	-	ADJ
ajlm-2099	121	39	rad	rad	PROPN
ajlm-2099	121	40	laboratories	laboratory	NOUN
ajlm-2099	121	41	,	,	PUNCT
ajlm-2099	121	42	hercules	hercules	PROPN
ajlm-2099	121	43	,	,	PUNCT
ajlm-2099	121	44	california	california	PROPN
ajlm-2099	121	45	,	,	PUNCT
ajlm-2099	121	46	united	united	PROPN
ajlm-2099	121	47	states	states	PROPN
ajlm-2099	121	48	)	)	PUNCT
ajlm-2099	121	49	and	and	CCONJ
ajlm-2099	121	50	reported	report	VERB
ajlm-2099	121	51	the	the	DET
ajlm-2099	121	52	same	same	ADJ
ajlm-2099	121	53	level	level	NOUN
ajlm-2099	121	54	of	of	ADP
ajlm-2099	121	55	agreement	agreement	NOUN
ajlm-2099	121	56	and	and	CCONJ
ajlm-2099	121	57	correlation	correlation	NOUN
ajlm-2099	121	58	with	with	ADP
ajlm-2099	121	59	disease	disease	NOUN
ajlm-2099	121	60	activity	activity	NOUN
ajlm-2099	121	61	as	as	SCONJ
ajlm-2099	121	62	achieved	achieve	VERB
ajlm-2099	121	63	with	with	ADP
ajlm-2099	121	64	iif	iif	PROPN
ajlm-2099	121	65	.	.	PUNCT
ajlm-2099	122	1	according	accord	VERB
ajlm-2099	122	2	to	to	ADP
ajlm-2099	122	3	our	our	PRON
ajlm-2099	122	4	data	datum	NOUN
ajlm-2099	122	5	,	,	PUNCT
ajlm-2099	122	6	the	the	DET
ajlm-2099	122	7	athena	athena	PROPN
ajlm-2099	122	8	multi	multi	PROPN
ajlm-2099	122	9	-	-	ADJ
ajlm-2099	122	10	lyte	lyte	ADJ
ajlm-2099	122	11	test	test	NOUN
ajlm-2099	122	12	system	system	NOUN
ajlm-2099	122	13	had	have	VERB
ajlm-2099	122	14	the	the	DET
ajlm-2099	122	15	same	same	ADJ
ajlm-2099	122	16	sensitivity	sensitivity	NOUN
ajlm-2099	122	17	as	as	ADP
ajlm-2099	122	18	iif	iif	PROPN
ajlm-2099	122	19	for	for	ADP
ajlm-2099	122	20	anti	anti	ADJ
ajlm-2099	122	21	-	-	ADJ
ajlm-2099	122	22	dsdna	dsdna	ADJ
ajlm-2099	122	23	detection	detection	NOUN
ajlm-2099	122	24	,	,	PUNCT
ajlm-2099	122	25	as	as	ADV
ajlm-2099	122	26	well	well	ADV
ajlm-2099	122	27	as	as	ADP
ajlm-2099	122	28	improved	improved	ADJ
ajlm-2099	122	29	specificity	specificity	NOUN
ajlm-2099	122	30	.	.	PUNCT
ajlm-2099	123	1	moreover	moreover	ADV
ajlm-2099	123	2	,	,	PUNCT
ajlm-2099	123	3	the	the	DET
ajlm-2099	123	4	combination	combination	NOUN
ajlm-2099	123	5	of	of	ADP
ajlm-2099	123	6	both	both	DET
ajlm-2099	123	7	methods	method	NOUN
ajlm-2099	123	8	increased	increase	VERB
ajlm-2099	123	9	the	the	DET
ajlm-2099	123	10	sensitivity	sensitivity	NOUN
ajlm-2099	123	11	to	to	ADP
ajlm-2099	123	12	47.6	47.6	NUM
ajlm-2099	123	13	%	%	NOUN
ajlm-2099	123	14	.	.	PUNCT
ajlm-2099	124	1	two	two	NUM
ajlm-2099	124	2	studies	study	NOUN
ajlm-2099	124	3	performed	perform	VERB
ajlm-2099	124	4	by	by	ADP
ajlm-2099	124	5	infantino	infantino	NOUN
ajlm-2099	124	6	and	and	CCONJ
ajlm-2099	124	7	colleagues	colleague	NOUN
ajlm-2099	124	8	in	in	ADP
ajlm-2099	124	9	italy	italy	PROPN
ajlm-2099	124	10	in	in	ADP
ajlm-2099	124	11	201514	201514	NUM
ajlm-2099	124	12	and	and	CCONJ
ajlm-2099	124	13	201815	201815	NUM
ajlm-2099	124	14	reported	report	VERB
ajlm-2099	124	15	that	that	SCONJ
ajlm-2099	124	16	the	the	DET
ajlm-2099	124	17	multiplex	multiplex	PROPN
ajlm-2099	124	18	bead	bead	NOUN
ajlm-2099	124	19	-	-	PUNCT
ajlm-2099	124	20	based	base	VERB
ajlm-2099	124	21	assay	assay	NOUN
ajlm-2099	124	22	was	be	AUX
ajlm-2099	124	23	more	more	ADV
ajlm-2099	124	24	sensitive	sensitive	ADJ
ajlm-2099	124	25	than	than	ADP
ajlm-2099	124	26	iif	iif	PROPN
ajlm-2099	124	27	but	but	CCONJ
ajlm-2099	124	28	was	be	AUX
ajlm-2099	124	29	slightly	slightly	ADV
ajlm-2099	124	30	less	less	ADJ
ajlm-2099	124	31	specific.15	specific.15	NOUN
ajlm-2099	124	32	based	base	VERB
ajlm-2099	124	33	on	on	ADP
ajlm-2099	124	34	our	our	PRON
ajlm-2099	124	35	observations	observation	NOUN
ajlm-2099	124	36	,	,	PUNCT
ajlm-2099	124	37	the	the	DET
ajlm-2099	124	38	athena	athena	PROPN
ajlm-2099	124	39	multi	multi	PROPN
ajlm-2099	124	40	-	-	ADJ
ajlm-2099	124	41	lyte	lyte	ADJ
ajlm-2099	124	42	test	test	NOUN
ajlm-2099	124	43	system	system	NOUN
ajlm-2099	124	44	for	for	ADP
ajlm-2099	124	45	anti	anti	ADJ
ajlm-2099	124	46	-	-	ADJ
ajlm-2099	124	47	dsdna	dsdna	ADJ
ajlm-2099	124	48	detection	detection	NOUN
ajlm-2099	124	49	provides	provide	VERB
ajlm-2099	124	50	multiple	multiple	ADJ
ajlm-2099	124	51	advantages	advantage	NOUN
ajlm-2099	124	52	,	,	PUNCT
ajlm-2099	124	53	as	as	SCONJ
ajlm-2099	124	54	it	it	PRON
ajlm-2099	124	55	is	be	AUX
ajlm-2099	124	56	a	a	DET
ajlm-2099	124	57	simple	simple	ADJ
ajlm-2099	124	58	and	and	CCONJ
ajlm-2099	124	59	rapid	rapid	ADJ
ajlm-2099	124	60	method	method	NOUN
ajlm-2099	124	61	with	with	ADP
ajlm-2099	124	62	a	a	DET
ajlm-2099	124	63	reasonable	reasonable	ADJ
ajlm-2099	124	64	cost	cost	NOUN
ajlm-2099	124	65	and	and	CCONJ
ajlm-2099	124	66	has	have	VERB
ajlm-2099	124	67	acceptable	acceptable	ADJ
ajlm-2099	124	68	clinical	clinical	ADJ
ajlm-2099	124	69	and	and	CCONJ
ajlm-2099	124	70	analytical	analytical	ADJ
ajlm-2099	124	71	performance	performance	NOUN
ajlm-2099	124	72	.	.	PUNCT
ajlm-2099	125	1	although	although	SCONJ
ajlm-2099	125	2	the	the	DET
ajlm-2099	125	3	combination	combination	NOUN
ajlm-2099	125	4	of	of	ADP
ajlm-2099	125	5	athena	athena	PROPN
ajlm-2099	125	6	multi	multi	PROPN
ajlm-2099	125	7	-	-	PROPN
ajlm-2099	125	8	lyte	lyte	ADJ
ajlm-2099	125	9	ana	ana	PROPN
ajlm-2099	125	10	-	-	PUNCT
ajlm-2099	125	11	ii	ii	PROPN
ajlm-2099	125	12	and	and	CCONJ
ajlm-2099	125	13	iif	iif	PROPN
ajlm-2099	125	14	provided	provide	VERB
ajlm-2099	125	15	better	well	ADJ
ajlm-2099	125	16	sensitivity	sensitivity	NOUN
ajlm-2099	125	17	,	,	PUNCT
ajlm-2099	125	18	economic	economic	ADJ
ajlm-2099	125	19	factors	factor	NOUN
ajlm-2099	125	20	might	might	AUX
ajlm-2099	125	21	hinder	hinder	VERB
ajlm-2099	125	22	the	the	DET
ajlm-2099	125	23	routine	routine	ADJ
ajlm-2099	125	24	use	use	NOUN
ajlm-2099	125	25	of	of	ADP
ajlm-2099	125	26	this	this	DET
ajlm-2099	125	27	combination	combination	NOUN
ajlm-2099	125	28	for	for	ADP
ajlm-2099	125	29	screening	screen	VERB
ajlm-2099	125	30	.	.	PUNCT
ajlm-2099	126	1	our	our	PRON
ajlm-2099	126	2	findings	finding	NOUN
ajlm-2099	126	3	favour	favour	VERB
ajlm-2099	126	4	the	the	DET
ajlm-2099	126	5	use	use	NOUN
ajlm-2099	126	6	of	of	ADP
ajlm-2099	126	7	the	the	DET
ajlm-2099	126	8	athena	athena	PROPN
ajlm-2099	126	9	multi	multi	PROPN
ajlm-2099	126	10	-	-	ADJ
ajlm-2099	126	11	lyte	lyte	ADJ
ajlm-2099	126	12	test	test	NOUN
ajlm-2099	126	13	for	for	ADP
ajlm-2099	126	14	patient	patient	ADJ
ajlm-2099	126	15	follow	follow	NOUN
ajlm-2099	126	16	-	-	PUNCT
ajlm-2099	126	17	ups	up	NOUN
ajlm-2099	126	18	because	because	SCONJ
ajlm-2099	126	19	this	this	DET
ajlm-2099	126	20	one	one	NUM
ajlm-2099	126	21	-	-	PUNCT
ajlm-2099	126	22	step	step	NOUN
ajlm-2099	126	23	quantitative	quantitative	ADJ
ajlm-2099	126	24	analysis	analysis	NOUN
ajlm-2099	126	25	is	be	AUX
ajlm-2099	126	26	simpler	simple	ADJ
ajlm-2099	126	27	than	than	ADP
ajlm-2099	126	28	the	the	DET
ajlm-2099	126	29	multiple	multiple	ADJ
ajlm-2099	126	30	dilutions	dilution	NOUN
ajlm-2099	126	31	required	require	VERB
ajlm-2099	126	32	for	for	ADP
ajlm-2099	126	33	the	the	DET
ajlm-2099	126	34	semi	semi	ADJ
ajlm-2099	126	35	-	-	ADJ
ajlm-2099	126	36	quantitative	quantitative	ADJ
ajlm-2099	126	37	iif	iif	NOUN
ajlm-2099	126	38	determination	determination	NOUN
ajlm-2099	126	39	of	of	ADP
ajlm-2099	126	40	antibody	antibody	NOUN
ajlm-2099	126	41	titres	titre	NOUN
ajlm-2099	126	42	.	.	PUNCT
ajlm-2099	127	1	the	the	DET
ajlm-2099	127	2	athena	athena	PROPN
ajlm-2099	127	3	multi	multi	PROPN
ajlm-2099	127	4	-	-	ADJ
ajlm-2099	127	5	lyte	lyte	ADJ
ajlm-2099	127	6	test	test	NOUN
ajlm-2099	127	7	systems	system	NOUN
ajlm-2099	127	8	exhibited	exhibit	VERB
ajlm-2099	127	9	almost	almost	ADV
ajlm-2099	127	10	perfect	perfect	ADJ
ajlm-2099	127	11	agreement	agreement	NOUN
ajlm-2099	127	12	with	with	ADP
ajlm-2099	127	13	elisa	elisa	NOUN
ajlm-2099	127	14	and	and	CCONJ
ajlm-2099	127	15	moderate	moderate	ADJ
ajlm-2099	127	16	agreement	agreement	NOUN
ajlm-2099	127	17	with	with	ADP
ajlm-2099	127	18	iif	iif	PROPN
ajlm-2099	127	19	with	with	ADP
ajlm-2099	127	20	respect	respect	NOUN
ajlm-2099	127	21	to	to	ADP
ajlm-2099	127	22	anti	anti	ADJ
ajlm-2099	127	23	-	-	ADJ
ajlm-2099	127	24	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	127	25	detection	detection	NOUN
ajlm-2099	127	26	.	.	PUNCT
ajlm-2099	128	1	additionally	additionally	ADV
ajlm-2099	128	2	,	,	PUNCT
ajlm-2099	128	3	the	the	DET
ajlm-2099	128	4	athena	athena	PROPN
ajlm-2099	128	5	multi	multi	PROPN
ajlm-2099	128	6	-	-	ADJ
ajlm-2099	128	7	lyte	lyte	ADJ
ajlm-2099	128	8	assay	assay	PROPN
ajlm-2099	128	9	exhibited	exhibit	VERB
ajlm-2099	128	10	an	an	DET
ajlm-2099	128	11	almost	almost	ADV
ajlm-2099	128	12	perfect	perfect	ADJ
ajlm-2099	128	13	agreement	agreement	NOUN
ajlm-2099	128	14	with	with	ADP
ajlm-2099	128	15	elisa	elisa	NOUN
ajlm-2099	128	16	and	and	CCONJ
ajlm-2099	128	17	a	a	DET
ajlm-2099	128	18	perfect	perfect	ADJ
ajlm-2099	128	19	agreement	agreement	NOUN
ajlm-2099	128	20	with	with	ADP
ajlm-2099	128	21	iif	iif	PROPN
ajlm-2099	128	22	for	for	ADP
ajlm-2099	128	23	anti	anti	ADJ
ajlm-2099	128	24	-	-	ADJ
ajlm-2099	128	25	proteinase	proteinase	ADJ
ajlm-2099	128	26	3	3	NUM
ajlm-2099	128	27	detection	detection	NOUN
ajlm-2099	128	28	.	.	PUNCT
ajlm-2099	129	1	these	these	DET
ajlm-2099	129	2	results	result	NOUN
ajlm-2099	129	3	are	be	AUX
ajlm-2099	129	4	consistent	consistent	ADJ
ajlm-2099	129	5	with	with	ADP
ajlm-2099	129	6	the	the	DET
ajlm-2099	129	7	results	result	NOUN
ajlm-2099	129	8	of	of	ADP
ajlm-2099	129	9	previous	previous	ADJ
ajlm-2099	129	10	studies	study	NOUN
ajlm-2099	129	11	,	,	PUNCT
ajlm-2099	129	12	including	include	VERB
ajlm-2099	129	13	one	one	NUM
ajlm-2099	129	14	performed	perform	VERB
ajlm-2099	129	15	in	in	ADP
ajlm-2099	129	16	the	the	DET
ajlm-2099	129	17	netherlands	netherlands	PROPN
ajlm-2099	129	18	in	in	ADP
ajlm-2099	129	19	2007	2007	NUM
ajlm-2099	129	20	,	,	PUNCT
ajlm-2099	129	21	and	and	CCONJ
ajlm-2099	129	22	another	another	DET
ajlm-2099	129	23	multicentre	multicentre	NOUN
ajlm-2099	129	24	study	study	NOUN
ajlm-2099	129	25	performed	perform	VERB
ajlm-2099	129	26	in	in	ADP
ajlm-2099	129	27	2017	2017	NUM
ajlm-2099	129	28	that	that	PRON
ajlm-2099	129	29	recruited	recruit	VERB
ajlm-2099	129	30	patients	patient	NOUN
ajlm-2099	129	31	from	from	ADP
ajlm-2099	129	32	germany	germany	PROPN
ajlm-2099	129	33	,	,	PUNCT
ajlm-2099	129	34	denmark	denmark	PROPN
ajlm-2099	129	35	,	,	PUNCT
ajlm-2099	129	36	the	the	DET
ajlm-2099	129	37	netherlands	netherlands	PROPN
ajlm-2099	129	38	,	,	PUNCT
ajlm-2099	129	39	and	and	CCONJ
ajlm-2099	129	40	belgium.35,36	belgium.35,36	VERB
ajlm-2099	129	41	only	only	ADV
ajlm-2099	129	42	one	one	NUM
ajlm-2099	129	43	study	study	NOUN
ajlm-2099	129	44	,	,	PUNCT
ajlm-2099	129	45	conducted	conduct	VERB
ajlm-2099	129	46	in	in	ADP
ajlm-2099	129	47	the	the	DET
ajlm-2099	129	48	united	united	PROPN
ajlm-2099	129	49	states	states	PROPN
ajlm-2099	129	50	in	in	ADP
ajlm-2099	129	51	2018,37	2018,37	PROPN
ajlm-2099	129	52	reported	report	VERB
ajlm-2099	129	53	a	a	DET
ajlm-2099	129	54	moderate	moderate	ADJ
ajlm-2099	129	55	agreement	agreement	NOUN
ajlm-2099	129	56	between	between	ADP
ajlm-2099	129	57	a	a	DET
ajlm-2099	129	58	multiplex	multiplex	PROPN
ajlm-2099	129	59	bead	bead	NOUN
ajlm-2099	129	60	-	-	PUNCT
ajlm-2099	129	61	based	base	VERB
ajlm-2099	129	62	assay	assay	NOUN
ajlm-2099	129	63	and	and	CCONJ
ajlm-2099	129	64	elisa	elisa	VERB
ajlm-2099	129	65	for	for	ADP
ajlm-2099	129	66	both	both	CCONJ
ajlm-2099	129	67	anti	anti	ADJ
ajlm-2099	129	68	-	-	ADJ
ajlm-2099	129	69	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	129	70	(	(	PUNCT
ajlm-2099	129	71	κ	κ	X
ajlm-2099	129	72	=	=	NOUN
ajlm-2099	129	73	0.35	0.35	NUM
ajlm-2099	129	74	)	)	PUNCT
ajlm-2099	129	75	and	and	CCONJ
ajlm-2099	129	76	anti	anti	ADJ
ajlm-2099	129	77	-	-	ADJ
ajlm-2099	129	78	proteinase	proteinase	ADJ
ajlm-2099	129	79	3	3	NUM
ajlm-2099	129	80	(	(	PUNCT
ajlm-2099	129	81	κ	κ	NOUN
ajlm-2099	129	82	=	=	NOUN
ajlm-2099	129	83	0.53	0.53	NUM
ajlm-2099	129	84	)	)	PUNCT
ajlm-2099	129	85	detection	detection	NOUN
ajlm-2099	129	86	.	.	PUNCT
ajlm-2099	130	1	this	this	DET
ajlm-2099	130	2	difference	difference	NOUN
ajlm-2099	130	3	might	might	AUX
ajlm-2099	130	4	be	be	AUX
ajlm-2099	130	5	attributable	attributable	ADJ
ajlm-2099	130	6	to	to	ADP
ajlm-2099	130	7	the	the	DET
ajlm-2099	130	8	use	use	NOUN
ajlm-2099	130	9	of	of	ADP
ajlm-2099	130	10	kits	kit	NOUN
ajlm-2099	130	11	produced	produce	VERB
ajlm-2099	130	12	by	by	ADP
ajlm-2099	130	13	a	a	DET
ajlm-2099	130	14	different	different	ADJ
ajlm-2099	130	15	manufacturer	manufacturer	NOUN
ajlm-2099	130	16	(	(	PUNCT
ajlm-2099	130	17	bio	bio	ADJ
ajlm-2099	130	18	-	-	ADJ
ajlm-2099	130	19	plex	plex	ADJ
ajlm-2099	130	20	®	®	NOUN
ajlm-2099	130	21	2200	2200	NUM
ajlm-2099	130	22	testing	testing	NOUN
ajlm-2099	130	23	platform	platform	NOUN
ajlm-2099	130	24	,	,	PUNCT
ajlm-2099	130	25	bio	bio	PROPN
ajlm-2099	130	26	-	-	ADJ
ajlm-2099	130	27	rad	rad	PROPN
ajlm-2099	130	28	laboratories	laboratory	NOUN
ajlm-2099	130	29	,	,	PUNCT
ajlm-2099	130	30	hercules	hercules	PROPN
ajlm-2099	130	31	,	,	PUNCT
ajlm-2099	130	32	california	california	PROPN
ajlm-2099	130	33	,	,	PUNCT
ajlm-2099	130	34	united	united	PROPN
ajlm-2099	130	35	states	states	PROPN
ajlm-2099	130	36	)	)	PUNCT
ajlm-2099	130	37	.	.	PUNCT
ajlm-2099	131	1	the	the	DET
ajlm-2099	131	2	analytical	analytical	ADJ
ajlm-2099	131	3	performance	performance	NOUN
ajlm-2099	131	4	of	of	ADP
ajlm-2099	131	5	athena	athena	PROPN
ajlm-2099	131	6	multi	multi	PROPN
ajlm-2099	131	7	-	-	ADJ
ajlm-2099	131	8	lyte	lyte	ADJ
ajlm-2099	131	9	aiv	aiv	NOUN
ajlm-2099	131	10	was	be	AUX
ajlm-2099	131	11	superior	superior	ADJ
ajlm-2099	131	12	to	to	ADP
ajlm-2099	131	13	that	that	PRON
ajlm-2099	131	14	of	of	ADP
ajlm-2099	131	15	elisa	elisa	NOUN
ajlm-2099	131	16	for	for	ADP
ajlm-2099	131	17	both	both	CCONJ
ajlm-2099	131	18	anti	anti	ADJ
ajlm-2099	131	19	-	-	ADJ
ajlm-2099	131	20	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	131	21	and	and	CCONJ
ajlm-2099	131	22	anti	anti	ADJ
ajlm-2099	131	23	-	-	ADJ
ajlm-2099	131	24	proteinase	proteinase	ADJ
ajlm-2099	131	25	3	3	NUM
ajlm-2099	131	26	detection	detection	NOUN
ajlm-2099	131	27	.	.	PUNCT
ajlm-2099	132	1	for	for	ADP
ajlm-2099	132	2	anti	anti	ADJ
ajlm-2099	132	3	-	-	ADJ
ajlm-2099	132	4	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	132	5	testing	testing	NOUN
ajlm-2099	132	6	,	,	PUNCT
ajlm-2099	132	7	athena	athena	PROPN
ajlm-2099	132	8	multi	multi	PROPN
ajlm-2099	132	9	-	-	ADJ
ajlm-2099	132	10	lyte	lyte	ADJ
ajlm-2099	132	11	aiv	aiv	NOUN
ajlm-2099	132	12	was	be	AUX
ajlm-2099	132	13	more	more	ADV
ajlm-2099	132	14	sensitive	sensitive	ADJ
ajlm-2099	132	15	than	than	ADP
ajlm-2099	132	16	elisa	elisa	NOUN
ajlm-2099	132	17	,	,	PUNCT
ajlm-2099	132	18	while	while	SCONJ
ajlm-2099	132	19	both	both	DET
ajlm-2099	132	20	methods	method	NOUN
ajlm-2099	132	21	were	be	AUX
ajlm-2099	132	22	equally	equally	ADV
ajlm-2099	132	23	specific	specific	ADJ
ajlm-2099	132	24	.	.	PUNCT
ajlm-2099	133	1	for	for	ADP
ajlm-2099	133	2	anti	anti	ADJ
ajlm-2099	133	3	-	-	ADJ
ajlm-2099	133	4	proteinase	proteinase	ADJ
ajlm-2099	133	5	3	3	NUM
ajlm-2099	133	6	testing	testing	NOUN
ajlm-2099	133	7	,	,	PUNCT
ajlm-2099	133	8	both	both	DET
ajlm-2099	133	9	methods	method	NOUN
ajlm-2099	133	10	were	be	AUX
ajlm-2099	133	11	equally	equally	ADV
ajlm-2099	133	12	sensitive	sensitive	ADJ
ajlm-2099	133	13	,	,	PUNCT
ajlm-2099	133	14	whereas	whereas	SCONJ
ajlm-2099	133	15	athena	athena	PROPN
ajlm-2099	133	16	multi	multi	PROPN
ajlm-2099	133	17	-	-	ADJ
ajlm-2099	133	18	lyte	lyte	ADJ
ajlm-2099	133	19	aiv	aiv	NOUN
ajlm-2099	133	20	was	be	AUX
ajlm-2099	133	21	more	more	ADV
ajlm-2099	133	22	specific	specific	ADJ
ajlm-2099	133	23	.	.	PUNCT
ajlm-2099	134	1	regarding	regard	VERB
ajlm-2099	134	2	anca	anca	PROPN
ajlm-2099	134	3	detection	detection	NOUN
ajlm-2099	134	4	,	,	PUNCT
ajlm-2099	134	5	histopathology	histopathology	NOUN
ajlm-2099	134	6	is	be	AUX
ajlm-2099	134	7	the	the	DET
ajlm-2099	134	8	definitive	definitive	ADJ
ajlm-2099	134	9	diagnosis	diagnosis	NOUN
ajlm-2099	134	10	for	for	ADP
ajlm-2099	134	11	aiv.10	aiv.10	NOUN
ajlm-2099	134	12	however	however	ADV
ajlm-2099	134	13	,	,	PUNCT
ajlm-2099	134	14	these	these	DET
ajlm-2099	134	15	data	datum	NOUN
ajlm-2099	134	16	were	be	AUX
ajlm-2099	134	17	not	not	PART
ajlm-2099	134	18	available	available	ADJ
ajlm-2099	134	19	for	for	ADP
ajlm-2099	134	20	the	the	DET
ajlm-2099	134	21	patients	patient	NOUN
ajlm-2099	134	22	included	include	VERB
ajlm-2099	134	23	in	in	ADP
ajlm-2099	134	24	this	this	DET
ajlm-2099	134	25	study	study	NOUN
ajlm-2099	134	26	.	.	PUNCT
ajlm-2099	135	1	therefore	therefore	ADV
ajlm-2099	135	2	,	,	PUNCT
ajlm-2099	135	3	we	we	PRON
ajlm-2099	135	4	were	be	AUX
ajlm-2099	135	5	unable	unable	ADJ
ajlm-2099	135	6	to	to	PART
ajlm-2099	135	7	assess	assess	VERB
ajlm-2099	135	8	the	the	DET
ajlm-2099	135	9	clinical	clinical	ADJ
ajlm-2099	135	10	performance	performance	NOUN
ajlm-2099	135	11	of	of	ADP
ajlm-2099	135	12	athena	athena	PROPN
ajlm-2099	135	13	multi	multi	PROPN
ajlm-2099	135	14	-	-	ADJ
ajlm-2099	135	15	lyte	lyte	ADJ
ajlm-2099	135	16	aiv	aiv	NOUN
ajlm-2099	135	17	and	and	CCONJ
ajlm-2099	135	18	anca	anca	NOUN
ajlm-2099	135	19	iif	iif	PROPN
ajlm-2099	135	20	assays	assay	NOUN
ajlm-2099	135	21	.	.	PUNCT
ajlm-2099	136	1	still	still	ADV
ajlm-2099	136	2	,	,	PUNCT
ajlm-2099	136	3	the	the	DET
ajlm-2099	136	4	athena	athena	PROPN
ajlm-2099	136	5	multi	multi	PROPN
ajlm-2099	136	6	-	-	ADJ
ajlm-2099	136	7	lyte	lyte	ADJ
ajlm-2099	136	8	test	test	NOUN
ajlm-2099	136	9	systems	system	NOUN
ajlm-2099	136	10	provided	provide	VERB
ajlm-2099	136	11	good	good	ADJ
ajlm-2099	136	12	analytical	analytical	ADJ
ajlm-2099	136	13	performances	performance	NOUN
ajlm-2099	136	14	and	and	CCONJ
ajlm-2099	136	15	significant	significant	ADJ
ajlm-2099	136	16	agreement	agreement	NOUN
ajlm-2099	136	17	with	with	ADP
ajlm-2099	136	18	the	the	DET
ajlm-2099	136	19	results	result	NOUN
ajlm-2099	136	20	of	of	ADP
ajlm-2099	136	21	conventional	conventional	ADJ
ajlm-2099	136	22	assays	assay	NOUN
ajlm-2099	136	23	,	,	PUNCT
ajlm-2099	136	24	warranting	warrant	VERB
ajlm-2099	136	25	their	their	PRON
ajlm-2099	136	26	use	use	NOUN
ajlm-2099	136	27	for	for	ADP
ajlm-2099	136	28	anti	anti	ADJ
ajlm-2099	136	29	-	-	ADJ
ajlm-2099	136	30	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	136	31	and	and	CCONJ
ajlm-2099	136	32	anti	anti	ADJ
ajlm-2099	136	33	-	-	ADJ
ajlm-2099	136	34	proteinase	proteinase	ADJ
ajlm-2099	136	35	3	3	NUM
ajlm-2099	136	36	screening	screening	NOUN
ajlm-2099	136	37	.	.	PUNCT
ajlm-2099	137	1	limitations	limitation	NOUN
ajlm-2099	137	2	this	this	PRON
ajlm-2099	137	3	was	be	AUX
ajlm-2099	137	4	a	a	DET
ajlm-2099	137	5	single	single	ADJ
ajlm-2099	137	6	-	-	PUNCT
ajlm-2099	137	7	centre	centre	NOUN
ajlm-2099	137	8	study	study	NOUN
ajlm-2099	137	9	with	with	ADP
ajlm-2099	137	10	a	a	DET
ajlm-2099	137	11	relatively	relatively	ADV
ajlm-2099	137	12	small	small	ADJ
ajlm-2099	137	13	sample	sample	NOUN
ajlm-2099	137	14	size	size	NOUN
ajlm-2099	137	15	.	.	PUNCT
ajlm-2099	138	1	the	the	DET
ajlm-2099	138	2	study	study	NOUN
ajlm-2099	138	3	was	be	AUX
ajlm-2099	138	4	also	also	ADV
ajlm-2099	138	5	limited	limit	VERB
ajlm-2099	138	6	by	by	ADP
ajlm-2099	138	7	a	a	DET
ajlm-2099	138	8	lack	lack	NOUN
ajlm-2099	138	9	of	of	ADP
ajlm-2099	138	10	histopathology	histopathology	NOUN
ajlm-2099	138	11	data	datum	NOUN
ajlm-2099	138	12	for	for	ADP
ajlm-2099	138	13	patients	patient	NOUN
ajlm-2099	138	14	with	with	ADP
ajlm-2099	138	15	suspected	suspect	VERB
ajlm-2099	138	16	aiv	aiv	NOUN
ajlm-2099	138	17	.	.	PROPN
ajlm-2099	138	18	conclusion	conclusion	NOUN
ajlm-2099	138	19	the	the	DET
ajlm-2099	138	20	athena	athena	PROPN
ajlm-2099	138	21	multi	multi	PROPN
ajlm-2099	138	22	-	-	ADJ
ajlm-2099	138	23	lyte	lyte	ADJ
ajlm-2099	138	24	test	test	NOUN
ajlm-2099	138	25	systems	system	NOUN
ajlm-2099	138	26	are	be	AUX
ajlm-2099	138	27	reliable	reliable	ADJ
ajlm-2099	138	28	and	and	CCONJ
ajlm-2099	138	29	robust	robust	ADJ
ajlm-2099	138	30	for	for	ADP
ajlm-2099	138	31	the	the	DET
ajlm-2099	138	32	simultaneous	simultaneous	ADJ
ajlm-2099	138	33	detection	detection	NOUN
ajlm-2099	138	34	of	of	ADP
ajlm-2099	138	35	autoantibodies	autoantibody	NOUN
ajlm-2099	138	36	.	.	PUNCT
ajlm-2099	139	1	these	these	DET
ajlm-2099	139	2	tests	test	NOUN
ajlm-2099	139	3	aid	aid	VERB
ajlm-2099	139	4	in	in	ADP
ajlm-2099	139	5	the	the	DET
ajlm-2099	139	6	diagnosis	diagnosis	NOUN
ajlm-2099	139	7	and	and	CCONJ
ajlm-2099	139	8	follow	follow	VERB
ajlm-2099	139	9	-	-	PUNCT
ajlm-2099	139	10	up	up	NOUN
ajlm-2099	139	11	of	of	ADP
ajlm-2099	139	12	systemic	systemic	ADJ
ajlm-2099	139	13	rheumatic	rheumatic	ADJ
ajlm-2099	139	14	disorders	disorder	NOUN
ajlm-2099	139	15	and	and	CCONJ
ajlm-2099	139	16	the	the	DET
ajlm-2099	139	17	diagnosis	diagnosis	NOUN
ajlm-2099	139	18	of	of	ADP
ajlm-2099	139	19	vasculitic	vasculitic	ADJ
ajlm-2099	139	20	disorders	disorder	NOUN
ajlm-2099	139	21	.	.	PUNCT
ajlm-2099	140	1	multiplex	multiplex	PROPN
ajlm-2099	140	2	autoantibody	autoantibody	PROPN
ajlm-2099	140	3	testing	testing	NOUN
ajlm-2099	140	4	is	be	AUX
ajlm-2099	140	5	less	less	ADJ
ajlm-2099	140	6	time	time	NOUN
ajlm-2099	140	7	-	-	PUNCT
ajlm-2099	140	8	consuming	consume	VERB
ajlm-2099	140	9	than	than	ADP
ajlm-2099	140	10	traditional	traditional	ADJ
ajlm-2099	140	11	single	single	ADJ
ajlm-2099	140	12	-	-	PUNCT
ajlm-2099	140	13	antibody	antibody	NOUN
ajlm-2099	140	14	assessment	assessment	NOUN
ajlm-2099	140	15	and	and	CCONJ
ajlm-2099	140	16	requires	require	VERB
ajlm-2099	140	17	only	only	ADV
ajlm-2099	140	18	small	small	ADJ
ajlm-2099	140	19	sample	sample	NOUN
ajlm-2099	140	20	volumes	volume	NOUN
ajlm-2099	140	21	.	.	PUNCT
ajlm-2099	141	1	future	future	ADJ
ajlm-2099	141	2	studies	study	NOUN
ajlm-2099	141	3	that	that	PRON
ajlm-2099	141	4	include	include	VERB
ajlm-2099	141	5	the	the	DET
ajlm-2099	141	6	definitive	definitive	ADJ
ajlm-2099	141	7	diagnosis	diagnosis	NOUN
ajlm-2099	141	8	of	of	ADP
ajlm-2099	141	9	aiv	aiv	NOUN
ajlm-2099	141	10	according	accord	VERB
ajlm-2099	141	11	to	to	ADP
ajlm-2099	141	12	international	international	ADJ
ajlm-2099	141	13	standards	standard	NOUN
ajlm-2099	141	14	are	be	AUX
ajlm-2099	141	15	required	require	VERB
ajlm-2099	141	16	to	to	PART
ajlm-2099	141	17	yield	yield	VERB
ajlm-2099	141	18	a	a	DET
ajlm-2099	141	19	better	well	ADJ
ajlm-2099	141	20	understanding	understanding	NOUN
ajlm-2099	141	21	of	of	ADP
ajlm-2099	141	22	the	the	DET
ajlm-2099	141	23	clinical	clinical	ADJ
ajlm-2099	141	24	performances	performance	NOUN
ajlm-2099	141	25	of	of	ADP
ajlm-2099	141	26	anti	anti	ADJ
ajlm-2099	141	27	-	-	ADJ
ajlm-2099	141	28	myeloperoxidase	myeloperoxidase	ADJ
ajlm-2099	141	29	and	and	CCONJ
ajlm-2099	141	30	anti	anti	ADJ
ajlm-2099	141	31	-	-	ADJ
ajlm-2099	141	32	proteinase	proteinase	ADJ
ajlm-2099	141	33	3	3	NUM
ajlm-2099	141	34	tests	test	NOUN
ajlm-2099	141	35	.	.	PUNCT
ajlm-2099	142	1	we	we	PRON
ajlm-2099	142	2	recommend	recommend	VERB
ajlm-2099	142	3	the	the	DET
ajlm-2099	142	4	conduct	conduct	NOUN
ajlm-2099	142	5	of	of	ADP
ajlm-2099	142	6	a	a	DET
ajlm-2099	142	7	multicentre	multicentre	NOUN
ajlm-2099	142	8	study	study	NOUN
ajlm-2099	142	9	with	with	ADP
ajlm-2099	142	10	a	a	DET
ajlm-2099	142	11	larger	large	ADJ
ajlm-2099	142	12	sample	sample	NOUN
ajlm-2099	142	13	size	size	NOUN
ajlm-2099	142	14	to	to	PART
ajlm-2099	142	15	confirm	confirm	VERB
ajlm-2099	142	16	our	our	PRON
ajlm-2099	142	17	findings	finding	NOUN
ajlm-2099	142	18	.	.	PUNCT
ajlm-2099	143	1	acknowledgements	acknowledgement	NOUN
ajlm-2099	143	2	competing	compete	VERB
ajlm-2099	143	3	interests	interest	NOUN
ajlm-2099	143	4	the	the	DET
ajlm-2099	143	5	authors	author	NOUN
ajlm-2099	143	6	declare	declare	VERB
ajlm-2099	143	7	that	that	SCONJ
ajlm-2099	143	8	they	they	PRON
ajlm-2099	143	9	have	have	VERB
ajlm-2099	143	10	no	no	DET
ajlm-2099	143	11	financial	financial	ADJ
ajlm-2099	143	12	or	or	CCONJ
ajlm-2099	143	13	personal	personal	ADJ
ajlm-2099	143	14	relationships	relationship	NOUN
ajlm-2099	143	15	that	that	PRON
ajlm-2099	143	16	may	may	AUX
ajlm-2099	143	17	have	have	AUX
ajlm-2099	143	18	inappropriately	inappropriately	ADV
ajlm-2099	143	19	influenced	influence	VERB
ajlm-2099	143	20	them	they	PRON
ajlm-2099	143	21	in	in	ADP
ajlm-2099	143	22	writing	write	VERB
ajlm-2099	143	23	this	this	DET
ajlm-2099	143	24	article	article	NOUN
ajlm-2099	143	25	.	.	PUNCT
ajlm-2099	144	1	authors	author	NOUN
ajlm-2099	144	2	’	’	PART
ajlm-2099	144	3	contributions	contribution	NOUN
ajlm-2099	144	4	a.a.a	a.a.a	PROPN
ajlm-2099	144	5	.	.	PUNCT
ajlm-2099	144	6	,	,	PUNCT
ajlm-2099	144	7	a.a.e.s	a.a.e.s	PROPN
ajlm-2099	145	1	.	.	PROPN
ajlm-2099	145	2	,	,	PUNCT
ajlm-2099	145	3	h.m.k	h.m.k	INTJ
ajlm-2099	145	4	.	.	PUNCT
ajlm-2099	146	1	and	and	CCONJ
ajlm-2099	146	2	n.m.s	n.m.	NOUN
ajlm-2099	146	3	contributed	contribute	VERB
ajlm-2099	146	4	to	to	ADP
ajlm-2099	146	5	the	the	DET
ajlm-2099	146	6	study	study	NOUN
ajlm-2099	146	7	conceptualisation	conceptualisation	NOUN
ajlm-2099	146	8	and	and	CCONJ
ajlm-2099	146	9	design	design	NOUN
ajlm-2099	146	10	.	.	PUNCT
ajlm-2099	147	1	n.m.s	n.m.s	PROPN
ajlm-2099	147	2	.	.	PUNCT
ajlm-2099	148	1	and	and	CCONJ
ajlm-2099	148	2	a.a.a	a.a.a	PROPN
ajlm-2099	148	3	.	.	PROPN
ajlm-2099	148	4	contributed	contribute	VERB
ajlm-2099	148	5	to	to	ADP
ajlm-2099	148	6	sample	sample	NOUN
ajlm-2099	148	7	processing	processing	NOUN
ajlm-2099	148	8	,	,	PUNCT
ajlm-2099	148	9	data	datum	NOUN
ajlm-2099	148	10	analysis	analysis	NOUN
ajlm-2099	148	11	and	and	CCONJ
ajlm-2099	148	12	manuscript	manuscript	NOUN
ajlm-2099	148	13	writing	writing	NOUN
ajlm-2099	148	14	.	.	PUNCT
ajlm-2099	149	1	a.a.e.s	a.a.e.s	PROPN
ajlm-2099	149	2	.	.	PUNCT
ajlm-2099	150	1	and	and	CCONJ
ajlm-2099	150	2	h.m.k	h.m.k	PROPN
ajlm-2099	150	3	.	.	PROPN
ajlm-2099	150	4	contributed	contribute	VERB
ajlm-2099	150	5	to	to	PART
ajlm-2099	150	6	patient	patient	VERB
ajlm-2099	150	7	’s	’s	PART
ajlm-2099	150	8	selection	selection	NOUN
ajlm-2099	150	9	,	,	PUNCT
ajlm-2099	150	10	data	datum	NOUN
ajlm-2099	150	11	collection	collection	NOUN
ajlm-2099	150	12	and	and	CCONJ
ajlm-2099	150	13	manuscript	manuscript	NOUN
ajlm-2099	150	14	revision	revision	NOUN
ajlm-2099	150	15	.	.	PUNCT
ajlm-2099	151	1	finally	finally	ADV
ajlm-2099	151	2	,	,	PUNCT
ajlm-2099	151	3	the	the	DET
ajlm-2099	151	4	manuscript	manuscript	NOUN
ajlm-2099	151	5	has	have	AUX
ajlm-2099	151	6	been	be	AUX
ajlm-2099	151	7	read	read	VERB
ajlm-2099	151	8	and	and	CCONJ
ajlm-2099	151	9	approved	approve	VERB
ajlm-2099	151	10	by	by	ADP
ajlm-2099	151	11	all	all	DET
ajlm-2099	151	12	the	the	DET
ajlm-2099	151	13	authors	author	NOUN
ajlm-2099	151	14	.	.	PUNCT
ajlm-2099	152	1	sources	source	NOUN
ajlm-2099	152	2	of	of	ADP
ajlm-2099	152	3	support	support	NOUN
ajlm-2099	152	4	this	this	DET
ajlm-2099	152	5	research	research	NOUN
ajlm-2099	152	6	received	receive	VERB
ajlm-2099	152	7	no	no	DET
ajlm-2099	152	8	specific	specific	ADJ
ajlm-2099	152	9	grant	grant	NOUN
ajlm-2099	152	10	from	from	ADP
ajlm-2099	152	11	any	any	DET
ajlm-2099	152	12	funding	funding	NOUN
ajlm-2099	152	13	agency	agency	NOUN
ajlm-2099	152	14	in	in	ADP
ajlm-2099	152	15	the	the	DET
ajlm-2099	152	16	public	public	ADJ
ajlm-2099	152	17	,	,	PUNCT
ajlm-2099	152	18	commercial	commercial	ADJ
ajlm-2099	152	19	or	or	CCONJ
ajlm-2099	152	20	not	not	PART
ajlm-2099	152	21	-	-	PUNCT
ajlm-2099	152	22	for	for	ADP
ajlm-2099	152	23	-	-	PUNCT
ajlm-2099	152	24	profit	profit	NOUN
ajlm-2099	152	25	sectors	sector	NOUN
ajlm-2099	152	26	.	.	PUNCT
ajlm-2099	153	1	data	datum	NOUN
ajlm-2099	153	2	availability	availability	NOUN
ajlm-2099	153	3	data	datum	NOUN
ajlm-2099	153	4	supporting	support	VERB
ajlm-2099	153	5	the	the	DET
ajlm-2099	153	6	findings	finding	NOUN
ajlm-2099	153	7	of	of	ADP
ajlm-2099	153	8	this	this	DET
ajlm-2099	153	9	study	study	NOUN
ajlm-2099	153	10	are	be	AUX
ajlm-2099	153	11	available	available	ADJ
ajlm-2099	153	12	from	from	ADP
ajlm-2099	153	13	the	the	DET
ajlm-2099	153	14	corresponding	corresponding	ADJ
ajlm-2099	153	15	author	author	NOUN
ajlm-2099	153	16	,	,	PUNCT
ajlm-2099	153	17	a.a.a	a.a.a	PROPN
ajlm-2099	153	18	.	.	PROPN
ajlm-2099	153	19	,	,	PUNCT
ajlm-2099	153	20	on	on	ADP
ajlm-2099	153	21	request	request	NOUN
ajlm-2099	153	22	.	.	PUNCT
ajlm-2099	154	1	disclaimer	disclaimer	VERB
ajlm-2099	154	2	the	the	DET
ajlm-2099	154	3	views	view	NOUN
ajlm-2099	154	4	and	and	CCONJ
ajlm-2099	154	5	opinions	opinion	NOUN
ajlm-2099	154	6	expressed	express	VERB
ajlm-2099	154	7	in	in	ADP
ajlm-2099	154	8	this	this	DET
ajlm-2099	154	9	article	article	NOUN
ajlm-2099	154	10	are	be	AUX
ajlm-2099	154	11	those	those	PRON
ajlm-2099	154	12	of	of	ADP
ajlm-2099	154	13	the	the	DET
ajlm-2099	154	14	authors	author	NOUN
ajlm-2099	154	15	and	and	CCONJ
ajlm-2099	154	16	do	do	AUX
ajlm-2099	154	17	not	not	PART
ajlm-2099	154	18	necessarily	necessarily	ADV
ajlm-2099	154	19	reflect	reflect	VERB
ajlm-2099	154	20	the	the	DET
ajlm-2099	154	21	official	official	ADJ
ajlm-2099	154	22	policy	policy	NOUN
ajlm-2099	154	23	or	or	CCONJ
ajlm-2099	154	24	position	position	NOUN
ajlm-2099	154	25	of	of	ADP
ajlm-2099	154	26	any	any	DET
ajlm-2099	154	27	affiliated	affiliated	ADJ
ajlm-2099	154	28	agency	agency	NOUN
ajlm-2099	154	29	of	of	ADP
ajlm-2099	154	30	the	the	DET
ajlm-2099	154	31	authors	author	NOUN
ajlm-2099	154	32	.	.	PUNCT
ajlm-2099	155	1	references	reference	NOUN
ajlm-2099	155	2	kitching	kitching	PROPN
ajlm-2099	155	3	ar	ar	PROPN
ajlm-2099	155	4	,	,	PUNCT
ajlm-2099	155	5	anders	anders	PROPN
ajlm-2099	155	6	h	h	PROPN
ajlm-2099	155	7	-	-	PUNCT
ajlm-2099	155	8	j	j	PROPN
ajlm-2099	155	9	,	,	PUNCT
ajlm-2099	155	10	basu	basu	PROPN
ajlm-2099	155	11	n	n	PROPN
ajlm-2099	155	12	,	,	PUNCT
ajlm-2099	155	13	et	et	PROPN
ajlm-2099	155	14	al	al	PROPN
ajlm-2099	155	15	.	.	PROPN
ajlm-2099	155	16	anca	anca	PROPN
ajlm-2099	155	17	-	-	PUNCT
ajlm-2099	155	18	associated	associate	VERB
ajlm-2099	155	19	vasculitis	vasculitis	PROPN
ajlm-2099	155	20	.	.	PUNCT
ajlm-2099	156	1	nat	nat	PROPN
ajlm-2099	156	2	rev	rev	VERB
ajlm-2099	156	3	dis	dis	PROPN
ajlm-2099	156	4	primers	primer	NOUN
ajlm-2099	156	5	.	.	PUNCT
ajlm-2099	157	1	2020;6(1):71	2020;6(1):71	X
ajlm-2099	157	2	.	.	PUNCT
ajlm-2099	158	1	https://doi.org/10.1038/s41572-020-0204-y	https://doi.org/10.1038/s41572-020-0204-y	PROPN
ajlm-2099	158	2	carter	carter	PROPN
ajlm-2099	158	3	ee	ee	PROPN
ajlm-2099	158	4	,	,	PUNCT
ajlm-2099	158	5	barr	barr	PROPN
ajlm-2099	158	6	sg	sg	PROPN
ajlm-2099	158	7	,	,	PUNCT
ajlm-2099	158	8	clarke	clarke	PROPN
ajlm-2099	158	9	ae	ae	PROPN
ajlm-2099	158	10	.	.	PUNCT
ajlm-2099	159	1	the	the	DET
ajlm-2099	159	2	global	global	ADJ
ajlm-2099	159	3	burden	burden	NOUN
ajlm-2099	159	4	of	of	ADP
ajlm-2099	159	5	sle	sle	PROPN
ajlm-2099	159	6	:	:	PUNCT
ajlm-2099	159	7	prevalence	prevalence	NOUN
ajlm-2099	159	8	,	,	PUNCT
ajlm-2099	159	9	health	health	NOUN
ajlm-2099	159	10	disparities	disparity	NOUN
ajlm-2099	159	11	and	and	CCONJ
ajlm-2099	159	12	socioeconomic	socioeconomic	ADJ
ajlm-2099	159	13	impact	impact	NOUN
ajlm-2099	159	14	.	.	PUNCT
ajlm-2099	160	1	nat	nat	PROPN
ajlm-2099	160	2	rev	rev	PROPN
ajlm-2099	160	3	rheumatol	rheumatol	NOUN
ajlm-2099	160	4	.	.	PUNCT
ajlm-2099	161	1	2016;12(10):605–620	2016;12(10):605–620	NUM
ajlm-2099	161	2	.	.	PUNCT
ajlm-2099	162	1	https://doi.org/10.1038/nrrheum.2016.137	https://doi.org/10.1038/nrrheum.2016.137	PROPN
ajlm-2099	162	2	gheita	gheita	PROPN
ajlm-2099	162	3	ta	ta	PROPN
ajlm-2099	162	4	,	,	PUNCT
ajlm-2099	162	5	noor	noor	PROPN
ajlm-2099	162	6	ra	ra	PROPN
ajlm-2099	162	7	,	,	PUNCT
ajlm-2099	162	8	abualfadl	abualfadl	NOUN
ajlm-2099	162	9	e	e	PROPN
ajlm-2099	162	10	,	,	PUNCT
ajlm-2099	162	11	et	et	PROPN
ajlm-2099	162	12	al	al	PROPN
ajlm-2099	162	13	.	.	PROPN
ajlm-2099	163	1	adult	adult	PROPN
ajlm-2099	163	2	systemic	systemic	ADJ
ajlm-2099	163	3	lupus	lupus	PROPN
ajlm-2099	163	4	erythematosus	erythematosus	PROPN
ajlm-2099	163	5	in	in	ADP
ajlm-2099	163	6	egypt	egypt	PROPN
ajlm-2099	163	7	:	:	PUNCT
ajlm-2099	163	8	the	the	DET
ajlm-2099	163	9	nation	nation	NOUN
ajlm-2099	163	10	-	-	PUNCT
ajlm-2099	163	11	wide	wide	ADJ
ajlm-2099	163	12	spectrum	spectrum	NOUN
ajlm-2099	163	13	of	of	ADP
ajlm-2099	163	14	3661	3661	NUM
ajlm-2099	163	15	patients	patient	NOUN
ajlm-2099	163	16	and	and	CCONJ
ajlm-2099	163	17	world	world	NOUN
ajlm-2099	163	18	-	-	PUNCT
ajlm-2099	163	19	wide	wide	ADJ
ajlm-2099	163	20	standpoint	standpoint	NOUN
ajlm-2099	163	21	.	.	PUNCT
ajlm-2099	164	1	lupus	lupus	NOUN
ajlm-2099	164	2	.	.	PUNCT
ajlm-2099	165	1	2021;30(9):1526–1535	2021;30(9):1526–1535	NUM
ajlm-2099	165	2	.	.	PUNCT
ajlm-2099	166	1	https://doi.org/10.1177/09612033211014253	https://doi.org/10.1177/09612033211014253	PROPN
ajlm-2099	166	2	phillip	phillip	NOUN
ajlm-2099	166	3	r	r	NOUN
ajlm-2099	166	4	,	,	PUNCT
ajlm-2099	166	5	luqmani	luqmani	PROPN
ajlm-2099	166	6	r.	r.	PROPN
ajlm-2099	166	7	mortality	mortality	NOUN
ajlm-2099	166	8	in	in	ADP
ajlm-2099	166	9	systemic	systemic	ADJ
ajlm-2099	166	10	vasculitis	vasculitis	PROPN
ajlm-2099	166	11	:	:	PUNCT
ajlm-2099	166	12	a	a	DET
ajlm-2099	166	13	systematic	systematic	ADJ
ajlm-2099	166	14	review	review	NOUN
ajlm-2099	166	15	.	.	PUNCT
ajlm-2099	167	1	clin	clin	PROPN
ajlm-2099	167	2	exp	exp	NOUN
ajlm-2099	167	3	rheumatol	rheumatol	NOUN
ajlm-2099	167	4	.	.	PUNCT
ajlm-2099	168	1	2008;26(5	2008;26(5	NUM
ajlm-2099	168	2	suppl	suppl	ADJ
ajlm-2099	168	3	51):s94	51):s94	NUM
ajlm-2099	168	4	–	–	PUNCT
ajlm-2099	168	5	s104	s104	PROPN
ajlm-2099	168	6	.	.	PROPN
ajlm-2099	168	7	attia	attia	PROPN
ajlm-2099	168	8	dhs	dhs	PROPN
ajlm-2099	168	9	,	,	PUNCT
ajlm-2099	168	10	abdel	abdel	PROPN
ajlm-2099	168	11	noor	noor	PROPN
ajlm-2099	168	12	ra	ra	PROPN
ajlm-2099	168	13	,	,	PUNCT
ajlm-2099	168	14	salah	salah	PROPN
ajlm-2099	168	15	s.	s.	PROPN
ajlm-2099	168	16	shedding	shed	VERB
ajlm-2099	168	17	light	light	NOUN
ajlm-2099	168	18	on	on	ADP
ajlm-2099	168	19	vasculitis	vasculitis	PROPN
ajlm-2099	168	20	in	in	ADP
ajlm-2099	168	21	egypt	egypt	PROPN
ajlm-2099	168	22	:	:	PUNCT
ajlm-2099	168	23	a	a	DET
ajlm-2099	168	24	multicenter	multicenter	ADJ
ajlm-2099	168	25	retrospective	retrospective	ADJ
ajlm-2099	168	26	cohort	cohort	NOUN
ajlm-2099	168	27	study	study	NOUN
ajlm-2099	168	28	of	of	ADP
ajlm-2099	168	29	characteristics	characteristic	NOUN
ajlm-2099	168	30	,	,	PUNCT
ajlm-2099	168	31	management	management	NOUN
ajlm-2099	168	32	,	,	PUNCT
ajlm-2099	168	33	and	and	CCONJ
ajlm-2099	168	34	outcome	outcome	NOUN
ajlm-2099	168	35	.	.	PUNCT
ajlm-2099	169	1	clin	clin	PROPN
ajlm-2099	169	2	rheumatol	rheumatol	NOUN
ajlm-2099	169	3	.	.	PUNCT
ajlm-2099	170	1	2019;38(6):1675–1684	2019;38(6):1675–1684	INTJ
ajlm-2099	170	2	.	.	PUNCT
ajlm-2099	171	1	https://doi.org/10.1007/s10067-019-04441-4	https://doi.org/10.1007/s10067-019-04441-4	NUM
ajlm-2099	171	2	shahin	shahin	PROPN
ajlm-2099	171	3	aa	aa	PROPN
ajlm-2099	171	4	,	,	PUNCT
ajlm-2099	171	5	zayed	zayed	PROPN
ajlm-2099	171	6	hs	hs	PROPN
ajlm-2099	171	7	,	,	PUNCT
ajlm-2099	171	8	elrefai	elrefai	PROPN
ajlm-2099	171	9	rm	rm	PROPN
ajlm-2099	171	10	,	,	PUNCT
ajlm-2099	171	11	et	et	PROPN
ajlm-2099	171	12	al	al	PROPN
ajlm-2099	171	13	.	.	PUNCT
ajlm-2099	172	1	the	the	DET
ajlm-2099	172	2	distribution	distribution	NOUN
ajlm-2099	172	3	and	and	CCONJ
ajlm-2099	172	4	outcome	outcome	NOUN
ajlm-2099	172	5	of	of	ADP
ajlm-2099	172	6	vasculitic	vasculitic	ADJ
ajlm-2099	172	7	syndromes	syndrome	NOUN
ajlm-2099	172	8	among	among	ADP
ajlm-2099	172	9	egyptians	egyptians	PROPN
ajlm-2099	172	10	:	:	PUNCT
ajlm-2099	172	11	a	a	DET
ajlm-2099	172	12	multi	multi	ADJ
ajlm-2099	172	13	-	-	ADJ
ajlm-2099	172	14	centre	centre	ADJ
ajlm-2099	172	15	study	study	NOUN
ajlm-2099	172	16	including	include	VERB
ajlm-2099	172	17	630	630	NUM
ajlm-2099	172	18	patients	patient	NOUN
ajlm-2099	172	19	.	.	PUNCT
ajlm-2099	173	1	egypt	egypt	PROPN
ajlm-2099	173	2	rheumatol	rheumatol	PROPN
ajlm-2099	173	3	.	.	PUNCT
ajlm-2099	174	1	2018;40(4):243–248	2018;40(4):243–248	X
ajlm-2099	174	2	.	.	X
ajlm-2099	174	3	https://doi.org/10.1016/j.ejr.2018.01.001	https://doi.org/10.1016/j.ejr.2018.01.001	PROPN
ajlm-2099	174	4	watts	watts	PROPN
ajlm-2099	174	5	ra	ra	PROPN
ajlm-2099	174	6	,	,	PUNCT
ajlm-2099	174	7	mahr	mahr	NOUN
ajlm-2099	174	8	a	a	NOUN
ajlm-2099	174	9	,	,	PUNCT
ajlm-2099	174	10	mohammad	mohammad	PROPN
ajlm-2099	174	11	aj	aj	PROPN
ajlm-2099	174	12	,	,	PUNCT
ajlm-2099	174	13	gatenby	gatenby	PROPN
ajlm-2099	174	14	p	p	PROPN
ajlm-2099	174	15	,	,	PUNCT
ajlm-2099	174	16	basu	basu	PROPN
ajlm-2099	174	17	n	n	PROPN
ajlm-2099	174	18	,	,	PUNCT
ajlm-2099	174	19	flores	flore	NOUN
ajlm-2099	174	20	-	-	PUNCT
ajlm-2099	174	21	suárez	suárez	NOUN
ajlm-2099	174	22	lf	lf	PROPN
ajlm-2099	174	23	.	.	PUNCT
ajlm-2099	174	24	classification	classification	NOUN
ajlm-2099	174	25	,	,	PUNCT
ajlm-2099	174	26	epidemiology	epidemiology	NOUN
ajlm-2099	174	27	and	and	CCONJ
ajlm-2099	174	28	clinical	clinical	ADJ
ajlm-2099	174	29	subgrouping	subgrouping	NOUN
ajlm-2099	174	30	of	of	ADP
ajlm-2099	174	31	antineutrophil	antineutrophil	PROPN
ajlm-2099	174	32	cytoplasmic	cytoplasmic	ADJ
ajlm-2099	174	33	antibody	antibody	NOUN
ajlm-2099	174	34	(	(	PUNCT
ajlm-2099	174	35	anca)-associated	anca)-associated	PROPN
ajlm-2099	174	36	vasculitis	vasculitis	PROPN
ajlm-2099	174	37	.	.	PUNCT
ajlm-2099	175	1	nephrol	nephrol	PROPN
ajlm-2099	175	2	dial	dial	NOUN
ajlm-2099	175	3	transplant	transplant	NOUN
ajlm-2099	175	4	.	.	PUNCT
ajlm-2099	176	1	2015;30	2015;30	NUM
ajlm-2099	176	2	suppl	suppl	ADJ
ajlm-2099	176	3	1	1	NUM
ajlm-2099	176	4	:	:	PUNCT
ajlm-2099	176	5	i14	i14	NOUN
ajlm-2099	176	6	–	–	PUNCT
ajlm-2099	176	7	i22	i22	NOUN
ajlm-2099	176	8	.	.	PUNCT
ajlm-2099	177	1	https://doi.org/10.1093/ndt/gfv022	https://doi.org/10.1093/ndt/gfv022	PROPN
ajlm-2099	177	2	bruner	bruner	PROPN
ajlm-2099	177	3	bf	bf	PROPN
ajlm-2099	177	4	,	,	PUNCT
ajlm-2099	177	5	guthridge	guthridge	NOUN
ajlm-2099	177	6	jm	jm	PROPN
ajlm-2099	177	7	,	,	PUNCT
ajlm-2099	177	8	lu	lu	PROPN
ajlm-2099	177	9	r	r	PROPN
ajlm-2099	177	10	,	,	PUNCT
ajlm-2099	177	11	et	et	PROPN
ajlm-2099	177	12	al	al	PROPN
ajlm-2099	177	13	.	.	PROPN
ajlm-2099	177	14	comparison	comparison	NOUN
ajlm-2099	177	15	of	of	ADP
ajlm-2099	177	16	autoantibody	autoantibody	ADJ
ajlm-2099	177	17	specificities	specificity	NOUN
ajlm-2099	177	18	between	between	ADP
ajlm-2099	177	19	traditional	traditional	ADJ
ajlm-2099	177	20	and	and	CCONJ
ajlm-2099	177	21	bead	bead	NOUN
ajlm-2099	177	22	-	-	PUNCT
ajlm-2099	177	23	based	base	VERB
ajlm-2099	177	24	assays	assay	NOUN
ajlm-2099	177	25	in	in	ADP
ajlm-2099	177	26	a	a	DET
ajlm-2099	177	27	large	large	ADJ
ajlm-2099	177	28	,	,	PUNCT
ajlm-2099	177	29	diverse	diverse	ADJ
ajlm-2099	177	30	collection	collection	NOUN
ajlm-2099	177	31	of	of	ADP
ajlm-2099	177	32	patients	patient	NOUN
ajlm-2099	177	33	with	with	ADP
ajlm-2099	177	34	systemic	systemic	ADJ
ajlm-2099	177	35	lupus	lupus	NOUN
ajlm-2099	177	36	erythematosus	erythematosus	NOUN
ajlm-2099	177	37	and	and	CCONJ
ajlm-2099	177	38	family	family	NOUN
ajlm-2099	177	39	members	member	NOUN
ajlm-2099	177	40	.	.	PUNCT
ajlm-2099	178	1	arthritis	arthritis	NOUN
ajlm-2099	178	2	rheum	rheum	NOUN
ajlm-2099	178	3	.	.	PUNCT
ajlm-2099	179	1	2012;64(11):3677–3686	2012;64(11):3677–3686	X
ajlm-2099	179	2	.	.	PUNCT
ajlm-2099	179	3	https://doi.org/10.1002/art.34651	https://doi.org/10.1002/art.34651	PROPN
ajlm-2099	179	4	albon	albon	PROPN
ajlm-2099	179	5	s	s	PROPN
ajlm-2099	179	6	,	,	PUNCT
ajlm-2099	179	7	bunn	bunn	PROPN
ajlm-2099	179	8	c	c	PROPN
ajlm-2099	179	9	,	,	PUNCT
ajlm-2099	179	10	swana	swana	PROPN
ajlm-2099	179	11	g	g	PROPN
ajlm-2099	179	12	,	,	PUNCT
ajlm-2099	179	13	karim	karim	PROPN
ajlm-2099	179	14	y.	y.	PROPN
ajlm-2099	179	15	performance	performance	NOUN
ajlm-2099	179	16	of	of	ADP
ajlm-2099	179	17	a	a	DET
ajlm-2099	179	18	multiplex	multiplex	NOUN
ajlm-2099	179	19	assay	assay	NOUN
ajlm-2099	179	20	compared	compare	VERB
ajlm-2099	179	21	to	to	ADP
ajlm-2099	179	22	enzyme	enzyme	NOUN
ajlm-2099	179	23	and	and	CCONJ
ajlm-2099	179	24	precipitation	precipitation	NOUN
ajlm-2099	179	25	methods	method	NOUN
ajlm-2099	179	26	for	for	ADP
ajlm-2099	179	27	anti	anti	ADJ
ajlm-2099	179	28	-	-	ADJ
ajlm-2099	179	29	ena	ena	ADJ
ajlm-2099	179	30	testing	testing	NOUN
ajlm-2099	179	31	in	in	ADP
ajlm-2099	179	32	systemic	systemic	ADJ
ajlm-2099	179	33	lupus	lupus	NOUN
ajlm-2099	179	34	and	and	CCONJ
ajlm-2099	179	35	systemic	systemic	ADJ
ajlm-2099	179	36	sclerosis	sclerosis	NOUN
ajlm-2099	179	37	.	.	PUNCT
ajlm-2099	180	1	j	j	PROPN
ajlm-2099	180	2	immunol	immunol	NOUN
ajlm-2099	180	3	methods	method	NOUN
ajlm-2099	180	4	.	.	PUNCT
ajlm-2099	181	1	2011;365(1–2):126–131	2011;365(1–2):126–131	X
ajlm-2099	181	2	.	.	PUNCT
ajlm-2099	182	1	https://doi.org/10.1016/j.jim.2010.12.010	https://doi.org/10.1016/j.jim.2010.12.010	PROPN
ajlm-2099	182	2	yates	yates	PROPN
ajlm-2099	182	3	m	m	PROPN
ajlm-2099	182	4	,	,	PUNCT
ajlm-2099	182	5	watts	watts	PROPN
ajlm-2099	182	6	ra	ra	PROPN
ajlm-2099	182	7	,	,	PUNCT
ajlm-2099	182	8	bajema	bajema	VERB
ajlm-2099	182	9	i	i	PRON
ajlm-2099	182	10	,	,	PUNCT
ajlm-2099	182	11	et	et	PROPN
ajlm-2099	182	12	al	al	PROPN
ajlm-2099	182	13	.	.	PUNCT
ajlm-2099	183	1	eular	eular	PROPN
ajlm-2099	183	2	/	/	SYM
ajlm-2099	183	3	era	era	NOUN
ajlm-2099	183	4	-	-	PUNCT
ajlm-2099	183	5	edta	edta	NOUN
ajlm-2099	183	6	recommendations	recommendation	NOUN
ajlm-2099	183	7	for	for	ADP
ajlm-2099	183	8	the	the	DET
ajlm-2099	183	9	management	management	NOUN
ajlm-2099	183	10	of	of	ADP
ajlm-2099	183	11	anca	anca	NOUN
ajlm-2099	183	12	-	-	PUNCT
ajlm-2099	183	13	associated	associate	VERB
ajlm-2099	183	14	vasculitis	vasculitis	PROPN
ajlm-2099	183	15	.	.	PUNCT
ajlm-2099	184	1	ann	ann	PROPN
ajlm-2099	184	2	rheum	rheum	PROPN
ajlm-2099	184	3	dis	dis	PROPN
ajlm-2099	184	4	.	.	PUNCT
ajlm-2099	185	1	2016;75(9):1583–1594	2016;75(9):1583–1594	NUM
ajlm-2099	185	2	.	.	PUNCT
ajlm-2099	186	1	https://doi.org/10.1136/annrheumdis-2016-209133	https://doi.org/10.1136/annrheumdis-2016-209133	PROPN
ajlm-2099	186	2	zhao	zhao	PROPN
ajlm-2099	186	3	j	j	PROPN
ajlm-2099	186	4	,	,	PUNCT
ajlm-2099	186	5	wang	wang	PROPN
ajlm-2099	186	6	k	k	PROPN
ajlm-2099	186	7	,	,	PUNCT
ajlm-2099	186	8	wang	wang	PROPN
ajlm-2099	186	9	x	x	PROPN
ajlm-2099	186	10	,	,	PUNCT
ajlm-2099	186	11	et	et	PROPN
ajlm-2099	186	12	al	al	PROPN
ajlm-2099	186	13	.	.	PUNCT
ajlm-2099	187	1	the	the	DET
ajlm-2099	187	2	performance	performance	NOUN
ajlm-2099	187	3	of	of	ADP
ajlm-2099	187	4	different	different	ADJ
ajlm-2099	187	5	anti	anti	ADJ
ajlm-2099	187	6	-	-	ADJ
ajlm-2099	187	7	dsdna	dsdna	ADJ
ajlm-2099	187	8	autoantibodies	autoantibody	NOUN
ajlm-2099	187	9	assays	assay	NOUN
ajlm-2099	187	10	in	in	ADP
ajlm-2099	187	11	chinese	chinese	ADJ
ajlm-2099	187	12	systemic	systemic	ADJ
ajlm-2099	187	13	lupus	lupus	PROPN
ajlm-2099	187	14	erythematosus	erythematosus	PROPN
ajlm-2099	187	15	patients	patient	NOUN
ajlm-2099	187	16	.	.	PUNCT
ajlm-2099	188	1	clin	clin	PROPN
ajlm-2099	188	2	rheumatol	rheumatol	NOUN
ajlm-2099	188	3	.	.	PUNCT
ajlm-2099	189	1	2018;37(1):139–144	2018;37(1):139–144	X
ajlm-2099	189	2	.	.	PUNCT
ajlm-2099	190	1	https://doi.org/10.1007/s10067-017-3771-x	https://doi.org/10.1007/s10067-017-3771-x	PROPN
ajlm-2099	190	2	abuaf	abuaf	PROPN
ajlm-2099	190	3	n	n	CCONJ
ajlm-2099	190	4	,	,	PUNCT
ajlm-2099	190	5	desgruelles	desgruelle	NOUN
ajlm-2099	190	6	c	c	NOUN
ajlm-2099	190	7	,	,	PUNCT
ajlm-2099	190	8	moumaris	moumaris	PROPN
ajlm-2099	190	9	m	m	PROPN
ajlm-2099	190	10	,	,	PUNCT
ajlm-2099	190	11	et	et	PROPN
ajlm-2099	190	12	al	al	PROPN
ajlm-2099	190	13	.	.	PUNCT
ajlm-2099	191	1	detection	detection	NOUN
ajlm-2099	191	2	by	by	ADP
ajlm-2099	191	3	flow	flow	NOUN
ajlm-2099	191	4	cytometry	cytometry	NOUN
ajlm-2099	191	5	of	of	ADP
ajlm-2099	191	6	anti	anti	ADJ
ajlm-2099	191	7	-	-	ADJ
ajlm-2099	191	8	dna	dna	ADJ
ajlm-2099	191	9	autoantibodies	autoantibody	NOUN
ajlm-2099	191	10	and	and	CCONJ
ajlm-2099	191	11	circulating	circulate	VERB
ajlm-2099	191	12	dna	dna	PROPN
ajlm-2099	191	13	immune	immune	ADJ
ajlm-2099	191	14	complexes	complex	NOUN
ajlm-2099	191	15	in	in	ADP
ajlm-2099	191	16	lupus	lupus	PROPN
ajlm-2099	191	17	erythematosus	erythematosus	NOUN
ajlm-2099	191	18	.	.	PUNCT
ajlm-2099	192	1	j	j	PROPN
ajlm-2099	192	2	immunol	immunol	NOUN
ajlm-2099	192	3	res	re	NOUN
ajlm-2099	192	4	.	.	PUNCT
ajlm-2099	193	1	2019;2019:6047085	2019;2019:6047085	NUM
ajlm-2099	193	2	.	.	PUNCT
ajlm-2099	194	1	https://doi.org/10.1155/2019/6047085	https://doi.org/10.1155/2019/6047085	PROPN
ajlm-2099	194	2	slater	slater	PROPN
ajlm-2099	194	3	ng	ng	PROPN
ajlm-2099	194	4	,	,	PUNCT
ajlm-2099	194	5	cameron	cameron	PROPN
ajlm-2099	194	6	js	js	PROPN
ajlm-2099	194	7	,	,	PUNCT
ajlm-2099	194	8	lessof	lessof	PROPN
ajlm-2099	194	9	mh	mh	PROPN
ajlm-2099	194	10	.	.	PUNCT
ajlm-2099	195	1	the	the	DET
ajlm-2099	195	2	crithidia	crithidia	NOUN
ajlm-2099	195	3	luciliae	luciliae	PROPN
ajlm-2099	195	4	kinetoplast	kinetoplast	ADJ
ajlm-2099	195	5	immunofluorescence	immunofluorescence	NOUN
ajlm-2099	195	6	test	test	NOUN
ajlm-2099	195	7	in	in	ADP
ajlm-2099	195	8	systemic	systemic	ADJ
ajlm-2099	195	9	lupus	lupus	PROPN
ajlm-2099	195	10	erythematosus	erythematosus	PROPN
ajlm-2099	195	11	.	.	PUNCT
ajlm-2099	196	1	clin	clin	PROPN
ajlm-2099	196	2	exp	exp	NOUN
ajlm-2099	196	3	immunol	immunol	NOUN
ajlm-2099	196	4	.	.	PUNCT
ajlm-2099	197	1	1976;25(3):480–486	1976;25(3):480–486	NUM
ajlm-2099	197	2	.	.	PUNCT
ajlm-2099	197	3	infantino	infantino	PROPN
ajlm-2099	197	4	m	m	PROPN
ajlm-2099	197	5	,	,	PUNCT
ajlm-2099	197	6	meacci	meacci	PROPN
ajlm-2099	197	7	f	f	AUX
ajlm-2099	197	8	,	,	PUNCT
ajlm-2099	197	9	bentow	bentow	NOUN
ajlm-2099	197	10	c	c	NOUN
ajlm-2099	197	11	,	,	PUNCT
ajlm-2099	197	12	et	et	PROPN
ajlm-2099	197	13	al	al	PROPN
ajlm-2099	197	14	.	.	PUNCT
ajlm-2099	198	1	clinical	clinical	ADJ
ajlm-2099	198	2	comparison	comparison	NOUN
ajlm-2099	198	3	of	of	ADP
ajlm-2099	198	4	quanta	quanta	PROPN
ajlm-2099	198	5	flash	flash	PROPN
ajlm-2099	198	6	dsdna	dsdna	PROPN
ajlm-2099	198	7	chemiluminescent	chemiluminescent	PROPN
ajlm-2099	198	8	immunoassay	immunoassay	PROPN
ajlm-2099	198	9	with	with	ADP
ajlm-2099	198	10	four	four	NUM
ajlm-2099	198	11	current	current	ADJ
ajlm-2099	198	12	assays	assay	NOUN
ajlm-2099	198	13	for	for	ADP
ajlm-2099	198	14	the	the	DET
ajlm-2099	198	15	detection	detection	NOUN
ajlm-2099	198	16	of	of	ADP
ajlm-2099	198	17	anti	anti	ADJ
ajlm-2099	198	18	-	-	ADJ
ajlm-2099	198	19	dsdna	dsdna	ADJ
ajlm-2099	198	20	autoantibodies	autoantibody	NOUN
ajlm-2099	198	21	.	.	PUNCT
ajlm-2099	199	1	j	j	PROPN
ajlm-2099	199	2	immunol	immunol	NOUN
ajlm-2099	199	3	res	re	NOUN
ajlm-2099	199	4	.	.	PUNCT
ajlm-2099	200	1	2015;2015:902821	2015;2015:902821	NUM
ajlm-2099	200	2	.	.	PUNCT
ajlm-2099	201	1	https://doi.org/10.1155/2015/902821	https://doi.org/10.1155/2015/902821	PROPN
ajlm-2099	201	2	infantino	infantino	PROPN
ajlm-2099	201	3	m	m	PROPN
ajlm-2099	201	4	,	,	PUNCT
ajlm-2099	201	5	manfredi	manfredi	PROPN
ajlm-2099	201	6	m	m	PROPN
ajlm-2099	201	7	,	,	PUNCT
ajlm-2099	201	8	merone	merone	NOUN
ajlm-2099	201	9	m	m	NOUN
ajlm-2099	201	10	,	,	PUNCT
ajlm-2099	201	11	et	et	PROPN
ajlm-2099	201	12	al	al	PROPN
ajlm-2099	201	13	.	.	PROPN
ajlm-2099	202	1	analytical	analytical	ADJ
ajlm-2099	202	2	variability	variability	NOUN
ajlm-2099	202	3	in	in	ADP
ajlm-2099	202	4	the	the	DET
ajlm-2099	202	5	determination	determination	NOUN
ajlm-2099	202	6	of	of	ADP
ajlm-2099	202	7	anti	anti	ADJ
ajlm-2099	202	8	-	-	ADJ
ajlm-2099	202	9	double	double	ADJ
ajlm-2099	202	10	-	-	PUNCT
ajlm-2099	202	11	stranded	strand	VERB
ajlm-2099	202	12	dna	dna	NOUN
ajlm-2099	202	13	antibodies	antibodie	VERB
ajlm-2099	202	14	:	:	PUNCT
ajlm-2099	202	15	the	the	DET
ajlm-2099	202	16	strong	strong	ADJ
ajlm-2099	202	17	need	need	NOUN
ajlm-2099	202	18	of	of	ADP
ajlm-2099	202	19	a	a	DET
ajlm-2099	202	20	better	well	ADJ
ajlm-2099	202	21	definition	definition	NOUN
ajlm-2099	202	22	of	of	ADP
ajlm-2099	202	23	the	the	DET
ajlm-2099	202	24	old	old	ADJ
ajlm-2099	202	25	and	and	CCONJ
ajlm-2099	202	26	new	new	ADJ
ajlm-2099	202	27	tests	test	NOUN
ajlm-2099	202	28	.	.	PUNCT
ajlm-2099	203	1	immunol	immunol	NOUN
ajlm-2099	203	2	res	re	NOUN
ajlm-2099	203	3	.	.	PUNCT
ajlm-2099	204	1	2018;66(3):340–347	2018;66(3):340–347	NUM
ajlm-2099	204	2	.	.	NUM
ajlm-2099	204	3	https://doi.org/10.1007/s12026-018-8992-9	https://doi.org/10.1007/s12026-018-8992-9	NUM
ajlm-2099	204	4	pisetsky	pisetsky	PROPN
ajlm-2099	204	5	ds	ds	PROPN
ajlm-2099	204	6	.	.	PUNCT
ajlm-2099	204	7	anti	anti	ADJ
ajlm-2099	204	8	-	-	ADJ
ajlm-2099	204	9	dna	dna	ADJ
ajlm-2099	204	10	antibodies	antibodie	VERB
ajlm-2099	204	11	–	–	PUNCT
ajlm-2099	204	12	quintessential	quintessential	ADJ
ajlm-2099	204	13	biomarkers	biomarker	NOUN
ajlm-2099	204	14	of	of	ADP
ajlm-2099	204	15	sle	sle	PROPN
ajlm-2099	204	16	.	.	PUNCT
ajlm-2099	205	1	nat	nat	PROPN
ajlm-2099	205	2	rev	rev	PROPN
ajlm-2099	205	3	rheumatol	rheumatol	NOUN
ajlm-2099	205	4	.	.	PUNCT
ajlm-2099	206	1	2016;12(2):102–110	2016;12(2):102–110	X
ajlm-2099	206	2	.	.	PUNCT
ajlm-2099	207	1	https://doi.org/10.1038/nrrheum.2015.151	https://doi.org/10.1038/nrrheum.2015.151	NOUN
ajlm-2099	207	2	enocsson	enocsson	NOUN
ajlm-2099	207	3	h	h	NOUN
ajlm-2099	207	4	,	,	PUNCT
ajlm-2099	207	5	sjowall	sjowall	NOUN
ajlm-2099	207	6	c	c	PROPN
ajlm-2099	207	7	,	,	PUNCT
ajlm-2099	207	8	wirestam	wirestam	PROPN
ajlm-2099	207	9	l	l	NOUN
ajlm-2099	207	10	,	,	PUNCT
ajlm-2099	207	11	et	et	PROPN
ajlm-2099	207	12	al	al	PROPN
ajlm-2099	207	13	.	.	PROPN
ajlm-2099	208	1	four	four	NUM
ajlm-2099	208	2	anti	anti	ADJ
ajlm-2099	208	3	-	-	ADJ
ajlm-2099	208	4	dsdna	dsdna	ADJ
ajlm-2099	208	5	antibody	antibody	NOUN
ajlm-2099	208	6	assays	assay	NOUN
ajlm-2099	208	7	in	in	ADP
ajlm-2099	208	8	relation	relation	NOUN
ajlm-2099	208	9	to	to	ADP
ajlm-2099	208	10	systemic	systemic	ADJ
ajlm-2099	208	11	lupus	lupus	NOUN
ajlm-2099	208	12	erythematosus	erythematosus	NOUN
ajlm-2099	208	13	disease	disease	NOUN
ajlm-2099	208	14	specificity	specificity	NOUN
ajlm-2099	208	15	and	and	CCONJ
ajlm-2099	208	16	activity	activity	NOUN
ajlm-2099	208	17	.	.	PUNCT
ajlm-2099	209	1	j	j	PROPN
ajlm-2099	209	2	rheumatol	rheumatol	NOUN
ajlm-2099	209	3	.	.	PUNCT
ajlm-2099	210	1	2015;42(5):817–825	2015;42(5):817–825	PROPN
ajlm-2099	210	2	.	.	PUNCT
ajlm-2099	211	1	https://doi.org/10.3899/jrheum.140677	https://doi.org/10.3899/jrheum.140677	PROPN
ajlm-2099	211	2	aringer	aring	ADJ
ajlm-2099	211	3	m.	m.	NOUN
ajlm-2099	211	4	eular	eular	PROPN
ajlm-2099	211	5	/	/	SYM
ajlm-2099	211	6	acr	acr	PROPN
ajlm-2099	211	7	classification	classification	NOUN
ajlm-2099	211	8	criteria	criterion	NOUN
ajlm-2099	211	9	for	for	ADP
ajlm-2099	211	10	sle	sle	PROPN
ajlm-2099	211	11	.	.	PUNCT
ajlm-2099	212	1	semin	semin	PROPN
ajlm-2099	212	2	arthritis	arthritis	PROPN
ajlm-2099	212	3	rheum	rheum	PROPN
ajlm-2099	212	4	.	.	PUNCT
ajlm-2099	213	1	2019;49(3s):s14	2019;49(3s):s14	X
ajlm-2099	213	2	–	–	PUNCT
ajlm-2099	213	3	s17	s17	NOUN
ajlm-2099	213	4	.	.	PUNCT
ajlm-2099	214	1	https://doi.org/10.1016/j.semarthrit.2019.09.009	https://doi.org/10.1016/j.semarthrit.2019.09.009	PROPN
ajlm-2099	214	2	agmon	agmon	PROPN
ajlm-2099	214	3	-	-	PUNCT
ajlm-2099	214	4	levin	levin	PROPN
ajlm-2099	214	5	n	n	PROPN
ajlm-2099	214	6	,	,	PUNCT
ajlm-2099	214	7	damoiseaux	damoiseaux	PROPN
ajlm-2099	214	8	j	j	PROPN
ajlm-2099	214	9	,	,	PUNCT
ajlm-2099	214	10	kallenberg	kallenberg	PROPN
ajlm-2099	214	11	c	c	PROPN
ajlm-2099	214	12	,	,	PUNCT
ajlm-2099	214	13	et	et	PROPN
ajlm-2099	214	14	al	al	PROPN
ajlm-2099	214	15	.	.	PUNCT
ajlm-2099	215	1	international	international	ADJ
ajlm-2099	215	2	recommendations	recommendation	NOUN
ajlm-2099	215	3	for	for	ADP
ajlm-2099	215	4	the	the	DET
ajlm-2099	215	5	assessment	assessment	NOUN
ajlm-2099	215	6	of	of	ADP
ajlm-2099	215	7	autoantibodies	autoantibody	NOUN
ajlm-2099	215	8	to	to	ADP
ajlm-2099	215	9	cellular	cellular	ADJ
ajlm-2099	215	10	antigens	antigen	NOUN
ajlm-2099	215	11	referred	refer	VERB
ajlm-2099	215	12	to	to	ADP
ajlm-2099	215	13	as	as	ADP
ajlm-2099	215	14	anti	anti	ADJ
ajlm-2099	215	15	-	-	ADJ
ajlm-2099	215	16	nuclear	nuclear	ADJ
ajlm-2099	215	17	antibodies	antibody	NOUN
ajlm-2099	215	18	.	.	PUNCT
ajlm-2099	216	1	ann	ann	PROPN
ajlm-2099	216	2	rheum	rheum	PROPN
ajlm-2099	216	3	dis	dis	PROPN
ajlm-2099	216	4	.	.	PUNCT
ajlm-2099	217	1	2014;73(1):17–23	2014;73(1):17–23	X
ajlm-2099	217	2	.	.	PUNCT
ajlm-2099	218	1	https://doi.org/10.1136/annrheumdis-2013-203863	https://doi.org/10.1136/annrheumdis-2013-203863	PROPN
ajlm-2099	218	2	csernok	csernok	PROPN
ajlm-2099	218	3	e	e	NOUN
ajlm-2099	218	4	,	,	PUNCT
ajlm-2099	218	5	damoiseaux	damoiseaux	PROPN
ajlm-2099	218	6	j	j	PROPN
ajlm-2099	218	7	,	,	PUNCT
ajlm-2099	218	8	rasmussen	rasmussen	PROPN
ajlm-2099	218	9	n	n	PROPN
ajlm-2099	218	10	,	,	PUNCT
ajlm-2099	218	11	et	et	PROPN
ajlm-2099	218	12	al	al	PROPN
ajlm-2099	218	13	.	.	PUNCT
ajlm-2099	218	14	evaluation	evaluation	NOUN
ajlm-2099	218	15	of	of	ADP
ajlm-2099	218	16	automated	automate	VERB
ajlm-2099	218	17	multi	multi	ADJ
ajlm-2099	218	18	-	-	ADJ
ajlm-2099	218	19	parametric	parametric	ADJ
ajlm-2099	218	20	indirect	indirect	ADJ
ajlm-2099	218	21	immunofluorescence	immunofluorescence	NOUN
ajlm-2099	218	22	assays	assay	NOUN
ajlm-2099	218	23	to	to	PART
ajlm-2099	218	24	detect	detect	VERB
ajlm-2099	218	25	anti	anti	ADJ
ajlm-2099	218	26	-	-	ADJ
ajlm-2099	218	27	neutrophil	neutrophil	ADJ
ajlm-2099	218	28	cytoplasmic	cytoplasmic	ADJ
ajlm-2099	218	29	antibodies	antibody	NOUN
ajlm-2099	218	30	(	(	PUNCT
ajlm-2099	218	31	anca	anca	NOUN
ajlm-2099	218	32	)	)	PUNCT
ajlm-2099	218	33	in	in	ADP
ajlm-2099	218	34	granulomatosis	granulomatosis	NOUN
ajlm-2099	218	35	with	with	ADP
ajlm-2099	218	36	polyangiitis	polyangiitis	PROPN
ajlm-2099	218	37	(	(	PUNCT
ajlm-2099	218	38	gpa	gpa	PROPN
ajlm-2099	218	39	)	)	PUNCT
ajlm-2099	218	40	and	and	CCONJ
ajlm-2099	218	41	microscopic	microscopic	ADJ
ajlm-2099	218	42	polyangiitis	polyangiitis	PROPN
ajlm-2099	218	43	(	(	PUNCT
ajlm-2099	218	44	mpa	mpa	PROPN
ajlm-2099	218	45	)	)	PUNCT
ajlm-2099	218	46	.	.	PUNCT
ajlm-2099	219	1	autoimmun	autoimmun	PROPN
ajlm-2099	219	2	rev	rev	PROPN
ajlm-2099	219	3	.	.	PUNCT
ajlm-2099	220	1	2016;15(7):736–741	2016;15(7):736–741	NUM
ajlm-2099	220	2	.	.	PUNCT
ajlm-2099	221	1	https://doi.org/10.1016/j.autrev.2016.03.010	https://doi.org/10.1016/j.autrev.2016.03.010	NOUN
ajlm-2099	221	2	csernok	csernok	PROPN
ajlm-2099	221	3	e	e	NOUN
ajlm-2099	221	4	,	,	PUNCT
ajlm-2099	221	5	mahrhold	mahrhold	ADJ
ajlm-2099	221	6	j	j	PROPN
ajlm-2099	221	7	,	,	PUNCT
ajlm-2099	221	8	hellmich	hellmich	PROPN
ajlm-2099	221	9	b.	b.	PROPN
ajlm-2099	221	10	anti	anti	ADJ
ajlm-2099	221	11	-	-	ADJ
ajlm-2099	221	12	neutrophil	neutrophil	ADJ
ajlm-2099	221	13	cytoplasm	cytoplasm	ADJ
ajlm-2099	221	14	antibodies	antibody	NOUN
ajlm-2099	221	15	(	(	PUNCT
ajlm-2099	221	16	anca	anca	NOUN
ajlm-2099	221	17	):	):	PUNCT
ajlm-2099	221	18	recent	recent	ADJ
ajlm-2099	221	19	methodological	methodological	ADJ
ajlm-2099	221	20	advances	advance	NOUN
ajlm-2099	221	21	–	–	PUNCT
ajlm-2099	221	22	lead	lead	VERB
ajlm-2099	221	23	to	to	ADP
ajlm-2099	221	24	new	new	ADJ
ajlm-2099	221	25	consensus	consensus	NOUN
ajlm-2099	221	26	recommendations	recommendation	NOUN
ajlm-2099	221	27	for	for	ADP
ajlm-2099	221	28	anca	anca	NOUN
ajlm-2099	221	29	detection	detection	NOUN
ajlm-2099	221	30	.	.	PUNCT
ajlm-2099	222	1	j	j	PROPN
ajlm-2099	222	2	immunol	immunol	NOUN
ajlm-2099	222	3	methods	method	NOUN
ajlm-2099	222	4	.	.	PUNCT
ajlm-2099	223	1	2018;456:1–6	2018;456:1–6	NUM
ajlm-2099	223	2	.	.	PUNCT
ajlm-2099	224	1	https://doi.org/10.1016/j.jim.2018.01.007	https://doi.org/10.1016/j.jim.2018.01.007	AUX
ajlm-2099	224	2	savige	savige	VERB
ajlm-2099	224	3	j	j	PROPN
ajlm-2099	224	4	,	,	PUNCT
ajlm-2099	224	5	gillis	gillis	PROPN
ajlm-2099	224	6	d	d	PROPN
ajlm-2099	224	7	,	,	PUNCT
ajlm-2099	224	8	benson	benson	PROPN
ajlm-2099	224	9	e	e	PROPN
ajlm-2099	224	10	,	,	PUNCT
ajlm-2099	224	11	et	et	PROPN
ajlm-2099	224	12	al	al	PROPN
ajlm-2099	224	13	.	.	PUNCT
ajlm-2099	225	1	international	international	ADJ
ajlm-2099	225	2	consensus	consensus	NOUN
ajlm-2099	225	3	statement	statement	NOUN
ajlm-2099	225	4	on	on	ADP
ajlm-2099	225	5	testing	testing	NOUN
ajlm-2099	225	6	and	and	CCONJ
ajlm-2099	225	7	reporting	reporting	NOUN
ajlm-2099	225	8	of	of	ADP
ajlm-2099	225	9	antineutrophil	antineutrophil	PROPN
ajlm-2099	225	10	cytoplasmic	cytoplasmic	ADJ
ajlm-2099	225	11	antibodies	antibody	NOUN
ajlm-2099	225	12	(	(	PUNCT
ajlm-2099	225	13	anca	anca	NOUN
ajlm-2099	225	14	)	)	PUNCT
ajlm-2099	225	15	.	.	PUNCT
ajlm-2099	226	1	am	be	AUX
ajlm-2099	226	2	j	j	PROPN
ajlm-2099	226	3	clin	clin	PROPN
ajlm-2099	226	4	pathol	pathol	NOUN
ajlm-2099	226	5	.	.	PUNCT
ajlm-2099	227	1	1999;111(4):507–513	1999;111(4):507–513	NUM
ajlm-2099	227	2	.	.	PUNCT
ajlm-2099	228	1	https://doi.org/10.1093/ajcp/111.4.507	https://doi.org/10.1093/ajcp/111.4.507	PROPN
ajlm-2099	228	2	damoiseaux	damoiseaux	PROPN
ajlm-2099	228	3	j	j	PROPN
ajlm-2099	228	4	,	,	PUNCT
ajlm-2099	228	5	csernok	csernok	PROPN
ajlm-2099	228	6	e	e	PROPN
ajlm-2099	228	7	,	,	PUNCT
ajlm-2099	228	8	rasmussen	rasmussen	PROPN
ajlm-2099	228	9	n	n	PROPN
ajlm-2099	228	10	,	,	PUNCT
ajlm-2099	228	11	et	et	PROPN
ajlm-2099	228	12	al	al	PROPN
ajlm-2099	228	13	.	.	PUNCT
ajlm-2099	228	14	detection	detection	NOUN
ajlm-2099	228	15	of	of	ADP
ajlm-2099	228	16	antineutrophil	antineutrophil	PROPN
ajlm-2099	228	17	cytoplasmic	cytoplasmic	ADJ
ajlm-2099	228	18	antibodies	antibody	NOUN
ajlm-2099	228	19	(	(	PUNCT
ajlm-2099	228	20	ancas	ancas	NOUN
ajlm-2099	228	21	):	):	PUNCT
ajlm-2099	228	22	a	a	DET
ajlm-2099	228	23	multicentre	multicentre	ADJ
ajlm-2099	228	24	european	european	ADJ
ajlm-2099	228	25	vasculitis	vasculitis	PROPN
ajlm-2099	228	26	study	study	NOUN
ajlm-2099	228	27	group	group	NOUN
ajlm-2099	228	28	(	(	PUNCT
ajlm-2099	228	29	euvas	euvas	ADJ
ajlm-2099	228	30	)	)	PUNCT
ajlm-2099	228	31	evaluation	evaluation	NOUN
ajlm-2099	228	32	of	of	ADP
ajlm-2099	228	33	the	the	DET
ajlm-2099	228	34	value	value	NOUN
ajlm-2099	228	35	of	of	ADP
ajlm-2099	228	36	indirect	indirect	ADJ
ajlm-2099	228	37	immunofluorescence	immunofluorescence	NOUN
ajlm-2099	228	38	(	(	PUNCT
ajlm-2099	228	39	iif	iif	PROPN
ajlm-2099	228	40	)	)	PUNCT
ajlm-2099	228	41	versus	versus	ADP
ajlm-2099	228	42	antigen	antigen	ADV
ajlm-2099	228	43	-	-	PUNCT
ajlm-2099	228	44	specific	specific	ADJ
ajlm-2099	228	45	immunoassays	immunoassay	NOUN
ajlm-2099	228	46	.	.	PUNCT
ajlm-2099	229	1	ann	ann	PROPN
ajlm-2099	229	2	rheum	rheum	PROPN
ajlm-2099	229	3	dis	dis	PROPN
ajlm-2099	229	4	.	.	PUNCT
ajlm-2099	230	1	2017;76(4):647–653	2017;76(4):647–653	NUM
ajlm-2099	230	2	.	.	PUNCT
ajlm-2099	230	3	https://doi.org/10.1136/annrheumdis-2016-209507	https://doi.org/10.1136/annrheumdis-2016-209507	PROPN
ajlm-2099	230	4	conrad	conrad	PROPN
ajlm-2099	230	5	k	k	PROPN
ajlm-2099	230	6	,	,	PUNCT
ajlm-2099	230	7	roggenbuck	roggenbuck	PROPN
ajlm-2099	230	8	d	d	PROPN
ajlm-2099	230	9	,	,	PUNCT
ajlm-2099	230	10	reinhold	reinhold	PROPN
ajlm-2099	230	11	d	d	PROPN
ajlm-2099	230	12	,	,	PUNCT
ajlm-2099	230	13	sack	sack	NOUN
ajlm-2099	230	14	u.	u.	NOUN
ajlm-2099	230	15	autoantibody	autoantibody	ADJ
ajlm-2099	230	16	diagnostics	diagnostic	NOUN
ajlm-2099	230	17	in	in	ADP
ajlm-2099	230	18	clinical	clinical	ADJ
ajlm-2099	230	19	practice	practice	NOUN
ajlm-2099	230	20	.	.	PUNCT
ajlm-2099	231	1	autoimmun	autoimmun	PROPN
ajlm-2099	231	2	rev	rev	PROPN
ajlm-2099	231	3	.	.	PUNCT
ajlm-2099	232	1	2012;11(3):207–211	2012;11(3):207–211	NUM
ajlm-2099	232	2	.	.	PUNCT
ajlm-2099	233	1	https://doi.org/10.1016/j.autrev.2011.05.014	https://doi.org/10.1016/j.autrev.2011.05.014	PROPN
ajlm-2099	233	2	sowa	sowa	PROPN
ajlm-2099	233	3	m	m	PROPN
ajlm-2099	233	4	,	,	PUNCT
ajlm-2099	233	5	grossmann	grossmann	PROPN
ajlm-2099	233	6	k	k	PROPN
ajlm-2099	233	7	,	,	PUNCT
ajlm-2099	233	8	knutter	knutter	PROPN
ajlm-2099	233	9	i	i	PROPN
ajlm-2099	233	10	,	,	PUNCT
ajlm-2099	233	11	et	et	PROPN
ajlm-2099	233	12	al	al	PROPN
ajlm-2099	233	13	.	.	PROPN
ajlm-2099	233	14	simultaneous	simultaneous	ADJ
ajlm-2099	233	15	automated	automate	VERB
ajlm-2099	233	16	screening	screening	NOUN
ajlm-2099	233	17	and	and	CCONJ
ajlm-2099	233	18	confirmatory	confirmatory	NOUN
ajlm-2099	233	19	testing	testing	NOUN
ajlm-2099	233	20	for	for	ADP
ajlm-2099	233	21	vasculitis	vasculitis	NOUN
ajlm-2099	233	22	-	-	PUNCT
ajlm-2099	233	23	specific	specific	ADJ
ajlm-2099	233	24	anca	anca	NOUN
ajlm-2099	233	25	.	.	PUNCT
ajlm-2099	234	1	plos	plos	PROPN
ajlm-2099	234	2	one	one	NUM
ajlm-2099	234	3	.	.	PUNCT
ajlm-2099	235	1	2014;9(9):e107743	2014;9(9):e107743	X
ajlm-2099	235	2	.	.	PUNCT
ajlm-2099	236	1	https://doi.org/10.1371/journal.pone.0107743	https://doi.org/10.1371/journal.pone.0107743	PROPN
ajlm-2099	236	2	shrestha	shrestha	PROPN
ajlm-2099	236	3	b	b	PROPN
ajlm-2099	236	4	,	,	PUNCT
ajlm-2099	236	5	dunn	dunn	PROPN
ajlm-2099	236	6	l.	l.	PROPN
ajlm-2099	236	7	the	the	DET
ajlm-2099	236	8	declaration	declaration	NOUN
ajlm-2099	236	9	of	of	ADP
ajlm-2099	236	10	helsinki	helsinki	PROPN
ajlm-2099	236	11	on	on	ADP
ajlm-2099	236	12	medical	medical	ADJ
ajlm-2099	236	13	research	research	NOUN
ajlm-2099	236	14	involving	involve	VERB
ajlm-2099	236	15	human	human	ADJ
ajlm-2099	236	16	subjects	subject	NOUN
ajlm-2099	236	17	:	:	PUNCT
ajlm-2099	236	18	a	a	DET
ajlm-2099	236	19	review	review	NOUN
ajlm-2099	236	20	of	of	ADP
ajlm-2099	236	21	seventh	seventh	ADJ
ajlm-2099	236	22	revision	revision	NOUN
ajlm-2099	236	23	.	.	PUNCT
ajlm-2099	237	1	j	j	PROPN
ajlm-2099	237	2	nepal	nepal	PROPN
ajlm-2099	237	3	health	health	PROPN
ajlm-2099	237	4	res	re	NOUN
ajlm-2099	237	5	counc	counc	NOUN
ajlm-2099	237	6	.	.	PUNCT
ajlm-2099	238	1	2020;17(4):548–552	2020;17(4):548–552	NUM
ajlm-2099	238	2	.	.	X
ajlm-2099	238	3	https://doi.org/10.33314/jnhrc.v17i4.1042	https://doi.org/10.33314/jnhrc.v17i4.1042	NUM
ajlm-2099	238	4	sullivan	sullivan	PROPN
ajlm-2099	238	5	km	km	PROPN
ajlm-2099	238	6	,	,	PUNCT
ajlm-2099	238	7	dean	dean	PROPN
ajlm-2099	238	8	a	a	PRON
ajlm-2099	239	1	,	,	PUNCT
ajlm-2099	239	2	soe	soe	PROPN
ajlm-2099	239	3	mm	mm	PROPN
ajlm-2099	239	4	.	.	PUNCT
ajlm-2099	239	5	openepi	openepi	PROPN
ajlm-2099	239	6	:	:	PUNCT
ajlm-2099	239	7	a	a	DET
ajlm-2099	239	8	web	web	NOUN
ajlm-2099	239	9	-	-	PUNCT
ajlm-2099	239	10	based	base	VERB
ajlm-2099	239	11	epidemiologic	epidemiologic	ADJ
ajlm-2099	239	12	and	and	CCONJ
ajlm-2099	239	13	statistical	statistical	ADJ
ajlm-2099	239	14	calculator	calculator	NOUN
ajlm-2099	239	15	for	for	ADP
ajlm-2099	239	16	public	public	ADJ
ajlm-2099	239	17	health	health	NOUN
ajlm-2099	239	18	.	.	PUNCT
ajlm-2099	240	1	public	public	ADJ
ajlm-2099	240	2	health	health	PROPN
ajlm-2099	240	3	rep	rep	PROPN
ajlm-2099	240	4	.	.	PROPN
ajlm-2099	240	5	2009;124(3):471–474	2009;124(3):471–474	NUM
ajlm-2099	240	6	.	.	PUNCT
ajlm-2099	241	1	https://doi.org/10.1177/003335490912400320	https://doi.org/10.1177/003335490912400320	NOUN
ajlm-2099	241	2	guchelaar	guchelaar	NOUN
ajlm-2099	241	3	nad	nad	PROPN
ajlm-2099	241	4	,	,	PUNCT
ajlm-2099	241	5	waling	wale	VERB
ajlm-2099	241	6	mm	mm	PROPN
ajlm-2099	241	7	,	,	PUNCT
ajlm-2099	241	8	adhin	adhin	PROPN
ajlm-2099	241	9	aa	aa	PROPN
ajlm-2099	241	10	,	,	PUNCT
ajlm-2099	241	11	van	van	PROPN
ajlm-2099	241	12	daele	daele	PROPN
ajlm-2099	241	13	pla	pla	PROPN
ajlm-2099	241	14	,	,	PUNCT
ajlm-2099	241	15	schreurs	schreur	VERB
ajlm-2099	241	16	mwj	mwj	PROPN
ajlm-2099	241	17	,	,	PUNCT
ajlm-2099	241	18	rombach	rombach	VERB
ajlm-2099	241	19	sm	sm	INTJ
ajlm-2099	241	20	.	.	PUNCT
ajlm-2099	242	1	the	the	DET
ajlm-2099	242	2	value	value	NOUN
ajlm-2099	242	3	of	of	ADP
ajlm-2099	242	4	anti	anti	ADJ
ajlm-2099	242	5	-	-	ADJ
ajlm-2099	242	6	neutrophil	neutrophil	ADJ
ajlm-2099	242	7	cytoplasmic	cytoplasmic	ADJ
ajlm-2099	242	8	antibodies	antibody	NOUN
ajlm-2099	242	9	(	(	PUNCT
ajlm-2099	242	10	anca	anca	NOUN
ajlm-2099	242	11	)	)	PUNCT
ajlm-2099	242	12	testing	testing	NOUN
ajlm-2099	242	13	for	for	ADP
ajlm-2099	242	14	the	the	DET
ajlm-2099	242	15	diagnosis	diagnosis	NOUN
ajlm-2099	242	16	of	of	ADP
ajlm-2099	242	17	anca	anca	NOUN
ajlm-2099	242	18	-	-	PUNCT
ajlm-2099	242	19	associated	associate	VERB
ajlm-2099	242	20	vasculitis	vasculitis	PROPN
ajlm-2099	242	21	,	,	PUNCT
ajlm-2099	242	22	a	a	DET
ajlm-2099	242	23	systematic	systematic	ADJ
ajlm-2099	242	24	review	review	NOUN
ajlm-2099	242	25	and	and	CCONJ
ajlm-2099	242	26	meta	meta	ADJ
ajlm-2099	242	27	-	-	PUNCT
ajlm-2099	242	28	analysis	analysis	NOUN
ajlm-2099	242	29	.	.	PUNCT
ajlm-2099	243	1	autoimmun	autoimmun	PROPN
ajlm-2099	243	2	rev	rev	PROPN
ajlm-2099	243	3	.	.	PUNCT
ajlm-2099	244	1	2021;20(1):102716	2021;20(1):102716	NOUN
ajlm-2099	244	2	.	.	PUNCT
ajlm-2099	245	1	https://doi.org/10.1016/j.autrev.2020.102716	https://doi.org/10.1016/j.autrev.2020.102716	NOUN
ajlm-2099	245	2	wei	wei	PROPN
ajlm-2099	245	3	q	q	PROPN
ajlm-2099	245	4	,	,	PUNCT
ajlm-2099	245	5	jiang	jiang	PROPN
ajlm-2099	245	6	y	y	PROPN
ajlm-2099	245	7	,	,	PUNCT
ajlm-2099	245	8	xiao	xiao	PROPN
ajlm-2099	245	9	m	m	PROPN
ajlm-2099	245	10	,	,	PUNCT
ajlm-2099	245	11	et	et	PROPN
ajlm-2099	245	12	al	al	PROPN
ajlm-2099	245	13	.	.	PROPN
ajlm-2099	245	14	comparison	comparison	NOUN
ajlm-2099	245	15	of	of	ADP
ajlm-2099	245	16	chemiluminescence	chemiluminescence	NOUN
ajlm-2099	245	17	microparticle	microparticle	PROPN
ajlm-2099	245	18	immunoassay	immunoassay	PROPN
ajlm-2099	245	19	,	,	PUNCT
ajlm-2099	245	20	indirect	indirect	ADJ
ajlm-2099	245	21	immunofluorescence	immunofluorescence	NOUN
ajlm-2099	245	22	assay	assay	NOUN
ajlm-2099	245	23	,	,	PUNCT
ajlm-2099	245	24	linear	linear	ADJ
ajlm-2099	245	25	immunoassay	immunoassay	NOUN
ajlm-2099	245	26	and	and	CCONJ
ajlm-2099	245	27	multiple	multiple	ADJ
ajlm-2099	245	28	microbead	microbead	ADJ
ajlm-2099	245	29	immunoassay	immunoassay	NOUN
ajlm-2099	245	30	detecting	detect	VERB
ajlm-2099	245	31	autoantibodies	autoantibody	NOUN
ajlm-2099	245	32	in	in	ADP
ajlm-2099	245	33	systemic	systemic	ADJ
ajlm-2099	245	34	lupus	lupus	PROPN
ajlm-2099	245	35	erythematosus	erythematosus	PROPN
ajlm-2099	245	36	.	.	PUNCT
ajlm-2099	246	1	scand	scand	PROPN
ajlm-2099	246	2	j	j	PROPN
ajlm-2099	246	3	immunol	immunol	NOUN
ajlm-2099	246	4	.	.	PUNCT
ajlm-2099	247	1	2020;91(3):e12849	2020;91(3):e12849	X
ajlm-2099	247	2	.	.	PUNCT
ajlm-2099	248	1	https://doi.org/10.1111/sji.12849	https://doi.org/10.1111/sji.12849	PROPN
ajlm-2099	248	2	mclaren	mclaren	PROPN
ajlm-2099	248	3	js	js	PROPN
ajlm-2099	248	4	,	,	PUNCT
ajlm-2099	248	5	stimson	stimson	PROPN
ajlm-2099	248	6	rh	rh	PROPN
ajlm-2099	248	7	,	,	PUNCT
ajlm-2099	248	8	mcrorie	mcrorie	NOUN
ajlm-2099	248	9	er	er	INTJ
ajlm-2099	248	10	,	,	PUNCT
ajlm-2099	248	11	coia	coia	PROPN
ajlm-2099	248	12	je	je	PROPN
ajlm-2099	248	13	,	,	PUNCT
ajlm-2099	248	14	luqmani	luqmani	PROPN
ajlm-2099	248	15	ra	ra	PROPN
ajlm-2099	248	16	.	.	PUNCT
ajlm-2099	249	1	the	the	DET
ajlm-2099	249	2	diagnostic	diagnostic	ADJ
ajlm-2099	249	3	value	value	NOUN
ajlm-2099	249	4	of	of	ADP
ajlm-2099	249	5	anti	anti	ADJ
ajlm-2099	249	6	-	-	ADJ
ajlm-2099	249	7	neutrophil	neutrophil	ADJ
ajlm-2099	249	8	cytoplasmic	cytoplasmic	ADJ
ajlm-2099	249	9	antibody	antibody	NOUN
ajlm-2099	249	10	testing	testing	NOUN
ajlm-2099	249	11	in	in	ADP
ajlm-2099	249	12	a	a	DET
ajlm-2099	249	13	routine	routine	ADJ
ajlm-2099	249	14	clinical	clinical	ADJ
ajlm-2099	249	15	setting	setting	NOUN
ajlm-2099	249	16	.	.	PUNCT
ajlm-2099	250	1	qjm	qjm	INTJ
ajlm-2099	250	2	.	.	PUNCT
ajlm-2099	251	1	2001;94(11):615–621	2001;94(11):615–621	NUM
ajlm-2099	251	2	.	.	PUNCT
ajlm-2099	251	3	https://doi.org/10.1093/qjmed/94.11.615	https://doi.org/10.1093/qjmed/94.11.615	ADJ
ajlm-2099	251	4	schober	schober	PROPN
ajlm-2099	251	5	p	p	PROPN
ajlm-2099	251	6	,	,	PUNCT
ajlm-2099	251	7	boer	boer	PROPN
ajlm-2099	251	8	c	c	PROPN
ajlm-2099	251	9	,	,	PUNCT
ajlm-2099	251	10	schwarte	schwarte	PROPN
ajlm-2099	251	11	la	la	PROPN
ajlm-2099	251	12	.	.	PUNCT
ajlm-2099	252	1	correlation	correlation	NOUN
ajlm-2099	252	2	coefficients	coefficient	NOUN
ajlm-2099	252	3	:	:	PUNCT
ajlm-2099	252	4	appropriate	appropriate	ADJ
ajlm-2099	252	5	use	use	NOUN
ajlm-2099	252	6	and	and	CCONJ
ajlm-2099	252	7	interpretation	interpretation	NOUN
ajlm-2099	252	8	.	.	PUNCT
ajlm-2099	253	1	anesth	anesth	PROPN
ajlm-2099	253	2	analg	analg	PROPN
ajlm-2099	253	3	.	.	PUNCT
ajlm-2099	254	1	2018;126(5):1763–1768	2018;126(5):1763–1768	NUM
ajlm-2099	254	2	.	.	PUNCT
ajlm-2099	255	1	https://doi.org/10.1213/ane.0000000000002864	https://doi.org/10.1213/ane.0000000000002864	PROPN
ajlm-2099	255	2	saboor	saboor	PROPN
ajlm-2099	255	3	soomro	soomro	PROPN
ajlm-2099	255	4	r	r	NOUN
ajlm-2099	255	5	,	,	PUNCT
ajlm-2099	255	6	shah	shah	PROPN
ajlm-2099	255	7	ia	ia	PROPN
ajlm-2099	255	8	,	,	PUNCT
ajlm-2099	255	9	saboor	saboor	NOUN
ajlm-2099	255	10	a	a	DET
ajlm-2099	255	11	,	,	PUNCT
ajlm-2099	255	12	bhutto	bhutto	PROPN
ajlm-2099	255	13	aub	aub	PROPN
ajlm-2099	255	14	,	,	PUNCT
ajlm-2099	255	15	memon	memon	PROPN
ajlm-2099	255	16	s.	s.	PROPN
ajlm-2099	255	17	sensitivity	sensitivity	PROPN
ajlm-2099	255	18	and	and	CCONJ
ajlm-2099	255	19	specificity	specificity	NOUN
ajlm-2099	255	20	of	of	ADP
ajlm-2099	255	21	hepatitis	hepatitis	PROPN
ajlm-2099	255	22	b	b	PROPN
ajlm-2099	255	23	virus	virus	NOUN
ajlm-2099	255	24	screening	screen	VERB
ajlm-2099	255	25	via	via	ADP
ajlm-2099	255	26	rapid	rapid	ADJ
ajlm-2099	255	27	immunoassay	immunoassay	PROPN
ajlm-2099	255	28	chromatographic	chromatographic	ADJ
ajlm-2099	255	29	test	test	NOUN
ajlm-2099	255	30	.	.	PUNCT
ajlm-2099	256	1	cureus	cureus	NOUN
ajlm-2099	256	2	.	.	PUNCT
ajlm-2099	257	1	2021;13(1):e12909	2021;13(1):e12909	X
ajlm-2099	257	2	.	.	X
ajlm-2099	257	3	https://doi.org/10.7759/cureus.12909	https://doi.org/10.7759/cureus.12909	PROPN
ajlm-2099	257	4	hanly	hanly	ADV
ajlm-2099	257	5	jg	jg	PROPN
ajlm-2099	257	6	,	,	PUNCT
ajlm-2099	257	7	thompson	thompson	PROPN
ajlm-2099	257	8	k	k	PROPN
ajlm-2099	257	9	,	,	PUNCT
ajlm-2099	257	10	mccurdy	mccurdy	NOUN
ajlm-2099	257	11	g	g	PROPN
ajlm-2099	257	12	,	,	PUNCT
ajlm-2099	257	13	fougere	fougere	NOUN
ajlm-2099	257	14	l	l	NOUN
ajlm-2099	257	15	,	,	PUNCT
ajlm-2099	257	16	theriault	theriault	VERB
ajlm-2099	257	17	c	c	NOUN
ajlm-2099	257	18	,	,	PUNCT
ajlm-2099	257	19	wilton	wilton	PROPN
ajlm-2099	257	20	k.	k.	PROPN
ajlm-2099	257	21	measurement	measurement	PROPN
ajlm-2099	257	22	of	of	ADP
ajlm-2099	257	23	autoantibodies	autoantibody	NOUN
ajlm-2099	257	24	using	use	VERB
ajlm-2099	257	25	multiplex	multiplex	PROPN
ajlm-2099	257	26	methodology	methodology	NOUN
ajlm-2099	257	27	in	in	ADP
ajlm-2099	257	28	patients	patient	NOUN
ajlm-2099	257	29	with	with	ADP
ajlm-2099	257	30	systemic	systemic	ADJ
ajlm-2099	257	31	lupus	lupus	PROPN
ajlm-2099	257	32	erythematosus	erythematosus	PROPN
ajlm-2099	257	33	.	.	PUNCT
ajlm-2099	258	1	j	j	PROPN
ajlm-2099	258	2	immunol	immunol	NOUN
ajlm-2099	258	3	methods	method	NOUN
ajlm-2099	258	4	.	.	PUNCT
ajlm-2099	259	1	2010;352(1–2):147–152	2010;352(1–2):147–152	NUM
ajlm-2099	259	2	.	.	PUNCT
ajlm-2099	260	1	https://doi.org/10.1016/j.jim.2009.10.003	https://doi.org/10.1016/j.jim.2009.10.003	PROPN
ajlm-2099	260	2	venner	venner	NOUN
ajlm-2099	260	3	aa	aa	NOUN
ajlm-2099	260	4	,	,	PUNCT
ajlm-2099	260	5	ibañez	ibañez	NOUN
ajlm-2099	260	6	d	d	NOUN
ajlm-2099	260	7	,	,	PUNCT
ajlm-2099	260	8	gladman	gladman	NOUN
ajlm-2099	260	9	dd	dd	PROPN
ajlm-2099	260	10	,	,	PUNCT
ajlm-2099	260	11	et	et	PROPN
ajlm-2099	260	12	al	al	PROPN
ajlm-2099	260	13	.	.	PROPN
ajlm-2099	260	14	comparison	comparison	NOUN
ajlm-2099	260	15	of	of	ADP
ajlm-2099	260	16	three	three	NUM
ajlm-2099	260	17	anti	anti	ADJ
ajlm-2099	260	18	-	-	ADJ
ajlm-2099	260	19	dsdna	dsdna	ADJ
ajlm-2099	260	20	assays	assay	NOUN
ajlm-2099	260	21	:	:	PUNCT
ajlm-2099	260	22	performance	performance	NOUN
ajlm-2099	260	23	and	and	CCONJ
ajlm-2099	260	24	correlation	correlation	NOUN
ajlm-2099	260	25	with	with	ADP
ajlm-2099	260	26	systemic	systemic	ADJ
ajlm-2099	260	27	lupus	lupus	PROPN
ajlm-2099	260	28	erythematosus	erythematosus	NOUN
ajlm-2099	260	29	disease	disease	NOUN
ajlm-2099	260	30	activity	activity	NOUN
ajlm-2099	260	31	.	.	PUNCT
ajlm-2099	261	1	clin	clin	PROPN
ajlm-2099	261	2	biochem	biochem	PROPN
ajlm-2099	261	3	.	.	PUNCT
ajlm-2099	262	1	2013;46(4–5):317–320	2013;46(4–5):317–320	NOUN
ajlm-2099	262	2	.	.	PUNCT
ajlm-2099	263	1	https://doi.org/10.1016/j.clinbiochem.2012.12.004	https://doi.org/10.1016/j.clinbiochem.2012.12.004	PROPN
ajlm-2099	263	2	damoiseaux	damoiseaux	PROPN
ajlm-2099	263	3	j	j	PROPN
ajlm-2099	263	4	,	,	PUNCT
ajlm-2099	263	5	vaessen	vaessen	PROPN
ajlm-2099	263	6	m	m	PRON
ajlm-2099	263	7	,	,	PUNCT
ajlm-2099	263	8	knapen	knapen	VERB
ajlm-2099	263	9	y	y	PROPN
ajlm-2099	263	10	,	,	PUNCT
ajlm-2099	263	11	et	et	PROPN
ajlm-2099	263	12	al	al	PROPN
ajlm-2099	263	13	.	.	PUNCT
ajlm-2099	264	1	evaluation	evaluation	NOUN
ajlm-2099	264	2	of	of	ADP
ajlm-2099	264	3	the	the	DET
ajlm-2099	264	4	fidis	fidi	NOUN
ajlm-2099	264	5	vasculitis	vasculitis	PROPN
ajlm-2099	264	6	multiplex	multiplex	PROPN
ajlm-2099	264	7	immunoassay	immunoassay	PROPN
ajlm-2099	264	8	for	for	ADP
ajlm-2099	264	9	diagnosis	diagnosis	NOUN
ajlm-2099	264	10	and	and	CCONJ
ajlm-2099	264	11	follow	follow	VERB
ajlm-2099	264	12	-	-	PUNCT
ajlm-2099	264	13	up	up	NOUN
ajlm-2099	264	14	of	of	ADP
ajlm-2099	264	15	anca	anca	NOUN
ajlm-2099	264	16	-	-	PUNCT
ajlm-2099	264	17	associated	associate	VERB
ajlm-2099	264	18	vasculitis	vasculitis	NOUN
ajlm-2099	264	19	and	and	CCONJ
ajlm-2099	264	20	goodpasture	goodpasture	NOUN
ajlm-2099	264	21	’s	’s	PART
ajlm-2099	264	22	disease	disease	NOUN
ajlm-2099	264	23	.	.	PUNCT
ajlm-2099	265	1	ann	ann	PROPN
ajlm-2099	265	2	n	n	PROPN
ajlm-2099	265	3	y	y	PROPN
ajlm-2099	265	4	acad	acad	PROPN
ajlm-2099	265	5	sci	sci	PROPN
ajlm-2099	265	6	.	.	PUNCT
ajlm-2099	266	1	2007;1109(1):454–463	2007;1109(1):454–463	PROPN
ajlm-2099	266	2	.	.	PUNCT
ajlm-2099	267	1	https://doi.org/10.1196/annals.1398.051	https://doi.org/10.1196/annals.1398.051	ADJ
ajlm-2099	267	2	bossuyt	bossuyt	NOUN
ajlm-2099	267	3	x	x	NOUN
ajlm-2099	267	4	,	,	PUNCT
ajlm-2099	267	5	rasmussen	rasmussen	PROPN
ajlm-2099	267	6	n	n	PROPN
ajlm-2099	267	7	,	,	PUNCT
ajlm-2099	267	8	van	van	PROPN
ajlm-2099	267	9	paassen	paassen	PROPN
ajlm-2099	267	10	p	p	PROPN
ajlm-2099	267	11	,	,	PUNCT
ajlm-2099	267	12	et	et	PROPN
ajlm-2099	267	13	al	al	PROPN
ajlm-2099	267	14	.	.	PUNCT
ajlm-2099	268	1	a	a	DET
ajlm-2099	268	2	multicentre	multicentre	NOUN
ajlm-2099	268	3	study	study	NOUN
ajlm-2099	268	4	to	to	PART
ajlm-2099	268	5	improve	improve	VERB
ajlm-2099	268	6	clinical	clinical	ADJ
ajlm-2099	268	7	interpretation	interpretation	NOUN
ajlm-2099	268	8	of	of	ADP
ajlm-2099	268	9	proteinase-3	proteinase-3	NUM
ajlm-2099	268	10	and	and	CCONJ
ajlm-2099	268	11	myeloperoxidase	myeloperoxidase	VERB
ajlm-2099	268	12	anti	anti	ADJ
ajlm-2099	268	13	-	-	ADJ
ajlm-2099	268	14	neutrophil	neutrophil	ADJ
ajlm-2099	268	15	cytoplasmic	cytoplasmic	ADJ
ajlm-2099	268	16	antibodies	antibody	NOUN
ajlm-2099	268	17	.	.	PUNCT
ajlm-2099	269	1	rheumatology	rheumatology	NOUN
ajlm-2099	269	2	.	.	PUNCT
ajlm-2099	270	1	2017;56(9):1533–1541	2017;56(9):1533–1541	NOUN
ajlm-2099	270	2	.	.	PUNCT
ajlm-2099	271	1	https://doi.org/10.1093/rheumatology/kex170	https://doi.org/10.1093/rheumatology/kex170	PROPN
ajlm-2099	271	2	sun	sun	PROPN
ajlm-2099	271	3	q	q	PROPN
ajlm-2099	271	4	,	,	PUNCT
ajlm-2099	271	5	calderon	calderon	PROPN
ajlm-2099	271	6	b	b	PROPN
ajlm-2099	271	7	,	,	PUNCT
ajlm-2099	272	1	zhao	zhao	PROPN
ajlm-2099	272	2	z.	z.	PROPN
ajlm-2099	272	3	discrepancies	discrepancy	NOUN
ajlm-2099	272	4	between	between	ADP
ajlm-2099	272	5	two	two	NUM
ajlm-2099	272	6	immunoassays	immunoassay	NOUN
ajlm-2099	272	7	for	for	ADP
ajlm-2099	272	8	the	the	DET
ajlm-2099	272	9	determination	determination	NOUN
ajlm-2099	272	10	of	of	ADP
ajlm-2099	272	11	mpo	mpo	PROPN
ajlm-2099	272	12	and	and	CCONJ
ajlm-2099	272	13	pr3	pr3	NOUN
ajlm-2099	272	14	autoantibodies	autoantibody	NOUN
ajlm-2099	272	15	.	.	PUNCT
ajlm-2099	273	1	clin	clin	PROPN
ajlm-2099	273	2	chim	chim	PROPN
ajlm-2099	273	3	acta	acta	PROPN
ajlm-2099	273	4	.	.	PUNCT
ajlm-2099	274	1	2017;470:93–96	2017;470:93–96	NUM
ajlm-2099	274	2	.	.	PUNCT
ajlm-2099	274	3	https://doi.org/10.1016/j.cca.2017.05.008	https://doi.org/10.1016/j.cca.2017.05.008	NOUN